package_date,short_name,bc_id,ncit_code,parent_bc_id,bc_categories,synonyms,result_scales,definition,system,system_name,code,dec_id,ncit_dec_code,dec_label,data_type,example_set
2025-09-23,6MWT - Distance at 6 Minutes,C115805,C115805,C115409,QRS;Functional Tests;6MWT;6 Minute Walk Functional Test;Six Minute Walk,SIXMW106;SIXMW1-Distance at 6 Minutes,Quantitative,6 Minute Walk Test (6MWT) Distance at 6 minutes.,http://loinc.org/,LOINC,64098-7,C93300,C93300,Assistive Device,string,cane
2025-09-23,6MWT - Distance at 6 Minutes,C115805,C115805,C115409,QRS;Functional Tests;6MWT;6 Minute Walk Functional Test;Six Minute Walk,SIXMW106;SIXMW1-Distance at 6 Minutes,Quantitative,6 Minute Walk Test (6MWT) Distance at 6 minutes.,http://loinc.org/,LOINC,64098-7,C82515,C82515,Collection Date Time,datetime,
2025-09-23,6MWT - Distance at 6 Minutes,C115805,C115805,C115409,QRS;Functional Tests;6MWT;6 Minute Walk Functional Test;Six Minute Walk,SIXMW106;SIXMW1-Distance at 6 Minutes,Quantitative,6 Minute Walk Test (6MWT) Distance at 6 minutes.,http://loinc.org/,LOINC,64098-7,C42578,C42578,Unit of Length,string,meter
2025-09-23,6MWT - Distance at 6 Minutes,C115805,C115805,C115409,QRS;Functional Tests;6MWT;6 Minute Walk Functional Test;Six Minute Walk,SIXMW106;SIXMW1-Distance at 6 Minutes,Quantitative,6 Minute Walk Test (6MWT) Distance at 6 minutes.,http://loinc.org/,LOINC,64098-7,C25372,C25372,Category,string,SIX MINUTE WALK
2025-09-23,6MWT - Distance at 6 Minutes,C115805,C115805,C115409,QRS;Functional Tests;6MWT;6 Minute Walk Functional Test;Six Minute Walk,SIXMW106;SIXMW1-Distance at 6 Minutes,Quantitative,6 Minute Walk Test (6MWT) Distance at 6 minutes.,http://loinc.org/,LOINC,64098-7,C91106,C91106,Clinical or Research Assessment Answer,integer,
2025-09-23,APACHE II - Total APACHE II Score,C121113,C121113,C120994,QRS;APACHE II;Acute Physiology and Chronic Health Evaluation II Clinical Classification,APCH1-Total APACHE II Score;APCH116,Ordinal,Acute Physiology and Chronic Health Evaluation II (APACHE II) Total APACHE II score.,http://loinc.org/,LOINC,9264-3,C25372,C25372,Category,string,APACHE II
2025-09-23,APACHE II - Total APACHE II Score,C121113,C121113,C120994,QRS;APACHE II;Acute Physiology and Chronic Health Evaluation II Clinical Classification,APCH1-Total APACHE II Score;APCH116,Ordinal,Acute Physiology and Chronic Health Evaluation II (APACHE II) Total APACHE II score.,http://loinc.org/,LOINC,9264-3,C91106,C91106,Clinical or Research Assessment Answer,integer,
2025-09-23,APACHE II - Total APACHE II Score,C121113,C121113,C120994,QRS;APACHE II;Acute Physiology and Chronic Health Evaluation II Clinical Classification,APCH1-Total APACHE II Score;APCH116,Ordinal,Acute Physiology and Chronic Health Evaluation II (APACHE II) Total APACHE II score.,http://loinc.org/,LOINC,9264-3,C82515,C82515,Collection Date Time,datetime,
2025-09-23,APACHE II - Total APACHE II Score,C121113,C121113,C120994,QRS;APACHE II;Acute Physiology and Chronic Health Evaluation II Clinical Classification,APCH1-Total APACHE II Score;APCH116,Ordinal,Acute Physiology and Chronic Health Evaluation II (APACHE II) Total APACHE II score.,http://loinc.org/,LOINC,9264-3,C46126,C46126,Ordinal Position,integer,0;1;2;3;4;5;6;7;8;9;10;11;12;13;14;15;16;17;18;19;20;21;22;23;24;25;26;27;28;29;30;31;32;33;34;35;36;37;38;39;40;41;42;43;44;45;46;47;48;49;50;51;52;53;54;55;56;57;58;59;60;61;62;63;64;65;66;67;68;69;70
2025-09-23,Allergen-induced Antibody Measurement,C182150,C182150,,Allergen-induced Antibody Measurement,,,"The determination of the allergen-induced, binding antibody in a biospecimen.",,,,,,,,
2025-09-23,Allergen-induced IgA Antibody Measurement,C187776,C187776,C182150,Laboratory Tests;Immunogenicity Specimen Assessments;Immunoglobulin A Measurements;Allergen-induced Antibody Measurements,ARIGAAB;Allergen-induced IgA Antibody,Quantitative;Ordinal,The determination of the amount of allergen-induced IgA antibody in a sample.,,,,C70713,C70713,Biospecimen Type,string,Serum;Plasma;Blood;Saliva;Urine;Cerebrospinal Fluid
2025-09-23,Allergen-induced IgA Antibody Measurement,C187776,C187776,C182150,Laboratory Tests;Immunogenicity Specimen Assessments;Immunoglobulin A Measurements;Allergen-induced Antibody Measurements,ARIGAAB;Allergen-induced IgA Antibody,Quantitative;Ordinal,The determination of the amount of allergen-induced IgA antibody in a sample.,,,,C82535,C82535,Test Method,string,Immunoassay
2025-09-23,Allergen-induced IgA Antibody Measurement,C187776,C187776,C182150,Laboratory Tests;Immunogenicity Specimen Assessments;Immunoglobulin A Measurements;Allergen-induced Antibody Measurements,ARIGAAB;Allergen-induced IgA Antibody,Quantitative;Ordinal,The determination of the amount of allergen-induced IgA antibody in a sample.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Allergen-induced IgA Antibody Measurement,C187776,C187776,C182150,Laboratory Tests;Immunogenicity Specimen Assessments;Immunoglobulin A Measurements;Allergen-induced Antibody Measurements,ARIGAAB;Allergen-induced IgA Antibody,Quantitative;Ordinal,The determination of the amount of allergen-induced IgA antibody in a sample.,,,,C48207,C48207,Unit of Concentration,string,mg/dL;g/L;umol/L;U/mL
2025-09-23,Allergen-induced IgA Antibody Measurement,C187776,C187776,C182150,Laboratory Tests;Immunogenicity Specimen Assessments;Immunoglobulin A Measurements;Allergen-induced Antibody Measurements,ARIGAAB;Allergen-induced IgA Antibody,Quantitative;Ordinal,The determination of the amount of allergen-induced IgA antibody in a sample.,,,,C70856,C70856,Observation Result,decimal,
2025-09-23,Allergen-induced IgA Antibody Measurement,C187776,C187776,C182150,Laboratory Tests;Immunogenicity Specimen Assessments;Immunoglobulin A Measurements;Allergen-induced Antibody Measurements,ARIGAAB;Allergen-induced IgA Antibody,Quantitative;Ordinal,The determination of the amount of allergen-induced IgA antibody in a sample.,,,,C218437,C218437,Immunogenicity Specimen Test Operational Objective,string,Screen;Confirm;Quantify;Overall Subject Status
2025-09-23,Allergen-induced IgA Antibody Measurement,C187776,C187776,C182150,Laboratory Tests;Immunogenicity Specimen Assessments;Immunoglobulin A Measurements;Allergen-induced Antibody Measurements,ARIGAAB;Allergen-induced IgA Antibody,Quantitative;Ordinal,The determination of the amount of allergen-induced IgA antibody in a sample.,,,,C42647,C42647,Binder Excipient,string,American Cockroach Antigen;Bermuda Grass Pollen;Cat Dander Antigen;Dog Dander Antigen;English Plantain Pollen;German Cockroach Antigen;Gliadin Antigen;Grass Mix Pollens;Mold Mix Antigens;Orchard Grass Pollen;Silver Birch Pollen;Timothy Grass Pollen;Weed Mix Pollens;Western Ragweed Pollen;Alternaria Alternata;Penicillium Chrysogenum;Mucor Racemosus
2025-09-23,Allergen-induced IgA Antibody Measurement,C187776,C187776,C182150,Laboratory Tests;Immunogenicity Specimen Assessments;Immunoglobulin A Measurements;Allergen-induced Antibody Measurements,ARIGAAB;Allergen-induced IgA Antibody,Quantitative;Ordinal,The determination of the amount of allergen-induced IgA antibody in a sample.,,,,C25692,C25692,Subcategory,string,
2025-09-23,Allergen-induced IgA Antibody Measurement,C187776,C187776,C182150,Laboratory Tests;Immunogenicity Specimen Assessments;Immunoglobulin A Measurements;Allergen-induced Antibody Measurements,ARIGAAB;Allergen-induced IgA Antibody,Quantitative;Ordinal,The determination of the amount of allergen-induced IgA antibody in a sample.,,,,C25372,C25372,Category,string,
2025-09-23,Allergen-induced IgE Antibody Measurement,C181398,C181398,C182150,Laboratory Tests;Immunogenicity Specimen Assessments;Immunoglobulin E Measurements;Allergen-induced Antibody Measurements,ARIGEAB;Allergen-induced IgE Antibody,Quantitative;Ordinal,"The determination of the allergen-induced, binding IgE antibody in a biospecimen.",,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Allergen-induced IgE Antibody Measurement,C181398,C181398,C182150,Laboratory Tests;Immunogenicity Specimen Assessments;Immunoglobulin E Measurements;Allergen-induced Antibody Measurements,ARIGEAB;Allergen-induced IgE Antibody,Quantitative;Ordinal,"The determination of the allergen-induced, binding IgE antibody in a biospecimen.",,,,C25372,C25372,Category,string,
2025-09-23,Allergen-induced IgE Antibody Measurement,C181398,C181398,C182150,Laboratory Tests;Immunogenicity Specimen Assessments;Immunoglobulin E Measurements;Allergen-induced Antibody Measurements,ARIGEAB;Allergen-induced IgE Antibody,Quantitative;Ordinal,"The determination of the allergen-induced, binding IgE antibody in a biospecimen.",,,,C70713,C70713,Biospecimen Type,string,Serum;Plasma
2025-09-23,Allergen-induced IgE Antibody Measurement,C181398,C181398,C182150,Laboratory Tests;Immunogenicity Specimen Assessments;Immunoglobulin E Measurements;Allergen-induced Antibody Measurements,ARIGEAB;Allergen-induced IgE Antibody,Quantitative;Ordinal,"The determination of the allergen-induced, binding IgE antibody in a biospecimen.",,,,C48207,C48207,Unit of Concentration,string,IU/mL;ng/mL;ng/dL;U/mL
2025-09-23,Allergen-induced IgE Antibody Measurement,C181398,C181398,C182150,Laboratory Tests;Immunogenicity Specimen Assessments;Immunoglobulin E Measurements;Allergen-induced Antibody Measurements,ARIGEAB;Allergen-induced IgE Antibody,Quantitative;Ordinal,"The determination of the allergen-induced, binding IgE antibody in a biospecimen.",,,,C70856,C70856,Observation Result,string,0 Absent or undetectable allergen specific IgE;1 Low level of allergen specific IgE;2 Moderate level of allergen specific IgE;3 High level of allergen specific IgE;4 Very high level of allergen specific IgE;5 Ultra high level of allergen specific IgE;6 Extremely high level of allergen specific IgE
2025-09-23,Allergen-induced IgE Antibody Measurement,C181398,C181398,C182150,Laboratory Tests;Immunogenicity Specimen Assessments;Immunoglobulin E Measurements;Allergen-induced Antibody Measurements,ARIGEAB;Allergen-induced IgE Antibody,Quantitative;Ordinal,"The determination of the allergen-induced, binding IgE antibody in a biospecimen.",,,,C46126,C46126,Ordinal Position,integer,0;1;2;3;4;5;6
2025-09-23,Allergen-induced IgE Antibody Measurement,C181398,C181398,C182150,Laboratory Tests;Immunogenicity Specimen Assessments;Immunoglobulin E Measurements;Allergen-induced Antibody Measurements,ARIGEAB;Allergen-induced IgE Antibody,Quantitative;Ordinal,"The determination of the allergen-induced, binding IgE antibody in a biospecimen.",,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Radioallergosorbent test
2025-09-23,Allergen-induced IgE Antibody Measurement,C181398,C181398,C182150,Laboratory Tests;Immunogenicity Specimen Assessments;Immunoglobulin E Measurements;Allergen-induced Antibody Measurements,ARIGEAB;Allergen-induced IgE Antibody,Quantitative;Ordinal,"The determination of the allergen-induced, binding IgE antibody in a biospecimen.",,,,C218437,C218437,Immunogenicity Specimen Test Operational Objective,string,Screen;Confirm;Quantify;Overall Subject Status
2025-09-23,Allergen-induced IgE Antibody Measurement,C181398,C181398,C182150,Laboratory Tests;Immunogenicity Specimen Assessments;Immunoglobulin E Measurements;Allergen-induced Antibody Measurements,ARIGEAB;Allergen-induced IgE Antibody,Quantitative;Ordinal,"The determination of the allergen-induced, binding IgE antibody in a biospecimen.",,,,C42647,C42647,Binder Excipient,string,American Cockroach Antigen;Animal Mix Antigens;Peanut Antigen;Bee Mix Venom Antigens;Bermuda Grass Pollen;Box Elder Pollen;Cashew Nut Antigen;Cat Dander Antigen;Common Ragweed Pollen;Cow Milk Antigen;American House Dust Mite Antigen;European House Dust Mite Antigen;Dog Dander Antigen;Egg White Antigen;English Plantain Pollen;German Cockroach Antigen;Soybean Antigen;Grass Mix Pollens;Corylus Avellana Nut Antigen;Chemical Mix Antigens;Mixed Antigens;Mold Mix Antigens;Nut Mix Antigens;Olive Tree Pollen;Orchard Grass Pollen;Russian Thistle Pollen;Shellfish Mix Antigens;Silver Birch Pollen;Timothy Grass Pollen;Tree Mix Pollens;Triticum Aestivum Antigen;Triticum Species Antigen;Walnut Antigen;Weed Mix Pollens;Western Ragweed Pollen;White Elm Pollen;White Oak Pollen;Wild Rye Grass Pollen;Corn Antigen;Aspergillus Fumigatus;Alternaria Alternata;Cladosporium Herbarum;Penicillium Chrysogenum;Fusarium Proliferatum;Malassezia;Mucor Racemosus
2025-09-23,Allergen-induced IgE Antibody Measurement,C181398,C181398,C182150,Laboratory Tests;Immunogenicity Specimen Assessments;Immunoglobulin E Measurements;Allergen-induced Antibody Measurements,ARIGEAB;Allergen-induced IgE Antibody,Quantitative;Ordinal,"The determination of the allergen-induced, binding IgE antibody in a biospecimen.",,,,C25692,C25692,Subcategory,string,
2025-09-23,Allergen-induced IgE Antibody Measurement,C181398,C181398,C182150,Laboratory Tests;Immunogenicity Specimen Assessments;Immunoglobulin E Measurements;Allergen-induced Antibody Measurements,ARIGEAB;Allergen-induced IgE Antibody,Quantitative;Ordinal,"The determination of the allergen-induced, binding IgE antibody in a biospecimen.",,,,C82535,C82535,Test Method,string,Immunoassay
2025-09-23,Allergen-induced IgM Antibody Measurement,C187779,C187779,C182150,Laboratory Tests;Immunogenicity Specimen Assessments;Immunoglobulin M Measurements;Allergen-induced Antibody Measurements,ARIGMAB;Allergen-induced IgM Antibody,Quantitative,The determination of the amount of allergen-induced IgM antibody in a sample.,,,,C70856,C70856,Observation Result,string,
2025-09-23,Allergen-induced IgM Antibody Measurement,C187779,C187779,C182150,Laboratory Tests;Immunogenicity Specimen Assessments;Immunoglobulin M Measurements;Allergen-induced Antibody Measurements,ARIGMAB;Allergen-induced IgM Antibody,Quantitative,The determination of the amount of allergen-induced IgM antibody in a sample.,,,,C218437,C218437,Immunogenicity Specimen Test Operational Objective,string,Screen;Confirm;Quantify;Overall Subject Status
2025-09-23,Allergen-induced IgM Antibody Measurement,C187779,C187779,C182150,Laboratory Tests;Immunogenicity Specimen Assessments;Immunoglobulin M Measurements;Allergen-induced Antibody Measurements,ARIGMAB;Allergen-induced IgM Antibody,Quantitative,The determination of the amount of allergen-induced IgM antibody in a sample.,,,,C42647,C42647,Binder Excipient,string,Keyhole Limpet Hemocyanin
2025-09-23,Allergen-induced IgM Antibody Measurement,C187779,C187779,C182150,Laboratory Tests;Immunogenicity Specimen Assessments;Immunoglobulin M Measurements;Allergen-induced Antibody Measurements,ARIGMAB;Allergen-induced IgM Antibody,Quantitative,The determination of the amount of allergen-induced IgM antibody in a sample.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Allergen-induced IgM Antibody Measurement,C187779,C187779,C182150,Laboratory Tests;Immunogenicity Specimen Assessments;Immunoglobulin M Measurements;Allergen-induced Antibody Measurements,ARIGMAB;Allergen-induced IgM Antibody,Quantitative,The determination of the amount of allergen-induced IgM antibody in a sample.,,,,C25372,C25372,Category,string,
2025-09-23,Allergen-induced IgM Antibody Measurement,C187779,C187779,C182150,Laboratory Tests;Immunogenicity Specimen Assessments;Immunoglobulin M Measurements;Allergen-induced Antibody Measurements,ARIGMAB;Allergen-induced IgM Antibody,Quantitative,The determination of the amount of allergen-induced IgM antibody in a sample.,,,,C82535,C82535,Test Method,string,Immunoassay;Enzyme-linked Immunosorbent Assay
2025-09-23,Allergen-induced IgM Antibody Measurement,C187779,C187779,C182150,Laboratory Tests;Immunogenicity Specimen Assessments;Immunoglobulin M Measurements;Allergen-induced Antibody Measurements,ARIGMAB;Allergen-induced IgM Antibody,Quantitative,The determination of the amount of allergen-induced IgM antibody in a sample.,,,,C48207,C48207,Unit of Concentration,string,mmol/L;g/L;mg/dL;mg/mL;umol/L
2025-09-23,Allergen-induced IgM Antibody Measurement,C187779,C187779,C182150,Laboratory Tests;Immunogenicity Specimen Assessments;Immunoglobulin M Measurements;Allergen-induced Antibody Measurements,ARIGMAB;Allergen-induced IgM Antibody,Quantitative,The determination of the amount of allergen-induced IgM antibody in a sample.,,,,C25692,C25692,Subcategory,string,
2025-09-23,Allergen-induced IgM Antibody Measurement,C187779,C187779,C182150,Laboratory Tests;Immunogenicity Specimen Assessments;Immunoglobulin M Measurements;Allergen-induced Antibody Measurements,ARIGMAB;Allergen-induced IgM Antibody,Quantitative,The determination of the amount of allergen-induced IgM antibody in a sample.,,,,C70713,C70713,Biospecimen Type,string,Serum;Plasma
2025-09-23,Alzheimer's Disease Assessment Scale-Cognitive CDISC Version Functional Test,C100762,C100762,C81250,Research or Clinical Assessment Tools;Clinical Classification Instruments;QRS,,,"The CDISC version of the Alzheimer's Disease Assessment Scale-Cognitive (CDISC ADAS-Cog) containing 15 summary-level tests. This version is based on combining the total pool of ADAS-Cog tests that were observed during a review of multiple case report forms administered in clinical trials of Alzheimer's disease, as well as the CRF administered in the Alzheimer's Disease Neuroimaging Initiative (ADNI) observational study.  (Modified from Mohs RC, Rosen WG, Davis KL. The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. Psychopharmacol Bull 1983;19(3):448-450. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141(11):1356-1364. Mohs RC, Knopman D, Petersen RC et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11 Suppl 2:S13-S21. Wouters H, van Gool WA, Schmand B, Lindeboom R. Revising the ADAS-cog for a more accurate assessment of cognitive impairment. Alzheimer Dis Assoc Disord 2008;22(3):236-244.).",,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Alzheimer's Disease Assessment Scale-Cognitive CDISC Version Functional Test,C100762,C100762,C81250,Research or Clinical Assessment Tools;Clinical Classification Instruments;QRS,,,"The CDISC version of the Alzheimer's Disease Assessment Scale-Cognitive (CDISC ADAS-Cog) containing 15 summary-level tests. This version is based on combining the total pool of ADAS-Cog tests that were observed during a review of multiple case report forms administered in clinical trials of Alzheimer's disease, as well as the CRF administered in the Alzheimer's Disease Neuroimaging Initiative (ADNI) observational study.  (Modified from Mohs RC, Rosen WG, Davis KL. The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. Psychopharmacol Bull 1983;19(3):448-450. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141(11):1356-1364. Mohs RC, Knopman D, Petersen RC et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11 Suppl 2:S13-S21. Wouters H, van Gool WA, Schmand B, Lindeboom R. Revising the ADAS-cog for a more accurate assessment of cognitive impairment. Alzheimer Dis Assoc Disord 2008;22(3):236-244.).",,,,C82556,C82556,Not-Done Reason,string,Participant refused;Participant unable for physical reasons;Participant unable for cognitive reasons;Not done for reasons other than physical/cognitive
2025-09-23,Alzheimer's Disease Assessment Scale-Cognitive CDISC Version Functional Test,C100762,C100762,C81250,Research or Clinical Assessment Tools;Clinical Classification Instruments;QRS,,,"The CDISC version of the Alzheimer's Disease Assessment Scale-Cognitive (CDISC ADAS-Cog) containing 15 summary-level tests. This version is based on combining the total pool of ADAS-Cog tests that were observed during a review of multiple case report forms administered in clinical trials of Alzheimer's disease, as well as the CRF administered in the Alzheimer's Disease Neuroimaging Initiative (ADNI) observational study.  (Modified from Mohs RC, Rosen WG, Davis KL. The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. Psychopharmacol Bull 1983;19(3):448-450. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141(11):1356-1364. Mohs RC, Knopman D, Petersen RC et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11 Suppl 2:S13-S21. Wouters H, van Gool WA, Schmand B, Lindeboom R. Revising the ADAS-cog for a more accurate assessment of cognitive impairment. Alzheimer Dis Assoc Disord 2008;22(3):236-244.).",,,,C25372,C25372,Category,string,EQ-5D-5L
2025-09-23,Alzheimer's Disease Assessment Scale-Cognitive CDISC Version Functional Test,C100762,C100762,C81250,Research or Clinical Assessment Tools;Clinical Classification Instruments;QRS,,,"The CDISC version of the Alzheimer's Disease Assessment Scale-Cognitive (CDISC ADAS-Cog) containing 15 summary-level tests. This version is based on combining the total pool of ADAS-Cog tests that were observed during a review of multiple case report forms administered in clinical trials of Alzheimer's disease, as well as the CRF administered in the Alzheimer's Disease Neuroimaging Initiative (ADNI) observational study.  (Modified from Mohs RC, Rosen WG, Davis KL. The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. Psychopharmacol Bull 1983;19(3):448-450. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141(11):1356-1364. Mohs RC, Knopman D, Petersen RC et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11 Suppl 2:S13-S21. Wouters H, van Gool WA, Schmand B, Lindeboom R. Revising the ADAS-cog for a more accurate assessment of cognitive impairment. Alzheimer Dis Assoc Disord 2008;22(3):236-244.).",,,,C82525,C82525,Test Occurrence,string,N;Y
2025-09-23,Autoantibody Measurement,C181397,C181397,,Laboratory Tests;Immunogenicity Specimen Assessments;Autoantibody Measurement,,,The determination of the binding autoantibody in a biospecimen.,,,,,,,,
2025-09-23,Automated Breast Ultrasound,C186741,C186741,C19337,Diagnostic Imaging;Medical Imaging,Automated Ultrasound;Diagnostic Ulatrasound;Ultrasound,Nominal,"A method of ultrasonography for secondary breast cancer screening in asymptomatic women with dense breasts. It uses an ultrasound scanner and a transducer device which moves automatically in a scan box. The patient lies in a supine position and automated breast ultrasound is performed in anteroposterior, medial, and lateral views routinely, and in the superior or inferior view additionally in cases of large breasts. The image series is used for 3-dimensional image reconstruction and tumor detection.",,,,C117530,C117530,End Date and Time of Procedure,datetime,
2025-09-23,Automated Breast Ultrasound,C186741,C186741,C19337,Diagnostic Imaging;Medical Imaging,Automated Ultrasound;Diagnostic Ulatrasound;Ultrasound,Nominal,"A method of ultrasonography for secondary breast cancer screening in asymptomatic women with dense breasts. It uses an ultrasound scanner and a transducer device which moves automatically in a scan box. The patient lies in a supine position and automated breast ultrasound is performed in anteroposterior, medial, and lateral views routinely, and in the superior or inferior view additionally in cases of large breasts. The image series is used for 3-dimensional image reconstruction and tumor detection.",,,,C25185,C25185,Laterality,string,Left;Right;Bilateral
2025-09-23,Automated Breast Ultrasound,C186741,C186741,C19337,Diagnostic Imaging;Medical Imaging,Automated Ultrasound;Diagnostic Ulatrasound;Ultrasound,Nominal,"A method of ultrasonography for secondary breast cancer screening in asymptomatic women with dense breasts. It uses an ultrasound scanner and a transducer device which moves automatically in a scan box. The patient lies in a supine position and automated breast ultrasound is performed in anteroposterior, medial, and lateral views routinely, and in the superior or inferior view additionally in cases of large breasts. The image series is used for 3-dimensional image reconstruction and tumor detection.",,,,C171000,C171000,Prespecified Event or Intervention Indicator,boolean,Y;N
2025-09-23,Automated Breast Ultrasound,C186741,C186741,C19337,Diagnostic Imaging;Medical Imaging,Automated Ultrasound;Diagnostic Ulatrasound;Ultrasound,Nominal,"A method of ultrasonography for secondary breast cancer screening in asymptomatic women with dense breasts. It uses an ultrasound scanner and a transducer device which moves automatically in a scan box. The patient lies in a supine position and automated breast ultrasound is performed in anteroposterior, medial, and lateral views routinely, and in the superior or inferior view additionally in cases of large breasts. The image series is used for 3-dimensional image reconstruction and tumor detection.",,,,C127786,C127786,Occurrence Indicator,boolean,Y;N
2025-09-23,Automated Breast Ultrasound,C186741,C186741,C19337,Diagnostic Imaging;Medical Imaging,Automated Ultrasound;Diagnostic Ulatrasound;Ultrasound,Nominal,"A method of ultrasonography for secondary breast cancer screening in asymptomatic women with dense breasts. It uses an ultrasound scanner and a transducer device which moves automatically in a scan box. The patient lies in a supine position and automated breast ultrasound is performed in anteroposterior, medial, and lateral views routinely, and in the superior or inferior view additionally in cases of large breasts. The image series is used for 3-dimensional image reconstruction and tumor detection.",,,,C54215,C54215,Directionality,string,
2025-09-23,Automated Breast Ultrasound,C186741,C186741,C19337,Diagnostic Imaging;Medical Imaging,Automated Ultrasound;Diagnostic Ulatrasound;Ultrasound,Nominal,"A method of ultrasonography for secondary breast cancer screening in asymptomatic women with dense breasts. It uses an ultrasound scanner and a transducer device which moves automatically in a scan box. The patient lies in a supine position and automated breast ultrasound is performed in anteroposterior, medial, and lateral views routinely, and in the superior or inferior view additionally in cases of large breasts. The image series is used for 3-dimensional image reconstruction and tumor detection.",,,,C117529,C117529,Start Date and Time of Procedure,datetime,
2025-09-23,Automated Breast Ultrasound,C186741,C186741,C19337,Diagnostic Imaging;Medical Imaging,Automated Ultrasound;Diagnostic Ulatrasound;Ultrasound,Nominal,"A method of ultrasonography for secondary breast cancer screening in asymptomatic women with dense breasts. It uses an ultrasound scanner and a transducer device which moves automatically in a scan box. The patient lies in a supine position and automated breast ultrasound is performed in anteroposterior, medial, and lateral views routinely, and in the superior or inferior view additionally in cases of large breasts. The image series is used for 3-dimensional image reconstruction and tumor detection.",,,,C25372,C25372,Category,string,
2025-09-23,Automated Breast Ultrasound,C186741,C186741,C19337,Diagnostic Imaging;Medical Imaging,Automated Ultrasound;Diagnostic Ulatrasound;Ultrasound,Nominal,"A method of ultrasonography for secondary breast cancer screening in asymptomatic women with dense breasts. It uses an ultrasound scanner and a transducer device which moves automatically in a scan box. The patient lies in a supine position and automated breast ultrasound is performed in anteroposterior, medial, and lateral views routinely, and in the superior or inferior view additionally in cases of large breasts. The image series is used for 3-dimensional image reconstruction and tumor detection.",,,,C25692,C25692,Subcategory,string,
2025-09-23,Automated Breast Ultrasound,C186741,C186741,C19337,Diagnostic Imaging;Medical Imaging,Automated Ultrasound;Diagnostic Ulatrasound;Ultrasound,Nominal,"A method of ultrasonography for secondary breast cancer screening in asymptomatic women with dense breasts. It uses an ultrasound scanner and a transducer device which moves automatically in a scan box. The patient lies in a supine position and automated breast ultrasound is performed in anteroposterior, medial, and lateral views routinely, and in the superior or inferior view additionally in cases of large breasts. The image series is used for 3-dimensional image reconstruction and tumor detection.",,,,C13717,C13717,Anatomic Site,string,Breast
2025-09-23,Automated Breast Ultrasound,C186741,C186741,C19337,Diagnostic Imaging;Medical Imaging,Automated Ultrasound;Diagnostic Ulatrasound;Ultrasound,Nominal,"A method of ultrasonography for secondary breast cancer screening in asymptomatic women with dense breasts. It uses an ultrasound scanner and a transducer device which moves automatically in a scan box. The patient lies in a supine position and automated breast ultrasound is performed in anteroposterior, medial, and lateral views routinely, and in the superior or inferior view additionally in cases of large breasts. The image series is used for 3-dimensional image reconstruction and tumor detection.",,,,C117511,C117511,Reported Name of Procedure,string,Automated Breast Ultrasound
2025-09-23,Automated Breast Ultrasound,C186741,C186741,C19337,Diagnostic Imaging;Medical Imaging,Automated Ultrasound;Diagnostic Ulatrasound;Ultrasound,Nominal,"A method of ultrasonography for secondary breast cancer screening in asymptomatic women with dense breasts. It uses an ultrasound scanner and a transducer device which moves automatically in a scan box. The patient lies in a supine position and automated breast ultrasound is performed in anteroposterior, medial, and lateral views routinely, and in the superior or inferior view additionally in cases of large breasts. The image series is used for 3-dimensional image reconstruction and tumor detection.",,,,C117512,C117512,Standardized Name of Procedure,string,
2025-09-23,BPRS-Anchored - Anxiety,C100373,C100373,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Anxiety;BPRSA102;BPRS-Anchored - Anxiety,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Anxiety.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,BPRS-Anchored - Anxiety,C100373,C100373,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Anxiety;BPRSA102;BPRS-Anchored - Anxiety,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Anxiety.,,,,C46126,C46126,Ordinal Position,integer,1;2;3;4;5;6;7;9
2025-09-23,BPRS-Anchored - Anxiety,C100373,C100373,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Anxiety;BPRSA102;BPRS-Anchored - Anxiety,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Anxiety.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,"Not reported;Very Mild;Mild;Moderate;Moderately Severe;Severe;Very Severe;Cannot be assessed adequately because of severe formal thought disorder, uncooperativeness, or marked evasiveness/guardedness, or Not assessed"
2025-09-23,BPRS-Anchored - Anxiety,C100373,C100373,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Anxiety;BPRSA102;BPRS-Anchored - Anxiety,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Anxiety.,,,,C25372,C25372,Category,string,BPRS-A
2025-09-23,BPRS-Anchored - Anxiety,C100373,C100373,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Anxiety;BPRSA102;BPRS-Anchored - Anxiety,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Anxiety.,,,,C82534,C82534,Evaluation Interval,string,-P1W
2025-09-23,BPRS-Anchored - Blunted Affect,C100387,C100387,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Blunted Affect;BPRSA116;BPRS-Anchored - Blunted Affect,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Blunted affect.,,,,C25372,C25372,Category,string,BPRS-A
2025-09-23,BPRS-Anchored - Blunted Affect,C100387,C100387,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Blunted Affect;BPRSA116;BPRS-Anchored - Blunted Affect,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Blunted affect.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,BPRS-Anchored - Blunted Affect,C100387,C100387,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Blunted Affect;BPRSA116;BPRS-Anchored - Blunted Affect,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Blunted affect.,,,,C82534,C82534,Evaluation Interval,string,DURING INTERVIEW
2025-09-23,BPRS-Anchored - Blunted Affect,C100387,C100387,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Blunted Affect;BPRSA116;BPRS-Anchored - Blunted Affect,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Blunted affect.,,,,C46126,C46126,Ordinal Position,integer,1;2;3;4;5;6;7
2025-09-23,BPRS-Anchored - Blunted Affect,C100387,C100387,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Blunted Affect;BPRSA116;BPRS-Anchored - Blunted Affect,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Blunted affect.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,Not observed;Very Mild;Mild;Moderate;Moderately Severe;Severe;Very Severe
2025-09-23,BPRS-Anchored - Conceptual Disorganization,C100375,C100375,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Conceptual Disorganization;BPRSA104;BPRS-Anchored - Conceptual Disorganization,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Conceptual disorganization.,,,,C46126,C46126,Ordinal Position,integer,1;2;3;4;5;6;7
2025-09-23,BPRS-Anchored - Conceptual Disorganization,C100375,C100375,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Conceptual Disorganization;BPRSA104;BPRS-Anchored - Conceptual Disorganization,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Conceptual disorganization.,,,,C82534,C82534,Evaluation Interval,string,DURING INTERVIEW
2025-09-23,BPRS-Anchored - Conceptual Disorganization,C100375,C100375,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Conceptual Disorganization;BPRSA104;BPRS-Anchored - Conceptual Disorganization,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Conceptual disorganization.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,BPRS-Anchored - Conceptual Disorganization,C100375,C100375,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Conceptual Disorganization;BPRSA104;BPRS-Anchored - Conceptual Disorganization,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Conceptual disorganization.,,,,C25372,C25372,Category,string,BPRS-A
2025-09-23,BPRS-Anchored - Conceptual Disorganization,C100375,C100375,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Conceptual Disorganization;BPRSA104;BPRS-Anchored - Conceptual Disorganization,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Conceptual disorganization.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,Not observed;Very Mild;Mild;Moderate;Moderately Severe;Severe;Very Severe
2025-09-23,BPRS-Anchored - Depressive Mood,C100380,C100380,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Depressive Mood;BPRSA109;BPRS-Anchored - Depressive Mood,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Depressive mood.,,,,C46126,C46126,Ordinal Position,integer,1;2;3;4;5;6;7;9
2025-09-23,BPRS-Anchored - Depressive Mood,C100380,C100380,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Depressive Mood;BPRSA109;BPRS-Anchored - Depressive Mood,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Depressive mood.,,,,C25372,C25372,Category,string,BPRS-A
2025-09-23,BPRS-Anchored - Depressive Mood,C100380,C100380,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Depressive Mood;BPRSA109;BPRS-Anchored - Depressive Mood,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Depressive mood.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,"Not reported;Very Mild;Mild;Moderate;Moderately Severe;Severe;Very Severe;Cannot be assessed adequately because of severe formal thought disorder, uncooperativeness, or marked evasiveness/guardedness;or Not assessed"
2025-09-23,BPRS-Anchored - Depressive Mood,C100380,C100380,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Depressive Mood;BPRSA109;BPRS-Anchored - Depressive Mood,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Depressive mood.,,,,C82534,C82534,Evaluation Interval,string,-P1W
2025-09-23,BPRS-Anchored - Depressive Mood,C100380,C100380,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Depressive Mood;BPRSA109;BPRS-Anchored - Depressive Mood,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Depressive mood.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,BPRS-Anchored - Disorientation,C100389,C100389,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Disorientation;BPRSA118;BPRS-Anchored - Disorientation,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Disorientation.,,,,C82534,C82534,Evaluation Interval,string,DURING INTERVIEW
2025-09-23,BPRS-Anchored - Disorientation,C100389,C100389,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Disorientation;BPRSA118;BPRS-Anchored - Disorientation,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Disorientation.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,BPRS-Anchored - Disorientation,C100389,C100389,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Disorientation;BPRSA118;BPRS-Anchored - Disorientation,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Disorientation.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,"Not observed;Very Mild;Mild;Moderate;Moderately Severe;Severe;Very Severe;Cannot be assessed adequately because of severe formal thought disorder, uncooperativeness, or marked evasiveness/guardedness;or Not assessed"
2025-09-23,BPRS-Anchored - Disorientation,C100389,C100389,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Disorientation;BPRSA118;BPRS-Anchored - Disorientation,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Disorientation.,,,,C46126,C46126,Ordinal Position,integer,1;2;3;4;5;6;7;9
2025-09-23,BPRS-Anchored - Disorientation,C100389,C100389,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Disorientation;BPRSA118;BPRS-Anchored - Disorientation,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Disorientation.,,,,C25372,C25372,Category,string,BPRS-A
2025-09-23,BPRS-Anchored - Emotional Withdrawal,C100374,C100374,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Emotional Withdrawal;BPRSA103;BPRS-Anchored - Emotional Withdrawal,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Emotional withdrawal.,,,,C25372,C25372,Category,string,BPRS-A
2025-09-23,BPRS-Anchored - Emotional Withdrawal,C100374,C100374,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Emotional Withdrawal;BPRSA103;BPRS-Anchored - Emotional Withdrawal,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Emotional withdrawal.,,,,C82534,C82534,Evaluation Interval,string,DURING INTERVIEW
2025-09-23,BPRS-Anchored - Emotional Withdrawal,C100374,C100374,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Emotional Withdrawal;BPRSA103;BPRS-Anchored - Emotional Withdrawal,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Emotional withdrawal.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,BPRS-Anchored - Emotional Withdrawal,C100374,C100374,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Emotional Withdrawal;BPRSA103;BPRS-Anchored - Emotional Withdrawal,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Emotional withdrawal.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,Not observed;Very Mild;Mild;Moderate;Moderately Severe;Severe;Very Severe
2025-09-23,BPRS-Anchored - Emotional Withdrawal,C100374,C100374,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Emotional Withdrawal;BPRSA103;BPRS-Anchored - Emotional Withdrawal,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Emotional withdrawal.,,,,C46126,C46126,Ordinal Position,integer,1;2;3;4;5;6;7
2025-09-23,BPRS-Anchored - Excitement,C100388,C100388,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Excitement;BPRSA117;BPRS-Anchored - Excitement,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Excitement.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,BPRS-Anchored - Excitement,C100388,C100388,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Excitement;BPRSA117;BPRS-Anchored - Excitement,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Excitement.,,,,C25372,C25372,Category,string,BPRS-A
2025-09-23,BPRS-Anchored - Excitement,C100388,C100388,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Excitement;BPRSA117;BPRS-Anchored - Excitement,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Excitement.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,Not observed;Very Mild;Mild;Moderate;Moderately Severe;Severe;Very Severe
2025-09-23,BPRS-Anchored - Excitement,C100388,C100388,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Excitement;BPRSA117;BPRS-Anchored - Excitement,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Excitement.,,,,C46126,C46126,Ordinal Position,integer,1;2;3;4;5;6;7
2025-09-23,BPRS-Anchored - Excitement,C100388,C100388,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Excitement;BPRSA117;BPRS-Anchored - Excitement,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Excitement.,,,,C82534,C82534,Evaluation Interval,string,DURING INTERVIEW
2025-09-23,BPRS-Anchored - Grandiosity,C100379,C100379,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Grandiosity;BPRSA108;BPRS-Anchored - Grandiosity,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Grandiosity.,,,,C82534,C82534,Evaluation Interval,string,-P1W
2025-09-23,BPRS-Anchored - Grandiosity,C100379,C100379,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Grandiosity;BPRSA108;BPRS-Anchored - Grandiosity,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Grandiosity.,,,,C46126,C46126,Ordinal Position,integer,1;2;3;4;5;6;7;9
2025-09-23,BPRS-Anchored - Grandiosity,C100379,C100379,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Grandiosity;BPRSA108;BPRS-Anchored - Grandiosity,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Grandiosity.,,,,C25372,C25372,Category,string,BPRS-A
2025-09-23,BPRS-Anchored - Grandiosity,C100379,C100379,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Grandiosity;BPRSA108;BPRS-Anchored - Grandiosity,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Grandiosity.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,BPRS-Anchored - Grandiosity,C100379,C100379,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Grandiosity;BPRSA108;BPRS-Anchored - Grandiosity,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Grandiosity.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,"Not reported;Very Mild;Mild;Moderate;Moderately Severe;Severe;Very Severe;Cannot be assessed adequately because of severe formal thought disorder, uncooperativeness, or marked evasiveness/guardedness, or Not assessed"
2025-09-23,BPRS-Anchored - Guilt Feelings,C100376,C100376,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Guilt Feelings;BPRSA105;BPRS-Anchored - Guilt Feelings,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Guilt feelings.,,,,C82534,C82534,Evaluation Interval,string,-P1W
2025-09-23,BPRS-Anchored - Guilt Feelings,C100376,C100376,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Guilt Feelings;BPRSA105;BPRS-Anchored - Guilt Feelings,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Guilt feelings.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,BPRS-Anchored - Guilt Feelings,C100376,C100376,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Guilt Feelings;BPRSA105;BPRS-Anchored - Guilt Feelings,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Guilt feelings.,,,,C25372,C25372,Category,string,BPRS-A
2025-09-23,BPRS-Anchored - Guilt Feelings,C100376,C100376,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Guilt Feelings;BPRSA105;BPRS-Anchored - Guilt Feelings,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Guilt feelings.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,"Not reported;Very Mild;Mild;Moderate;Moderately Severe;Severe;Very Severe;Cannot be assessed adequately because of severe formal thought disorder, uncooperativeness, or marked evasiveness/guardedness, or Not assessed"
2025-09-23,BPRS-Anchored - Guilt Feelings,C100376,C100376,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Guilt Feelings;BPRSA105;BPRS-Anchored - Guilt Feelings,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Guilt feelings.,,,,C46126,C46126,Ordinal Position,integer,1;2;3;4;5;6;7;9
2025-09-23,BPRS-Anchored - Hallucinatory Behavior,C100383,C100383,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Hallucinatory Behavior;BPRSA112;BPRS-Anchored - Hallucinatory Behavior,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Hallucinatory behavior.,,,,C82534,C82534,Evaluation Interval,string,-P1W
2025-09-23,BPRS-Anchored - Hallucinatory Behavior,C100383,C100383,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Hallucinatory Behavior;BPRSA112;BPRS-Anchored - Hallucinatory Behavior,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Hallucinatory behavior.,,,,C25372,C25372,Category,string,BPRS-A
2025-09-23,BPRS-Anchored - Hallucinatory Behavior,C100383,C100383,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Hallucinatory Behavior;BPRSA112;BPRS-Anchored - Hallucinatory Behavior,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Hallucinatory behavior.,,,,C46126,C46126,Ordinal Position,integer,1;2;3;4;5;6;7;9
2025-09-23,BPRS-Anchored - Hallucinatory Behavior,C100383,C100383,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Hallucinatory Behavior;BPRSA112;BPRS-Anchored - Hallucinatory Behavior,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Hallucinatory behavior.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,"Not reported;Very Mild;Mild;Moderate;Moderately Severe;Severe;Very Severe;Cannot be assessed adequately because of severe formal thought disorder, uncooperativeness, or marked evasiveness/guardedness, or Not assessed"
2025-09-23,BPRS-Anchored - Hallucinatory Behavior,C100383,C100383,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Hallucinatory Behavior;BPRSA112;BPRS-Anchored - Hallucinatory Behavior,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Hallucinatory behavior.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,BPRS-Anchored - Hostility,C100381,C100381,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Hostility;BPRSA110;BPRS-Anchored - Hostility,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Hostility.,,,,C25372,C25372,Category,string,BPRS-A
2025-09-23,BPRS-Anchored - Hostility,C100381,C100381,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Hostility;BPRSA110;BPRS-Anchored - Hostility,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Hostility.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,"Not reported;Very Mild;Mild;Moderate;Moderately Severe;Severe;Very Severe;Cannot be assessed adequately because of severe formal thought disorder, uncooperativeness, or marked evasiveness/guardedness, or Not assessed"
2025-09-23,BPRS-Anchored - Hostility,C100381,C100381,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Hostility;BPRSA110;BPRS-Anchored - Hostility,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Hostility.,,,,C82534,C82534,Evaluation Interval,string,-P1W
2025-09-23,BPRS-Anchored - Hostility,C100381,C100381,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Hostility;BPRSA110;BPRS-Anchored - Hostility,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Hostility.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,BPRS-Anchored - Hostility,C100381,C100381,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Hostility;BPRSA110;BPRS-Anchored - Hostility,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Hostility.,,,,C46126,C46126,Ordinal Position,integer,1;2;3;4;5;6;7;9
2025-09-23,BPRS-Anchored - Mannerisms and Posturing,C100378,C100378,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Mannerisms and Posturing;BPRSA107;BPRS-Anchored - Mannerisms and Posturing,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Mannerisms and posturing.,,,,C46126,C46126,Ordinal Position,integer,1;2;3;4;5;6;7
2025-09-23,BPRS-Anchored - Mannerisms and Posturing,C100378,C100378,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Mannerisms and Posturing;BPRSA107;BPRS-Anchored - Mannerisms and Posturing,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Mannerisms and posturing.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,Not observed;Very Mild;Mild;Moderate;Moderately Severe;Severe;Very Severe
2025-09-23,BPRS-Anchored - Mannerisms and Posturing,C100378,C100378,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Mannerisms and Posturing;BPRSA107;BPRS-Anchored - Mannerisms and Posturing,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Mannerisms and posturing.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,BPRS-Anchored - Mannerisms and Posturing,C100378,C100378,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Mannerisms and Posturing;BPRSA107;BPRS-Anchored - Mannerisms and Posturing,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Mannerisms and posturing.,,,,C25372,C25372,Category,string,BPRS-A
2025-09-23,BPRS-Anchored - Motor Retardation,C100384,C100384,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Motor Retardation;BPRSA113;BPRS-Anchored - Motor Retardation,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Motor retardation.,,,,C46126,C46126,Ordinal Position,integer,1;2;3;4;5;6;7
2025-09-23,BPRS-Anchored - Motor Retardation,C100384,C100384,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Motor Retardation;BPRSA113;BPRS-Anchored - Motor Retardation,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Motor retardation.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,Not observed;Very Mild;Mild;Moderate;Moderately Severe;Severe;Very Severe
2025-09-23,BPRS-Anchored - Motor Retardation,C100384,C100384,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Motor Retardation;BPRSA113;BPRS-Anchored - Motor Retardation,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Motor retardation.,,,,C25372,C25372,Category,string,BPRS-A
2025-09-23,BPRS-Anchored - Motor Retardation,C100384,C100384,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Motor Retardation;BPRSA113;BPRS-Anchored - Motor Retardation,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Motor retardation.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,BPRS-Anchored - Somatic Concern,C100372,C100372,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Somatic Concern;BPRSA101;BPRS-Anchored - Somatic Concern,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Somatic concern.,,,,C82534,C82534,Evaluation Interval,string,-P1W
2025-09-23,BPRS-Anchored - Somatic Concern,C100372,C100372,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Somatic Concern;BPRSA101;BPRS-Anchored - Somatic Concern,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Somatic concern.,,,,C25372,C25372,Category,string,BPRS-A
2025-09-23,BPRS-Anchored - Somatic Concern,C100372,C100372,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Somatic Concern;BPRSA101;BPRS-Anchored - Somatic Concern,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Somatic concern.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,BPRS-Anchored - Somatic Concern,C100372,C100372,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Somatic Concern;BPRSA101;BPRS-Anchored - Somatic Concern,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Somatic concern.,,,,C46126,C46126,Ordinal Position,integer,1;2;3;4;5;6;7;9
2025-09-23,BPRS-Anchored - Somatic Concern,C100372,C100372,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Somatic Concern;BPRSA101;BPRS-Anchored - Somatic Concern,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Somatic concern.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,"Not reported;Very Mild;Mild;Moderate;Moderately Severe;Severe;Very Severe;Cannot be assessed adequately because of severe formal thought disorder, uncooperativeness, or marked evasiveness/guardedness, or Not assessed"
2025-09-23,BPRS-Anchored - Suspiciousness,C100382,C100382,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Suspiciousness;BPRSA111;BPRS-Anchored - Suspiciousness,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Suspiciousness.,,,,C25372,C25372,Category,string,BPRS-A
2025-09-23,BPRS-Anchored - Suspiciousness,C100382,C100382,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Suspiciousness;BPRSA111;BPRS-Anchored - Suspiciousness,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Suspiciousness.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,"Not reported;Very Mild;Mild;Moderate;Moderately Severe;Severe;Very Severe;Cannot be assessed adequately because of severe formal thought disorder, uncooperativeness, or marked evasiveness/guardedness, or Not assessed"
2025-09-23,BPRS-Anchored - Suspiciousness,C100382,C100382,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Suspiciousness;BPRSA111;BPRS-Anchored - Suspiciousness,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Suspiciousness.,,,,C46126,C46126,Ordinal Position,integer,1;2;3;4;5;6;7;9
2025-09-23,BPRS-Anchored - Suspiciousness,C100382,C100382,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Suspiciousness;BPRSA111;BPRS-Anchored - Suspiciousness,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Suspiciousness.,,,,C82534,C82534,Evaluation Interval,string,-P1W
2025-09-23,BPRS-Anchored - Suspiciousness,C100382,C100382,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Suspiciousness;BPRSA111;BPRS-Anchored - Suspiciousness,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Suspiciousness.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,BPRS-Anchored - Tension,C100377,C100377,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Tension;BPRSA106;BPRS-Anchored - Tension,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Tension.,,,,C46126,C46126,Ordinal Position,integer,1;2;3;4;5;6;7
2025-09-23,BPRS-Anchored - Tension,C100377,C100377,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Tension;BPRSA106;BPRS-Anchored - Tension,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Tension.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,Not observed;Very Mild;Mild;Moderate;Moderately Severe;Severe;Very Severe
2025-09-23,BPRS-Anchored - Tension,C100377,C100377,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Tension;BPRSA106;BPRS-Anchored - Tension,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Tension.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,BPRS-Anchored - Tension,C100377,C100377,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Tension;BPRSA106;BPRS-Anchored - Tension,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Tension.,,,,C82534,C82534,Evaluation Interval,string,DURING INTERVIEW
2025-09-23,BPRS-Anchored - Tension,C100377,C100377,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Tension;BPRSA106;BPRS-Anchored - Tension,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Tension.,,,,C25372,C25372,Category,string,BPRS-A
2025-09-23,BPRS-Anchored - Uncooperativeness,C100385,C100385,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Uncooperativeness;BPRSA114;BPRS-Anchored - Uncooperativeness,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Uncooperativeness.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,BPRS-Anchored - Uncooperativeness,C100385,C100385,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Uncooperativeness;BPRSA114;BPRS-Anchored - Uncooperativeness,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Uncooperativeness.,,,,C82534,C82534,Evaluation Interval,string,DURING INTERVIEW
2025-09-23,BPRS-Anchored - Uncooperativeness,C100385,C100385,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Uncooperativeness;BPRSA114;BPRS-Anchored - Uncooperativeness,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Uncooperativeness.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,Not observed;Very Mild;Mild;Moderate;Moderately Severe;Severe;Very Severe
2025-09-23,BPRS-Anchored - Uncooperativeness,C100385,C100385,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Uncooperativeness;BPRSA114;BPRS-Anchored - Uncooperativeness,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Uncooperativeness.,,,,C25372,C25372,Category,string,BPRS-A
2025-09-23,BPRS-Anchored - Uncooperativeness,C100385,C100385,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Uncooperativeness;BPRSA114;BPRS-Anchored - Uncooperativeness,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Uncooperativeness.,,,,C46126,C46126,Ordinal Position,integer,1;2;3;4;5;6;7
2025-09-23,BPRS-Anchored - Unusual Thought Content,C100386,C100386,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Unusual Thought Content;BPRSA115;BPRS-Anchored - Unusual Thought Content,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Unusual thought content.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,BPRS-Anchored - Unusual Thought Content,C100386,C100386,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Unusual Thought Content;BPRSA115;BPRS-Anchored - Unusual Thought Content,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Unusual thought content.,,,,C82534,C82534,Evaluation Interval,string,-P1W
2025-09-23,BPRS-Anchored - Unusual Thought Content,C100386,C100386,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Unusual Thought Content;BPRSA115;BPRS-Anchored - Unusual Thought Content,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Unusual thought content.,,,,C25372,C25372,Category,string,BPRS-A
2025-09-23,BPRS-Anchored - Unusual Thought Content,C100386,C100386,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Unusual Thought Content;BPRSA115;BPRS-Anchored - Unusual Thought Content,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Unusual thought content.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,"Not reported;Very Mild;Mild;Moderate;Moderately Severe;Severe;Very Severe;Cannot be assessed adequately because of severe formal thought disorder, uncooperativeness, or marked evasiveness/guardedness, or Not assessed"
2025-09-23,BPRS-Anchored - Unusual Thought Content,C100386,C100386,C100109,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRSA1-Unusual Thought Content;BPRSA115;BPRS-Anchored - Unusual Thought Content,Ordinal,Brief Psychiatric Rating Scale-Anchored (BPRS-A) Unusual thought content.,,,,C46126,C46126,Ordinal Position,integer,1;2;3;4;5;6;7;9
2025-09-23,BPRS-Anchored Clinical Classification Question,C100109,C100109,C211913,QRS Instrument Questions,,,A question associated with the BPRS-Anchored clinical classification.,,,,,,,,
2025-09-23,BRCA Mutation Analysis,C146692,C146692,C18302,Genetic Testing;Gene Expression Analysis;Genetic Variation Analysis;Molecular Analysis;Genetic Molecular Analysis,BRCA Mutation Status;BRCA Family Gene Mutation Analysis,Ordinal,A procedure to test for the presence of mutations in BRCA family genes.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,BRCA Mutation Analysis,C146692,C146692,C18302,Genetic Testing;Gene Expression Analysis;Genetic Variation Analysis;Molecular Analysis;Genetic Molecular Analysis,BRCA Mutation Status;BRCA Family Gene Mutation Analysis,Ordinal,A procedure to test for the presence of mutations in BRCA family genes.,,,,C70856,C70856,Observation Result,string,Positive;Negative
2025-09-23,BRCA Mutation Analysis,C146692,C146692,C18302,Genetic Testing;Gene Expression Analysis;Genetic Variation Analysis;Molecular Analysis;Genetic Molecular Analysis,BRCA Mutation Status;BRCA Family Gene Mutation Analysis,Ordinal,A procedure to test for the presence of mutations in BRCA family genes.,,,,C25692,C25692,Subcategory,string,
2025-09-23,BRCA Mutation Analysis,C146692,C146692,C18302,Genetic Testing;Gene Expression Analysis;Genetic Variation Analysis;Molecular Analysis;Genetic Molecular Analysis,BRCA Mutation Status;BRCA Family Gene Mutation Analysis,Ordinal,A procedure to test for the presence of mutations in BRCA family genes.,,,,C25372,C25372,Category,string,
2025-09-23,BRCA Mutation Analysis,C146692,C146692,C18302,Genetic Testing;Gene Expression Analysis;Genetic Variation Analysis;Molecular Analysis;Genetic Molecular Analysis,BRCA Mutation Status;BRCA Family Gene Mutation Analysis,Ordinal,A procedure to test for the presence of mutations in BRCA family genes.,,,,C171435,C171435,Specimen Anatomic Site,string,
2025-09-23,BRCA Mutation Analysis,C146692,C146692,C18302,Genetic Testing;Gene Expression Analysis;Genetic Variation Analysis;Molecular Analysis;Genetic Molecular Analysis,BRCA Mutation Status;BRCA Family Gene Mutation Analysis,Ordinal,A procedure to test for the presence of mutations in BRCA family genes.,,,,C70713,C70713,Biospecimen Type,string,Blood;Saliva;Tissue
2025-09-23,BRCA Mutation Analysis,C146692,C146692,C18302,Genetic Testing;Gene Expression Analysis;Genetic Variation Analysis;Molecular Analysis;Genetic Molecular Analysis,BRCA Mutation Status;BRCA Family Gene Mutation Analysis,Ordinal,A procedure to test for the presence of mutations in BRCA family genes.,,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Overall Status
2025-09-23,BRCA1 Gene Mutation,C19635,C19635,C159204,Genetic Testing;Gene Expression Analysis;Molecular Analysis;Molecular Genetic Variation;Gene Abnormality,BRCA1;BRCA1 Mutation;Breast Cancer 1 Gene Mutation;BROVCA1 Gene Mutation;Mutation of the BRCA1 Gene,Ordinal,"A mutation that is typically a heritable, permanent change in the nucleotide sequence of the BRCA1 gene. Single nucleotide substitutions and small deletions or insertions (1-20 bases) account for the majority of mutations in the BRCA1 gene. Approximately 75% of these alterations result in a truncated form of the breast cancer type 1 susceptibility protein. Mutations in the BRCA1 gene predispose individuals to breast and ovarian cancers.",,,,C25692,C25692,Subcategory,string,
2025-09-23,BRCA1 Gene Mutation,C19635,C19635,C159204,Genetic Testing;Gene Expression Analysis;Molecular Analysis;Molecular Genetic Variation;Gene Abnormality,BRCA1;BRCA1 Mutation;Breast Cancer 1 Gene Mutation;BROVCA1 Gene Mutation;Mutation of the BRCA1 Gene,Ordinal,"A mutation that is typically a heritable, permanent change in the nucleotide sequence of the BRCA1 gene. Single nucleotide substitutions and small deletions or insertions (1-20 bases) account for the majority of mutations in the BRCA1 gene. Approximately 75% of these alterations result in a truncated form of the breast cancer type 1 susceptibility protein. Mutations in the BRCA1 gene predispose individuals to breast and ovarian cancers.",,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,BRCA1 Gene Mutation,C19635,C19635,C159204,Genetic Testing;Gene Expression Analysis;Molecular Analysis;Molecular Genetic Variation;Gene Abnormality,BRCA1;BRCA1 Mutation;Breast Cancer 1 Gene Mutation;BROVCA1 Gene Mutation;Mutation of the BRCA1 Gene,Ordinal,"A mutation that is typically a heritable, permanent change in the nucleotide sequence of the BRCA1 gene. Single nucleotide substitutions and small deletions or insertions (1-20 bases) account for the majority of mutations in the BRCA1 gene. Approximately 75% of these alterations result in a truncated form of the breast cancer type 1 susceptibility protein. Mutations in the BRCA1 gene predispose individuals to breast and ovarian cancers.",,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Overall Status
2025-09-23,BRCA1 Gene Mutation,C19635,C19635,C159204,Genetic Testing;Gene Expression Analysis;Molecular Analysis;Molecular Genetic Variation;Gene Abnormality,BRCA1;BRCA1 Mutation;Breast Cancer 1 Gene Mutation;BROVCA1 Gene Mutation;Mutation of the BRCA1 Gene,Ordinal,"A mutation that is typically a heritable, permanent change in the nucleotide sequence of the BRCA1 gene. Single nucleotide substitutions and small deletions or insertions (1-20 bases) account for the majority of mutations in the BRCA1 gene. Approximately 75% of these alterations result in a truncated form of the breast cancer type 1 susceptibility protein. Mutations in the BRCA1 gene predispose individuals to breast and ovarian cancers.",,,,C25372,C25372,Category,string,
2025-09-23,BRCA1 Gene Mutation,C19635,C19635,C159204,Genetic Testing;Gene Expression Analysis;Molecular Analysis;Molecular Genetic Variation;Gene Abnormality,BRCA1;BRCA1 Mutation;Breast Cancer 1 Gene Mutation;BROVCA1 Gene Mutation;Mutation of the BRCA1 Gene,Ordinal,"A mutation that is typically a heritable, permanent change in the nucleotide sequence of the BRCA1 gene. Single nucleotide substitutions and small deletions or insertions (1-20 bases) account for the majority of mutations in the BRCA1 gene. Approximately 75% of these alterations result in a truncated form of the breast cancer type 1 susceptibility protein. Mutations in the BRCA1 gene predispose individuals to breast and ovarian cancers.",,,,C70856,C70856,Observation Result,string,Present;Absent
2025-09-23,BRCA1 Gene Mutation,C19635,C19635,C159204,Genetic Testing;Gene Expression Analysis;Molecular Analysis;Molecular Genetic Variation;Gene Abnormality,BRCA1;BRCA1 Mutation;Breast Cancer 1 Gene Mutation;BROVCA1 Gene Mutation;Mutation of the BRCA1 Gene,Ordinal,"A mutation that is typically a heritable, permanent change in the nucleotide sequence of the BRCA1 gene. Single nucleotide substitutions and small deletions or insertions (1-20 bases) account for the majority of mutations in the BRCA1 gene. Approximately 75% of these alterations result in a truncated form of the breast cancer type 1 susceptibility protein. Mutations in the BRCA1 gene predispose individuals to breast and ovarian cancers.",,,,C70713,C70713,Biospecimen Type,string,Blood;Saliva;Tissue
2025-09-23,BRCA1 Gene Mutation,C19635,C19635,C159204,Genetic Testing;Gene Expression Analysis;Molecular Analysis;Molecular Genetic Variation;Gene Abnormality,BRCA1;BRCA1 Mutation;Breast Cancer 1 Gene Mutation;BROVCA1 Gene Mutation;Mutation of the BRCA1 Gene,Ordinal,"A mutation that is typically a heritable, permanent change in the nucleotide sequence of the BRCA1 gene. Single nucleotide substitutions and small deletions or insertions (1-20 bases) account for the majority of mutations in the BRCA1 gene. Approximately 75% of these alterations result in a truncated form of the breast cancer type 1 susceptibility protein. Mutations in the BRCA1 gene predispose individuals to breast and ovarian cancers.",,,,C171435,C171435,Specimen Anatomic Site,string,
2025-09-23,BRCA2 Gene Mutation,C19636,C19636,C159204,Genetic Testing;Gene Expression Analysis;Molecular Analysis;Molecular Genetic Variation;Gene Abnormality,BRCA2;BRCA2 Mutation;Breast Cancer 2 Gene Mutation;BROVCA2 Gene Mutation;Mutation of the BRCA2 Gene;XRCC11 Gene Mutation;BRCC2 Gene Mutation;FANCD1 Gene Mutation,Ordinal,"A mutation that is typically a heritable, permanent change in the nucleotide sequence of the BRCA2 gene. Single nucleotide substitutions and small deletions or insertions (1-20 bases) account for the majority of mutations in the BRCA2 gene. Most of these alterations result in a truncated form of the breast cancer type 2 susceptibility protein. Mutations in the BRCA2 gene predispose males to breast cancer.",,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,BRCA2 Gene Mutation,C19636,C19636,C159204,Genetic Testing;Gene Expression Analysis;Molecular Analysis;Molecular Genetic Variation;Gene Abnormality,BRCA2;BRCA2 Mutation;Breast Cancer 2 Gene Mutation;BROVCA2 Gene Mutation;Mutation of the BRCA2 Gene;XRCC11 Gene Mutation;BRCC2 Gene Mutation;FANCD1 Gene Mutation,Ordinal,"A mutation that is typically a heritable, permanent change in the nucleotide sequence of the BRCA2 gene. Single nucleotide substitutions and small deletions or insertions (1-20 bases) account for the majority of mutations in the BRCA2 gene. Most of these alterations result in a truncated form of the breast cancer type 2 susceptibility protein. Mutations in the BRCA2 gene predispose males to breast cancer.",,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Overall Status
2025-09-23,BRCA2 Gene Mutation,C19636,C19636,C159204,Genetic Testing;Gene Expression Analysis;Molecular Analysis;Molecular Genetic Variation;Gene Abnormality,BRCA2;BRCA2 Mutation;Breast Cancer 2 Gene Mutation;BROVCA2 Gene Mutation;Mutation of the BRCA2 Gene;XRCC11 Gene Mutation;BRCC2 Gene Mutation;FANCD1 Gene Mutation,Ordinal,"A mutation that is typically a heritable, permanent change in the nucleotide sequence of the BRCA2 gene. Single nucleotide substitutions and small deletions or insertions (1-20 bases) account for the majority of mutations in the BRCA2 gene. Most of these alterations result in a truncated form of the breast cancer type 2 susceptibility protein. Mutations in the BRCA2 gene predispose males to breast cancer.",,,,C70856,C70856,Observation Result,string,Present;Absent
2025-09-23,BRCA2 Gene Mutation,C19636,C19636,C159204,Genetic Testing;Gene Expression Analysis;Molecular Analysis;Molecular Genetic Variation;Gene Abnormality,BRCA2;BRCA2 Mutation;Breast Cancer 2 Gene Mutation;BROVCA2 Gene Mutation;Mutation of the BRCA2 Gene;XRCC11 Gene Mutation;BRCC2 Gene Mutation;FANCD1 Gene Mutation,Ordinal,"A mutation that is typically a heritable, permanent change in the nucleotide sequence of the BRCA2 gene. Single nucleotide substitutions and small deletions or insertions (1-20 bases) account for the majority of mutations in the BRCA2 gene. Most of these alterations result in a truncated form of the breast cancer type 2 susceptibility protein. Mutations in the BRCA2 gene predispose males to breast cancer.",,,,C70713,C70713,Biospecimen Type,string,Blood;Saliva;Tissue
2025-09-23,BRCA2 Gene Mutation,C19636,C19636,C159204,Genetic Testing;Gene Expression Analysis;Molecular Analysis;Molecular Genetic Variation;Gene Abnormality,BRCA2;BRCA2 Mutation;Breast Cancer 2 Gene Mutation;BROVCA2 Gene Mutation;Mutation of the BRCA2 Gene;XRCC11 Gene Mutation;BRCC2 Gene Mutation;FANCD1 Gene Mutation,Ordinal,"A mutation that is typically a heritable, permanent change in the nucleotide sequence of the BRCA2 gene. Single nucleotide substitutions and small deletions or insertions (1-20 bases) account for the majority of mutations in the BRCA2 gene. Most of these alterations result in a truncated form of the breast cancer type 2 susceptibility protein. Mutations in the BRCA2 gene predispose males to breast cancer.",,,,C25692,C25692,Subcategory,string,
2025-09-23,BRCA2 Gene Mutation,C19636,C19636,C159204,Genetic Testing;Gene Expression Analysis;Molecular Analysis;Molecular Genetic Variation;Gene Abnormality,BRCA2;BRCA2 Mutation;Breast Cancer 2 Gene Mutation;BROVCA2 Gene Mutation;Mutation of the BRCA2 Gene;XRCC11 Gene Mutation;BRCC2 Gene Mutation;FANCD1 Gene Mutation,Ordinal,"A mutation that is typically a heritable, permanent change in the nucleotide sequence of the BRCA2 gene. Single nucleotide substitutions and small deletions or insertions (1-20 bases) account for the majority of mutations in the BRCA2 gene. Most of these alterations result in a truncated form of the breast cancer type 2 susceptibility protein. Mutations in the BRCA2 gene predispose males to breast cancer.",,,,C25372,C25372,Category,string,
2025-09-23,BRCA2 Gene Mutation,C19636,C19636,C159204,Genetic Testing;Gene Expression Analysis;Molecular Analysis;Molecular Genetic Variation;Gene Abnormality,BRCA2;BRCA2 Mutation;Breast Cancer 2 Gene Mutation;BROVCA2 Gene Mutation;Mutation of the BRCA2 Gene;XRCC11 Gene Mutation;BRCC2 Gene Mutation;FANCD1 Gene Mutation,Ordinal,"A mutation that is typically a heritable, permanent change in the nucleotide sequence of the BRCA2 gene. Single nucleotide substitutions and small deletions or insertions (1-20 bases) account for the majority of mutations in the BRCA2 gene. Most of these alterations result in a truncated form of the breast cancer type 2 susceptibility protein. Mutations in the BRCA2 gene predispose males to breast cancer.",,,,C171435,C171435,Specimen Anatomic Site,string,
2025-09-23,Biopsy Procedure,C15189,C15189,C18020,Diagnostic Procedures;Biopsies,Bx,Nominal,"The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis.",,,,C54215,C54215,Directionality,string,
2025-09-23,Biopsy Procedure,C15189,C15189,C18020,Diagnostic Procedures;Biopsies,Bx,Nominal,"The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis.",,,,C171435,C171435,Specimen Anatomic Site,string,Liver;Lung;Breast
2025-09-23,Biopsy Procedure,C15189,C15189,C18020,Diagnostic Procedures;Biopsies,Bx,Nominal,"The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis.",,,,C117511,C117511,Reported Name of Procedure,string,
2025-09-23,Biopsy Procedure,C15189,C15189,C18020,Diagnostic Procedures;Biopsies,Bx,Nominal,"The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis.",,,,C117512,C117512,Standardized Name of Procedure,string,
2025-09-23,Biopsy Procedure,C15189,C15189,C18020,Diagnostic Procedures;Biopsies,Bx,Nominal,"The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis.",,,,C25372,C25372,Category,string,
2025-09-23,Biopsy Procedure,C15189,C15189,C18020,Diagnostic Procedures;Biopsies,Bx,Nominal,"The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis.",,,,C117529,C117529,Start Date and Time of Procedure,datetime,
2025-09-23,Biopsy Procedure,C15189,C15189,C18020,Diagnostic Procedures;Biopsies,Bx,Nominal,"The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis.",,,,C25185,C25185,Laterality,string,
2025-09-23,Biopsy Procedure,C15189,C15189,C18020,Diagnostic Procedures;Biopsies,Bx,Nominal,"The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis.",,,,C25692,C25692,Subcategory,string,
2025-09-23,Biopsy Procedure,C15189,C15189,C18020,Diagnostic Procedures;Biopsies,Bx,Nominal,"The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis.",,,,C171000,C171000,Prespecified Event or Intervention Indicator,boolean,Y;N
2025-09-23,Biopsy Procedure,C15189,C15189,C18020,Diagnostic Procedures;Biopsies,Bx,Nominal,"The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis.",,,,C127786,C127786,Occurrence Indicator,boolean,Y;N
2025-09-23,Biopsy Procedure,C15189,C15189,C18020,Diagnostic Procedures;Biopsies,Bx,Nominal,"The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis.",,,,C117530,C117530,End Date and Time of Procedure,datetime,
2025-09-23,Biopsy Procedure by Anatomic Location,C217124,C217124,,Diagnostic Procedures;Biopsies,,,A classification of biopsy procedures based on anatomic location.,,,,,,,,
2025-09-23,Brachytherapy,C15195,C15195,C15313,Procedures;Radiotherapy,Internal Radiation;Internal Radiation Brachytherapy,Nominal,"A type of radiation therapy in which radioactive material is placed inside the body, into a tumor or body cavity.",,,,C117511,C117511,Reported Name of Procedure,string,Brachytherapy
2025-09-23,Brachytherapy,C15195,C15195,C15313,Procedures;Radiotherapy,Internal Radiation;Internal Radiation Brachytherapy,Nominal,"A type of radiation therapy in which radioactive material is placed inside the body, into a tumor or body cavity.",,,,C25372,C25372,Category,string,
2025-09-23,Brachytherapy,C15195,C15195,C15313,Procedures;Radiotherapy,Internal Radiation;Internal Radiation Brachytherapy,Nominal,"A type of radiation therapy in which radioactive material is placed inside the body, into a tumor or body cavity.",,,,C25185,C25185,Laterality,string,Left;Right;Bilateral
2025-09-23,Brachytherapy,C15195,C15195,C15313,Procedures;Radiotherapy,Internal Radiation;Internal Radiation Brachytherapy,Nominal,"A type of radiation therapy in which radioactive material is placed inside the body, into a tumor or body cavity.",,,,C13717,C13717,Anatomic Site,string,
2025-09-23,Brachytherapy,C15195,C15195,C15313,Procedures;Radiotherapy,Internal Radiation;Internal Radiation Brachytherapy,Nominal,"A type of radiation therapy in which radioactive material is placed inside the body, into a tumor or body cavity.",,,,C127786,C127786,Occurrence Indicator,boolean,Y;N
2025-09-23,Brachytherapy,C15195,C15195,C15313,Procedures;Radiotherapy,Internal Radiation;Internal Radiation Brachytherapy,Nominal,"A type of radiation therapy in which radioactive material is placed inside the body, into a tumor or body cavity.",,,,C25692,C25692,Subcategory,string,
2025-09-23,Brachytherapy,C15195,C15195,C15313,Procedures;Radiotherapy,Internal Radiation;Internal Radiation Brachytherapy,Nominal,"A type of radiation therapy in which radioactive material is placed inside the body, into a tumor or body cavity.",,,,C117530,C117530,End Date and Time of Procedure,datetime,
2025-09-23,Brachytherapy,C15195,C15195,C15313,Procedures;Radiotherapy,Internal Radiation;Internal Radiation Brachytherapy,Nominal,"A type of radiation therapy in which radioactive material is placed inside the body, into a tumor or body cavity.",,,,C117529,C117529,Start Date and Time of Procedure,datetime,
2025-09-23,Brachytherapy,C15195,C15195,C15313,Procedures;Radiotherapy,Internal Radiation;Internal Radiation Brachytherapy,Nominal,"A type of radiation therapy in which radioactive material is placed inside the body, into a tumor or body cavity.",,,,C171000,C171000,Prespecified Event or Intervention Indicator,boolean,Y;N
2025-09-23,Brachytherapy,C15195,C15195,C15313,Procedures;Radiotherapy,Internal Radiation;Internal Radiation Brachytherapy,Nominal,"A type of radiation therapy in which radioactive material is placed inside the body, into a tumor or body cavity.",,,,C117512,C117512,Standardized Name of Procedure,string,
2025-09-23,Breast Cancer by AJCC v8 Anatomic Stage,C139533,C139533,C139532,Staging;Breast Cancer,Breast Carcinoma by AJCC v8 Anatomic Stage;TNM Staging,Ordinal,"A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. This staging system should only be used in global regions where biomarker tests are not routinely available. (from AJCC 8th Ed.)",,,,C25372,C25372,Category,string,
2025-09-23,Breast Cancer by AJCC v8 Anatomic Stage,C139533,C139533,C139532,Staging;Breast Cancer,Breast Carcinoma by AJCC v8 Anatomic Stage;TNM Staging,Ordinal,"A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. This staging system should only be used in global regions where biomarker tests are not routinely available. (from AJCC 8th Ed.)",,,,C25692,C25692,Subcategory,string,
2025-09-23,Breast Cancer by AJCC v8 Anatomic Stage,C139533,C139533,C139532,Staging;Breast Cancer,Breast Carcinoma by AJCC v8 Anatomic Stage;TNM Staging,Ordinal,"A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. This staging system should only be used in global regions where biomarker tests are not routinely available. (from AJCC 8th Ed.)",,,,C70856,C70856,Observation Result,string,Stage 0;Stage I;Stage II;Stage III;Stage IV
2025-09-23,Breast Cancer by AJCC v8 Anatomic Stage,C139533,C139533,C139532,Staging;Breast Cancer,Breast Carcinoma by AJCC v8 Anatomic Stage;TNM Staging,Ordinal,"A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. This staging system should only be used in global regions where biomarker tests are not routinely available. (from AJCC 8th Ed.)",,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Breast Cancer by AJCC v8 Prognostic Stage,C139554,C139554,C139532,Staging;Breast Cancer,Breast Carcinoma by AJCC v8 Prognostic Stage;Breast Cancer by AJCC v8 Prognostic Stage Group;TNM Staging,Ordinal,"A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. This staging system should be used in countries where HER2, ER, and PR biomarker tests are routinely performed for patient care (U.S., Canada, etc.). (from AJCC 8th Ed.)",,,,C25692,C25692,Subcategory,string,
2025-09-23,Breast Cancer by AJCC v8 Prognostic Stage,C139554,C139554,C139532,Staging;Breast Cancer,Breast Carcinoma by AJCC v8 Prognostic Stage;Breast Cancer by AJCC v8 Prognostic Stage Group;TNM Staging,Ordinal,"A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. This staging system should be used in countries where HER2, ER, and PR biomarker tests are routinely performed for patient care (U.S., Canada, etc.). (from AJCC 8th Ed.)",,,,C25372,C25372,Category,string,
2025-09-23,Breast Cancer by AJCC v8 Prognostic Stage,C139554,C139554,C139532,Staging;Breast Cancer,Breast Carcinoma by AJCC v8 Prognostic Stage;Breast Cancer by AJCC v8 Prognostic Stage Group;TNM Staging,Ordinal,"A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. This staging system should be used in countries where HER2, ER, and PR biomarker tests are routinely performed for patient care (U.S., Canada, etc.). (from AJCC 8th Ed.)",,,,C70856,C70856,Observation Result,string,Stage 0;Stage I;Stage II;Stage III;Stage IV
2025-09-23,Breast Cancer by AJCC v8 Prognostic Stage,C139554,C139554,C139532,Staging;Breast Cancer,Breast Carcinoma by AJCC v8 Prognostic Stage;Breast Cancer by AJCC v8 Prognostic Stage Group;TNM Staging,Ordinal,"A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. This staging system should be used in countries where HER2, ER, and PR biomarker tests are routinely performed for patient care (U.S., Canada, etc.). (from AJCC 8th Ed.)",,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Breast Cancer by AJCC v8 Stage,C139532,C139532,C4872,Staging;Breast Cancer,Breast Carcinoma by AJCC v8 Stage;TNM Staging,Ordinal,"A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. It applies to invasive (infiltrating) carcinoma of the breast and ductal carcinoma in situ of the breast. It does not apply to breast sarcoma, phyllodes tumor, and breast lymphoma. (from AJCC 8th Ed.)",,,,C25372,C25372,Category,string,
2025-09-23,Breast Cancer by AJCC v8 Stage,C139532,C139532,C4872,Staging;Breast Cancer,Breast Carcinoma by AJCC v8 Stage;TNM Staging,Ordinal,"A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. It applies to invasive (infiltrating) carcinoma of the breast and ductal carcinoma in situ of the breast. It does not apply to breast sarcoma, phyllodes tumor, and breast lymphoma. (from AJCC 8th Ed.)",,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Breast Cancer by AJCC v8 Stage,C139532,C139532,C4872,Staging;Breast Cancer,Breast Carcinoma by AJCC v8 Stage;TNM Staging,Ordinal,"A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. It applies to invasive (infiltrating) carcinoma of the breast and ductal carcinoma in situ of the breast. It does not apply to breast sarcoma, phyllodes tumor, and breast lymphoma. (from AJCC 8th Ed.)",,,,C25692,C25692,Subcategory,string,
2025-09-23,Breast Cancer by AJCC v8 Stage,C139532,C139532,C4872,Staging;Breast Cancer,Breast Carcinoma by AJCC v8 Stage;TNM Staging,Ordinal,"A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. It applies to invasive (infiltrating) carcinoma of the breast and ductal carcinoma in situ of the breast. It does not apply to breast sarcoma, phyllodes tumor, and breast lymphoma. (from AJCC 8th Ed.)",,,,C70856,C70856,Observation Result,string,Stage 0;Stage I;Stage II;Stage III;Stage IV
2025-09-23,Breast Carcinoma,C4872,C4872,,Cancer;Carcinoma,Cancer of the Breast,,"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.",,,,,,,,
2025-09-23,Breast Conservation Treatment,C15280,C15280,,Surgeries;Procedures,,,"Breast conservation treatment is defined as excision of the primary tumor and adjacent breast tissue, followed by radiation therapy.  This procedure is also referred to as lumpectomy, segmental mastectomy, or partial mastectomy. (from Consensus Statements: Treatment of Early-stage Breast Cancer, 1990)",,,,,,,,
2025-09-23,Breast Surgery,C157802,C157802,,Surgeries,,,A surgical procedure on the breast.,,,,,,,,
2025-09-23,Brief Psychiatric Rating Scale A Clinical Classification,C100761,C100761,C118969,QRS;Clinical or Research Assessment Classification;Brief Psychiatric Rating Scale A Clinical Classification;BPRS-A;BPRSA1;BPRS-Anchored Clinical Classification Question,BPRS-A;BPRSA1;Brief Psychiatric Rating Scale - Anchored,,"A standardized rating scale originally developed by Margaret G. Woerner, Salvatore Mannuzza and John M. Kane in 1988 which is used to evaluate the severity of an individual's psychiatric symptoms. This version consists of 18 questions or types of psychiatric symptoms such as depression, anxiety, hallucinations, motor skills, or other unusual behaviors and is completed during a semi-structured interview. Each symptom is rated on a scale of 1-7 or 1-9 with 1 being non-existent and 7 being very severe; 9 represents 'can not be assessed'.",,,,,,,,
2025-09-23,CDISC ADAS-Cog - Total Score,C208544,C208544,C100106,QRS;ADAS-Cog;Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version),ADCTS;CDISC ADAS-Cog - Total Score;Total Score,Ordinal,Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Total score.,,,,C25372,C25372,Category,string,ADAS-COG
2025-09-23,CDISC ADAS-Cog - Total Score,C208544,C208544,C100106,QRS;ADAS-Cog;Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version),ADCTS;CDISC ADAS-Cog - Total Score;Total Score,Ordinal,Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Total score.,,,,C25692,C25692,Subcategory,string,
2025-09-23,CDISC ADAS-Cog - Total Score,C208544,C208544,C100106,QRS;ADAS-Cog;Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version),ADCTS;CDISC ADAS-Cog - Total Score;Total Score,Ordinal,Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Total score.,,,,C41202,C41202,Completion Status,string,Not Done
2025-09-23,CDISC ADAS-Cog - Total Score,C208544,C208544,C100106,QRS;ADAS-Cog;Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version),ADCTS;CDISC ADAS-Cog - Total Score;Total Score,Ordinal,Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Total score.,,,,C46126,C46126,Ordinal Position,decimal,
2025-09-23,CDISC ADAS-Cog - Total Score,C208544,C208544,C100106,QRS;ADAS-Cog;Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version),ADCTS;CDISC ADAS-Cog - Total Score;Total Score,Ordinal,Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Total score.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,CDISC ADAS-Cog - Total Score,C208544,C208544,C100106,QRS;ADAS-Cog;Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version),ADCTS;CDISC ADAS-Cog - Total Score;Total Score,Ordinal,Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Total score.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,
2025-09-23,CDISC ADAS-Cog - Total Score,C208544,C208544,C100106,QRS;ADAS-Cog;Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version),ADCTS;CDISC ADAS-Cog - Total Score;Total Score,Ordinal,Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Total score.,,,,C82556,C82556,Not-Done Reason,string,
2025-09-23,CDISC ADAS-Cog - Total Score,C208544,C208544,C100106,QRS;ADAS-Cog;Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version),ADCTS;CDISC ADAS-Cog - Total Score;Total Score,Ordinal,Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Total score.,,,,C51824,C51824,Evaluator,string,Investigator;Neurologist
2025-09-23,CES - Ever Combat Patrols or Dangerous Duty,C132556,C132556,C132527,QRS;QRS Instrument Question;Clinical or Research Assessment Questionnaire;Combat Exposure Scale Questionnaire;CES;CES01;CES Questionnaire Question,CES01-Ever Combat Patrols/Dangerous Duty;CES0101;CES - Ever Combat Patrols or Dangerous Duty,Ordinal,Combat Exposure Scale (CES) Did you ever go on combat patrols or have other dangerous duty?,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,CES - Ever Combat Patrols or Dangerous Duty,C132556,C132556,C132527,QRS;QRS Instrument Question;Clinical or Research Assessment Questionnaire;Combat Exposure Scale Questionnaire;CES;CES01;CES Questionnaire Question,CES01-Ever Combat Patrols/Dangerous Duty;CES0101;CES - Ever Combat Patrols or Dangerous Duty,Ordinal,Combat Exposure Scale (CES) Did you ever go on combat patrols or have other dangerous duty?,,,,C25372,C25372,Category,string,CES
2025-09-23,CES - Ever Combat Patrols or Dangerous Duty,C132556,C132556,C132527,QRS;QRS Instrument Question;Clinical or Research Assessment Questionnaire;Combat Exposure Scale Questionnaire;CES;CES01;CES Questionnaire Question,CES01-Ever Combat Patrols/Dangerous Duty;CES0101;CES - Ever Combat Patrols or Dangerous Duty,Ordinal,Combat Exposure Scale (CES) Did you ever go on combat patrols or have other dangerous duty?,,,,C91106,C91106,Clinical or Research Assessment Answer,string,1-3 times;13-50 times;4-12 times;51+ times;No
2025-09-23,CES - Ever Combat Patrols or Dangerous Duty,C132556,C132556,C132527,QRS;QRS Instrument Question;Clinical or Research Assessment Questionnaire;Combat Exposure Scale Questionnaire;CES;CES01;CES Questionnaire Question,CES01-Ever Combat Patrols/Dangerous Duty;CES0101;CES - Ever Combat Patrols or Dangerous Duty,Ordinal,Combat Exposure Scale (CES) Did you ever go on combat patrols or have other dangerous duty?,,,,C46126,C46126,Ordinal Position,integer,1;2;3;4;5
2025-09-23,CES - Ever Surrounded by the Enemy,C132558,C132558,C132527,QRS;QRS Instrument Question;Clinical or Research Assessment Questionnaire;Combat Exposure Scale Questionnaire;CES;CES01;CES Questionnaire Question,CES01-Ever Surrounded by the Enemy;CES0103;CES - Ever Surrounded by the Enemy,Ordinal,Combat Exposure Scale (CES) Were you ever surrounded by the enemy?,,,,C25372,C25372,Category,string,CES
2025-09-23,CES - Ever Surrounded by the Enemy,C132558,C132558,C132527,QRS;QRS Instrument Question;Clinical or Research Assessment Questionnaire;Combat Exposure Scale Questionnaire;CES;CES01;CES Questionnaire Question,CES01-Ever Surrounded by the Enemy;CES0103;CES - Ever Surrounded by the Enemy,Ordinal,Combat Exposure Scale (CES) Were you ever surrounded by the enemy?,,,,C46126,C46126,Ordinal Position,integer,1;2;3;4;5
2025-09-23,CES - Ever Surrounded by the Enemy,C132558,C132558,C132527,QRS;QRS Instrument Question;Clinical or Research Assessment Questionnaire;Combat Exposure Scale Questionnaire;CES;CES01;CES Questionnaire Question,CES01-Ever Surrounded by the Enemy;CES0103;CES - Ever Surrounded by the Enemy,Ordinal,Combat Exposure Scale (CES) Were you ever surrounded by the enemy?,,,,C91106,C91106,Clinical or Research Assessment Answer,string,1-2 times;13-25 times;26+ times;3-12 times;No
2025-09-23,CES - Ever Surrounded by the Enemy,C132558,C132558,C132527,QRS;QRS Instrument Question;Clinical or Research Assessment Questionnaire;Combat Exposure Scale Questionnaire;CES;CES01;CES Questionnaire Question,CES01-Ever Surrounded by the Enemy;CES0103;CES - Ever Surrounded by the Enemy,Ordinal,Combat Exposure Scale (CES) Were you ever surrounded by the enemy?,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,CES - How Often Fire Rounds at Enemy,C132560,C132560,C132527,QRS;QRS Instrument Question;Clinical or Research Assessment Questionnaire;Combat Exposure Scale Questionnaire;CES;CES01;CES Questionnaire Question,CES01-How Often Fire Rounds at Enemy;CES0105;CES - How Often Fire Rounds at Enemy,Ordinal,Combat Exposure Scale (CES) How often did you fire rounds at the enemy?,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,CES - How Often Fire Rounds at Enemy,C132560,C132560,C132527,QRS;QRS Instrument Question;Clinical or Research Assessment Questionnaire;Combat Exposure Scale Questionnaire;CES;CES01;CES Questionnaire Question,CES01-How Often Fire Rounds at Enemy;CES0105;CES - How Often Fire Rounds at Enemy,Ordinal,Combat Exposure Scale (CES) How often did you fire rounds at the enemy?,,,,C25372,C25372,Category,string,CES
2025-09-23,CES - How Often Fire Rounds at Enemy,C132560,C132560,C132527,QRS;QRS Instrument Question;Clinical or Research Assessment Questionnaire;Combat Exposure Scale Questionnaire;CES;CES01;CES Questionnaire Question,CES01-How Often Fire Rounds at Enemy;CES0105;CES - How Often Fire Rounds at Enemy,Ordinal,Combat Exposure Scale (CES) How often did you fire rounds at the enemy?,,,,C91106,C91106,Clinical or Research Assessment Answer,string,1-2 times;13-50 times;3-12 times;51+ times;Never
2025-09-23,CES - How Often Fire Rounds at Enemy,C132560,C132560,C132527,QRS;QRS Instrument Question;Clinical or Research Assessment Questionnaire;Combat Exposure Scale Questionnaire;CES;CES01;CES Questionnaire Question,CES01-How Often Fire Rounds at Enemy;CES0105;CES - How Often Fire Rounds at Enemy,Ordinal,Combat Exposure Scale (CES) How often did you fire rounds at the enemy?,,,,C46126,C46126,Ordinal Position,integer,1;2;3;4;5
2025-09-23,CES - In Danger of Being Injured or Killed,C132562,C132562,C132527,QRS;QRS Instrument Question;Clinical or Research Assessment Questionnaire;Combat Exposure Scale Questionnaire;CES;CES01;CES Questionnaire Question,CES01-In Danger of Being Injured/Killed;CES0107;CES - In Danger of Being Injured or Killed,Ordinal,"Combat Exposure Scale (CES) How often were you in danger of being injured or killed (i.e., being pinned down, overrun, ambushed, near miss, etc.)?",,,,C46126,C46126,Ordinal Position,integer,1;2;3;4;5
2025-09-23,CES - In Danger of Being Injured or Killed,C132562,C132562,C132527,QRS;QRS Instrument Question;Clinical or Research Assessment Questionnaire;Combat Exposure Scale Questionnaire;CES;CES01;CES Questionnaire Question,CES01-In Danger of Being Injured/Killed;CES0107;CES - In Danger of Being Injured or Killed,Ordinal,"Combat Exposure Scale (CES) How often were you in danger of being injured or killed (i.e., being pinned down, overrun, ambushed, near miss, etc.)?",,,,C91106,C91106,Clinical or Research Assessment Answer,string,1-2 times;13-50 times;3-12 times;51+ times;Never
2025-09-23,CES - In Danger of Being Injured or Killed,C132562,C132562,C132527,QRS;QRS Instrument Question;Clinical or Research Assessment Questionnaire;Combat Exposure Scale Questionnaire;CES;CES01;CES Questionnaire Question,CES01-In Danger of Being Injured/Killed;CES0107;CES - In Danger of Being Injured or Killed,Ordinal,"Combat Exposure Scale (CES) How often were you in danger of being injured or killed (i.e., being pinned down, overrun, ambushed, near miss, etc.)?",,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,CES - In Danger of Being Injured or Killed,C132562,C132562,C132527,QRS;QRS Instrument Question;Clinical or Research Assessment Questionnaire;Combat Exposure Scale Questionnaire;CES;CES01;CES Questionnaire Question,CES01-In Danger of Being Injured/Killed;CES0107;CES - In Danger of Being Injured or Killed,Ordinal,"Combat Exposure Scale (CES) How often were you in danger of being injured or killed (i.e., being pinned down, overrun, ambushed, near miss, etc.)?",,,,C25372,C25372,Category,string,CES
2025-09-23,CES - See Someone Hit by Rounds,C132561,C132561,C132527,QRS;QRS Instrument Question;Clinical or Research Assessment Questionnaire;Combat Exposure Scale Questionnaire;CES;CES01;CES Questionnaire Question,CES01-See Someone Hit by Rounds;CES0106;CES - See Someone Hit by Rounds,Ordinal,Combat Exposure Scale (CES) How often did you see someone hit by incoming or outgoing rounds?,,,,C46126,C46126,Ordinal Position,integer,1;2;3;4;5
2025-09-23,CES - See Someone Hit by Rounds,C132561,C132561,C132527,QRS;QRS Instrument Question;Clinical or Research Assessment Questionnaire;Combat Exposure Scale Questionnaire;CES;CES01;CES Questionnaire Question,CES01-See Someone Hit by Rounds;CES0106;CES - See Someone Hit by Rounds,Ordinal,Combat Exposure Scale (CES) How often did you see someone hit by incoming or outgoing rounds?,,,,C91106,C91106,Clinical or Research Assessment Answer,string,1-2 times;13-50 times;3-12 times;51+ times;Never
2025-09-23,CES - See Someone Hit by Rounds,C132561,C132561,C132527,QRS;QRS Instrument Question;Clinical or Research Assessment Questionnaire;Combat Exposure Scale Questionnaire;CES;CES01;CES Questionnaire Question,CES01-See Someone Hit by Rounds;CES0106;CES - See Someone Hit by Rounds,Ordinal,Combat Exposure Scale (CES) How often did you see someone hit by incoming or outgoing rounds?,,,,C25372,C25372,Category,string,CES
2025-09-23,CES - See Someone Hit by Rounds,C132561,C132561,C132527,QRS;QRS Instrument Question;Clinical or Research Assessment Questionnaire;Combat Exposure Scale Questionnaire;CES;CES01;CES Questionnaire Question,CES01-See Someone Hit by Rounds;CES0106;CES - See Someone Hit by Rounds,Ordinal,Combat Exposure Scale (CES) How often did you see someone hit by incoming or outgoing rounds?,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,"CES - Soldiers in Unit Killed (KIA), Wounded, Missing (MIA)",C132559,C132559,C132527,QRS;QRS Instrument Question;Clinical or Research Assessment Questionnaire;Combat Exposure Scale Questionnaire;CES;CES01;CES Questionnaire Question,"CES01-Soldiers in Unit KIA, Wounded, MIA;CES0104;CES - Soldiers in Unit Killed (KIA), Wounded, Missing (MIA)",Ordinal,"Combat Exposure Scale (CES) What percentage of the soldiers in your unit were killed (KIA), wounded or missing in action (MIA)?",,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,"CES - Soldiers in Unit Killed (KIA), Wounded, Missing (MIA)",C132559,C132559,C132527,QRS;QRS Instrument Question;Clinical or Research Assessment Questionnaire;Combat Exposure Scale Questionnaire;CES;CES01;CES Questionnaire Question,"CES01-Soldiers in Unit KIA, Wounded, MIA;CES0104;CES - Soldiers in Unit Killed (KIA), Wounded, Missing (MIA)",Ordinal,"Combat Exposure Scale (CES) What percentage of the soldiers in your unit were killed (KIA), wounded or missing in action (MIA)?",,,,C91106,C91106,Clinical or Research Assessment Answer,string,1-25%;26-50%;51-75%;76% or more;None
2025-09-23,"CES - Soldiers in Unit Killed (KIA), Wounded, Missing (MIA)",C132559,C132559,C132527,QRS;QRS Instrument Question;Clinical or Research Assessment Questionnaire;Combat Exposure Scale Questionnaire;CES;CES01;CES Questionnaire Question,"CES01-Soldiers in Unit KIA, Wounded, MIA;CES0104;CES - Soldiers in Unit Killed (KIA), Wounded, Missing (MIA)",Ordinal,"Combat Exposure Scale (CES) What percentage of the soldiers in your unit were killed (KIA), wounded or missing in action (MIA)?",,,,C25372,C25372,Category,string,CES
2025-09-23,"CES - Soldiers in Unit Killed (KIA), Wounded, Missing (MIA)",C132559,C132559,C132527,QRS;QRS Instrument Question;Clinical or Research Assessment Questionnaire;Combat Exposure Scale Questionnaire;CES;CES01;CES Questionnaire Question,"CES01-Soldiers in Unit KIA, Wounded, MIA;CES0104;CES - Soldiers in Unit Killed (KIA), Wounded, Missing (MIA)",Ordinal,"Combat Exposure Scale (CES) What percentage of the soldiers in your unit were killed (KIA), wounded or missing in action (MIA)?",,,,C46126,C46126,Ordinal Position,integer,1;2;3;4;5
2025-09-23,CES - Were You Ever Under Enemy Fire,C132557,C132557,C132527,QRS;QRS Instrument Question;Clinical or Research Assessment Questionnaire;Combat Exposure Scale Questionnaire;CES;CES01;CES Questionnaire Question,CES01-Were You Ever Under Enemy Fire;CES0102;CES - Were You Ever Under Enemy Fire,Ordinal,Combat Exposure Scale (CES) Were you ever under enemy fire?,,,,C46126,C46126,Ordinal Position,integer,1;2;3;4;5
2025-09-23,CES - Were You Ever Under Enemy Fire,C132557,C132557,C132527,QRS;QRS Instrument Question;Clinical or Research Assessment Questionnaire;Combat Exposure Scale Questionnaire;CES;CES01;CES Questionnaire Question,CES01-Were You Ever Under Enemy Fire;CES0102;CES - Were You Ever Under Enemy Fire,Ordinal,Combat Exposure Scale (CES) Were you ever under enemy fire?,,,,C91106,C91106,Clinical or Research Assessment Answer,string,1-3 months;4-6 months;7+ months;<1 month;Never
2025-09-23,CES - Were You Ever Under Enemy Fire,C132557,C132557,C132527,QRS;QRS Instrument Question;Clinical or Research Assessment Questionnaire;Combat Exposure Scale Questionnaire;CES;CES01;CES Questionnaire Question,CES01-Were You Ever Under Enemy Fire;CES0102;CES - Were You Ever Under Enemy Fire,Ordinal,Combat Exposure Scale (CES) Were you ever under enemy fire?,,,,C25372,C25372,Category,string,CES
2025-09-23,CES - Were You Ever Under Enemy Fire,C132557,C132557,C132527,QRS;QRS Instrument Question;Clinical or Research Assessment Questionnaire;Combat Exposure Scale Questionnaire;CES;CES01;CES Questionnaire Question,CES01-Were You Ever Under Enemy Fire;CES0102;CES - Were You Ever Under Enemy Fire,Ordinal,Combat Exposure Scale (CES) Were you ever under enemy fire?,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,CES Questionnaire Question,C132527,C132527,C211913,QRS Instrument Questions,,,A question associated with the CES questionnaire.,,,,,,,,
2025-09-23,CGI Generic Modification Version - Change,C135815,C135815,C135705,QRS;Clinical or Research Assessment Questionnaire;Clinical Global Impression Generic Modification Version Questionnaire;CGI02;CGI;CGI Generic Modification Version Questionnaire Question,CGI02-Change;CGI0202;CGI Generic Modification Version - Change,Ordinal,"Clinical Global Impression Generic Modification Version (CGI Generic Modification Version) Rate total change whether or not, in your judgement, it is due entirely to drug treatment. Compared to the subject's condition <at previously assessed protocol specified time point>, how much has the subject changed?",,,,C91106,C91106,Clinical or Research Assessment Answer,string,Very much improved;Much improved;Minimally improved;No change;Minimally worse;Much worse;Very much worse
2025-09-23,CGI Generic Modification Version - Change,C135815,C135815,C135705,QRS;Clinical or Research Assessment Questionnaire;Clinical Global Impression Generic Modification Version Questionnaire;CGI02;CGI;CGI Generic Modification Version Questionnaire Question,CGI02-Change;CGI0202;CGI Generic Modification Version - Change,Ordinal,"Clinical Global Impression Generic Modification Version (CGI Generic Modification Version) Rate total change whether or not, in your judgement, it is due entirely to drug treatment. Compared to the subject's condition <at previously assessed protocol specified time point>, how much has the subject changed?",,,,C46126,C46126,Ordinal Position,integer,1;2;3;4;5;6;7
2025-09-23,CGI Generic Modification Version - Change,C135815,C135815,C135705,QRS;Clinical or Research Assessment Questionnaire;Clinical Global Impression Generic Modification Version Questionnaire;CGI02;CGI;CGI Generic Modification Version Questionnaire Question,CGI02-Change;CGI0202;CGI Generic Modification Version - Change,Ordinal,"Clinical Global Impression Generic Modification Version (CGI Generic Modification Version) Rate total change whether or not, in your judgement, it is due entirely to drug treatment. Compared to the subject's condition <at previously assessed protocol specified time point>, how much has the subject changed?",,,,C25372,C25372,Category,string,CGI
2025-09-23,CGI Generic Modification Version - Change,C135815,C135815,C135705,QRS;Clinical or Research Assessment Questionnaire;Clinical Global Impression Generic Modification Version Questionnaire;CGI02;CGI;CGI Generic Modification Version Questionnaire Question,CGI02-Change;CGI0202;CGI Generic Modification Version - Change,Ordinal,"Clinical Global Impression Generic Modification Version (CGI Generic Modification Version) Rate total change whether or not, in your judgement, it is due entirely to drug treatment. Compared to the subject's condition <at previously assessed protocol specified time point>, how much has the subject changed?",,,,C82535,C82535,Test Method,string,VERBAL RATING SCALE 4-POINT;VERBAL RATING SCALE 6-POINT;LIKERT SCALE 4-POINT;LIKERT SCALE 7-POINT
2025-09-23,CGI Generic Modification Version - Change,C135815,C135815,C135705,QRS;Clinical or Research Assessment Questionnaire;Clinical Global Impression Generic Modification Version Questionnaire;CGI02;CGI;CGI Generic Modification Version Questionnaire Question,CGI02-Change;CGI0202;CGI Generic Modification Version - Change,Ordinal,"Clinical Global Impression Generic Modification Version (CGI Generic Modification Version) Rate total change whether or not, in your judgement, it is due entirely to drug treatment. Compared to the subject's condition <at previously assessed protocol specified time point>, how much has the subject changed?",,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,CGI Generic Modification Version - Improvement,C135816,C135816,C135705,QRS;Clinical or Research Assessment Questionnaire;Clinical Global Impression Generic Modification Version Questionnaire;CGI02;CGI;CGI Generic Modification Version Questionnaire Question,CGI02-Improvement;CGI0203;CGI Generic Modification Version - Improvement,Ordinal,"Clinical Global Impression Generic Modification Version (CGI Generic Modification Version) Rate total improvement whether or not, in your judgement, it is due entirely to drug treatment. Compared to the subject's condition <at previously assessed protocol specified time point>, how much has the subject improved?",,,,C91106,C91106,Clinical or Research Assessment Answer,string,No change;Almost the same;A little better;Somewhat better;Moderately better;Much better;A great deal better
2025-09-23,CGI Generic Modification Version - Improvement,C135816,C135816,C135705,QRS;Clinical or Research Assessment Questionnaire;Clinical Global Impression Generic Modification Version Questionnaire;CGI02;CGI;CGI Generic Modification Version Questionnaire Question,CGI02-Improvement;CGI0203;CGI Generic Modification Version - Improvement,Ordinal,"Clinical Global Impression Generic Modification Version (CGI Generic Modification Version) Rate total improvement whether or not, in your judgement, it is due entirely to drug treatment. Compared to the subject's condition <at previously assessed protocol specified time point>, how much has the subject improved?",,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,CGI Generic Modification Version - Improvement,C135816,C135816,C135705,QRS;Clinical or Research Assessment Questionnaire;Clinical Global Impression Generic Modification Version Questionnaire;CGI02;CGI;CGI Generic Modification Version Questionnaire Question,CGI02-Improvement;CGI0203;CGI Generic Modification Version - Improvement,Ordinal,"Clinical Global Impression Generic Modification Version (CGI Generic Modification Version) Rate total improvement whether or not, in your judgement, it is due entirely to drug treatment. Compared to the subject's condition <at previously assessed protocol specified time point>, how much has the subject improved?",,,,C82535,C82535,Test Method,string,VERBAL RATING SCALE 4-POINT;VERBAL RATING SCALE 6-POINT;LIKERT SCALE 4-POINT;LIKERT SCALE 7-POINT
2025-09-23,CGI Generic Modification Version - Improvement,C135816,C135816,C135705,QRS;Clinical or Research Assessment Questionnaire;Clinical Global Impression Generic Modification Version Questionnaire;CGI02;CGI;CGI Generic Modification Version Questionnaire Question,CGI02-Improvement;CGI0203;CGI Generic Modification Version - Improvement,Ordinal,"Clinical Global Impression Generic Modification Version (CGI Generic Modification Version) Rate total improvement whether or not, in your judgement, it is due entirely to drug treatment. Compared to the subject's condition <at previously assessed protocol specified time point>, how much has the subject improved?",,,,C25372,C25372,Category,string,CGI
2025-09-23,CGI Generic Modification Version - Improvement,C135816,C135816,C135705,QRS;Clinical or Research Assessment Questionnaire;Clinical Global Impression Generic Modification Version Questionnaire;CGI02;CGI;CGI Generic Modification Version Questionnaire Question,CGI02-Improvement;CGI0203;CGI Generic Modification Version - Improvement,Ordinal,"Clinical Global Impression Generic Modification Version (CGI Generic Modification Version) Rate total improvement whether or not, in your judgement, it is due entirely to drug treatment. Compared to the subject's condition <at previously assessed protocol specified time point>, how much has the subject improved?",,,,C46126,C46126,Ordinal Position,integer,1;2;3;4;5;6;7
2025-09-23,CGI Generic Modification Version - Severity,C135814,C135814,C135705,QRS;Clinical or Research Assessment Questionnaire;Clinical Global Impression Generic Modification Version Questionnaire;CGI02;CGI;CGI Generic Modification Version Questionnaire Question,CGI02-Severity;CGI0201;CGI Generic Modification Version - Severity,Ordinal,"Clinical Global Impression Generic Modification Version (CGI Generic Modification Version) Considering your total clinical experience with this particular population, how severe is the subject's condition at this time?",,,,C25372,C25372,Category,string,CGI
2025-09-23,CGI Generic Modification Version - Severity,C135814,C135814,C135705,QRS;Clinical or Research Assessment Questionnaire;Clinical Global Impression Generic Modification Version Questionnaire;CGI02;CGI;CGI Generic Modification Version Questionnaire Question,CGI02-Severity;CGI0201;CGI Generic Modification Version - Severity,Ordinal,"Clinical Global Impression Generic Modification Version (CGI Generic Modification Version) Considering your total clinical experience with this particular population, how severe is the subject's condition at this time?",,,,C91106,C91106,Clinical or Research Assessment Answer,string,Normal;Mild;Moderate;Severe
2025-09-23,CGI Generic Modification Version - Severity,C135814,C135814,C135705,QRS;Clinical or Research Assessment Questionnaire;Clinical Global Impression Generic Modification Version Questionnaire;CGI02;CGI;CGI Generic Modification Version Questionnaire Question,CGI02-Severity;CGI0201;CGI Generic Modification Version - Severity,Ordinal,"Clinical Global Impression Generic Modification Version (CGI Generic Modification Version) Considering your total clinical experience with this particular population, how severe is the subject's condition at this time?",,,,C46126,C46126,Ordinal Position,integer,1;2;3;4
2025-09-23,CGI Generic Modification Version - Severity,C135814,C135814,C135705,QRS;Clinical or Research Assessment Questionnaire;Clinical Global Impression Generic Modification Version Questionnaire;CGI02;CGI;CGI Generic Modification Version Questionnaire Question,CGI02-Severity;CGI0201;CGI Generic Modification Version - Severity,Ordinal,"Clinical Global Impression Generic Modification Version (CGI Generic Modification Version) Considering your total clinical experience with this particular population, how severe is the subject's condition at this time?",,,,C82535,C82535,Test Method,string,VERBAL RATING SCALE 4-POINT;VERBAL RATING SCALE 6-POINT;LIKERT SCALE 4-POINT;LIKERT SCALE 7-POINT
2025-09-23,CGI Generic Modification Version - Severity,C135814,C135814,C135705,QRS;Clinical or Research Assessment Questionnaire;Clinical Global Impression Generic Modification Version Questionnaire;CGI02;CGI;CGI Generic Modification Version Questionnaire Question,CGI02-Severity;CGI0201;CGI Generic Modification Version - Severity,Ordinal,"Clinical Global Impression Generic Modification Version (CGI Generic Modification Version) Considering your total clinical experience with this particular population, how severe is the subject's condition at this time?",,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,CGI Generic Modification Version Questionnaire Question,C135705,C135705,C211913,QRS Instrument Questions,,,A question associated with the CGI Generic Modification Version questionnaire.,,,,,,,,
2025-09-23,Cellularity Measurement,C111153,C111153,C48938,Tumor Results;Tumor Measurements,CELLULAR;Cellularity Grade;Cellularity Index;Percent Cellularity,Quantitative,"The determination of the amount of degree, quality or condition of cells present in a sample.",,,,C48570,C48570,Percent Unit,string,%
2025-09-23,Cellularity Measurement,C111153,C111153,C48938,Tumor Results;Tumor Measurements,CELLULAR;Cellularity Grade;Cellularity Index;Percent Cellularity,Quantitative,"The determination of the amount of degree, quality or condition of cells present in a sample.",,,,C25372,C25372,Category,string,
2025-09-23,Cellularity Measurement,C111153,C111153,C48938,Tumor Results;Tumor Measurements,CELLULAR;Cellularity Grade;Cellularity Index;Percent Cellularity,Quantitative,"The determination of the amount of degree, quality or condition of cells present in a sample.",,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Cellularity Measurement,C111153,C111153,C48938,Tumor Results;Tumor Measurements,CELLULAR;Cellularity Grade;Cellularity Index;Percent Cellularity,Quantitative,"The determination of the amount of degree, quality or condition of cells present in a sample.",,,,C70856,C70856,Observation Result,integer,
2025-09-23,Cellularity Measurement,C111153,C111153,C48938,Tumor Results;Tumor Measurements,CELLULAR;Cellularity Grade;Cellularity Index;Percent Cellularity,Quantitative,"The determination of the amount of degree, quality or condition of cells present in a sample.",,,,C70713,C70713,Biospecimen Type,string,Tissue
2025-09-23,Cellularity Measurement,C111153,C111153,C48938,Tumor Results;Tumor Measurements,CELLULAR;Cellularity Grade;Cellularity Index;Percent Cellularity,Quantitative,"The determination of the amount of degree, quality or condition of cells present in a sample.",,,,C171435,C171435,Specimen Anatomic Site,string,
2025-09-23,Cellularity Measurement,C111153,C111153,C48938,Tumor Results;Tumor Measurements,CELLULAR;Cellularity Grade;Cellularity Index;Percent Cellularity,Quantitative,"The determination of the amount of degree, quality or condition of cells present in a sample.",,,,C25692,C25692,Subcategory,string,
2025-09-23,Child-Pugh - Ascites,C121069,C121069,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,CPS01-Ascites;CPS0102;Child-Pugh - Ascites,Ordinal,Child-Pugh Classification (Child-Pugh) Ascites.,http://loinc.org/,LOINC,98151-4,C51824,C51824,Evaluator,string,INVESTIGATOR
2025-09-23,Child-Pugh - Ascites,C121069,C121069,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,CPS01-Ascites;CPS0102;Child-Pugh - Ascites,Ordinal,Child-Pugh Classification (Child-Pugh) Ascites.,http://loinc.org/,LOINC,98151-4,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Child-Pugh - Ascites,C121069,C121069,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,CPS01-Ascites;CPS0102;Child-Pugh - Ascites,Ordinal,Child-Pugh Classification (Child-Pugh) Ascites.,http://loinc.org/,LOINC,98151-4,C25372,C25372,Category,string,CHILD-PUGH CLASSIFICATION
2025-09-23,Child-Pugh - Ascites,C121069,C121069,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,CPS01-Ascites;CPS0102;Child-Pugh - Ascites,Ordinal,Child-Pugh Classification (Child-Pugh) Ascites.,http://loinc.org/,LOINC,98151-4,C91106,C91106,Clinical or Research Assessment Answer,string,absent;moderate;slight
2025-09-23,Child-Pugh - Ascites,C121069,C121069,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,CPS01-Ascites;CPS0102;Child-Pugh - Ascites,Ordinal,Child-Pugh Classification (Child-Pugh) Ascites.,http://loinc.org/,LOINC,98151-4,C46126,C46126,Ordinal Position,integer,1;2;3
2025-09-23,Child-Pugh - Encephalopathy Grade,C121068,C121068,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,CPS01-Encephalopathy Grade;CPS0101;Child-Pugh - Encephalopathy Grade,Ordinal,Child-Pugh Classification (Child-Pugh) Encephalopathy grade.,http://loinc.org/,LOINC,98150-6,C46126,C46126,Ordinal Position,integer,1;2;3
2025-09-23,Child-Pugh - Encephalopathy Grade,C121068,C121068,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,CPS01-Encephalopathy Grade;CPS0101;Child-Pugh - Encephalopathy Grade,Ordinal,Child-Pugh Classification (Child-Pugh) Encephalopathy grade.,http://loinc.org/,LOINC,98150-6,C91106,C91106,Clinical or Research Assessment Answer,string,1 or 2;3 or 4;none
2025-09-23,Child-Pugh - Encephalopathy Grade,C121068,C121068,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,CPS01-Encephalopathy Grade;CPS0101;Child-Pugh - Encephalopathy Grade,Ordinal,Child-Pugh Classification (Child-Pugh) Encephalopathy grade.,http://loinc.org/,LOINC,98150-6,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Child-Pugh - Encephalopathy Grade,C121068,C121068,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,CPS01-Encephalopathy Grade;CPS0101;Child-Pugh - Encephalopathy Grade,Ordinal,Child-Pugh Classification (Child-Pugh) Encephalopathy grade.,http://loinc.org/,LOINC,98150-6,C51824,C51824,Evaluator,string,INVESTIGATOR
2025-09-23,Child-Pugh - Encephalopathy Grade,C121068,C121068,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,CPS01-Encephalopathy Grade;CPS0101;Child-Pugh - Encephalopathy Grade,Ordinal,Child-Pugh Classification (Child-Pugh) Encephalopathy grade.,http://loinc.org/,LOINC,98150-6,C25372,C25372,Category,string,CHILD-PUGH CLASSIFICATION
2025-09-23,Child-Pugh - Grade,C121075,C121075,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,CPS01-Grade;CPS0107;Child-Pugh - Grade,Ordinal,Child-Pugh Classification (Child-Pugh) Child-Pugh grade.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,A;B;C
2025-09-23,Child-Pugh - Grade,C121075,C121075,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,CPS01-Grade;CPS0107;Child-Pugh - Grade,Ordinal,Child-Pugh Classification (Child-Pugh) Child-Pugh grade.,,,,C25372,C25372,Category,string,CHILD-PUGH CLASSIFICATION
2025-09-23,Child-Pugh - Grade,C121075,C121075,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,CPS01-Grade;CPS0107;Child-Pugh - Grade,Ordinal,Child-Pugh Classification (Child-Pugh) Child-Pugh grade.,,,,C51824,C51824,Evaluator,string,INVESTIGATOR
2025-09-23,Child-Pugh - Grade,C121075,C121075,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,CPS01-Grade;CPS0107;Child-Pugh - Grade,Ordinal,Child-Pugh Classification (Child-Pugh) Child-Pugh grade.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,"Child-Pugh - PT, INR",C121073,C121073,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,"CPS01-PT, INR;CPS0105B;Child-Pugh - PT, INR",Ordinal,"Child-Pugh Classification (Child-Pugh) Prothrombin time, international normalized ratio (INR).",http://loinc.org/,LOINC,6301-6,C51824,C51824,Evaluator,string,INVESTIGATOR
2025-09-23,"Child-Pugh - PT, INR",C121073,C121073,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,"CPS01-PT, INR;CPS0105B;Child-Pugh - PT, INR",Ordinal,"Child-Pugh Classification (Child-Pugh) Prothrombin time, international normalized ratio (INR).",http://loinc.org/,LOINC,6301-6,C25372,C25372,Category,string,CHILD-PUGH CLASSIFICATION
2025-09-23,"Child-Pugh - PT, INR",C121073,C121073,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,"CPS01-PT, INR;CPS0105B;Child-Pugh - PT, INR",Ordinal,"Child-Pugh Classification (Child-Pugh) Prothrombin time, international normalized ratio (INR).",http://loinc.org/,LOINC,6301-6,C91106,C91106,Clinical or Research Assessment Answer,string,1.7-2.3;<1.7;>2.3
2025-09-23,"Child-Pugh - PT, INR",C121073,C121073,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,"CPS01-PT, INR;CPS0105B;Child-Pugh - PT, INR",Ordinal,"Child-Pugh Classification (Child-Pugh) Prothrombin time, international normalized ratio (INR).",http://loinc.org/,LOINC,6301-6,C46126,C46126,Ordinal Position,integer,1;2;3
2025-09-23,"Child-Pugh - PT, INR",C121073,C121073,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,"CPS01-PT, INR;CPS0105B;Child-Pugh - PT, INR",Ordinal,"Child-Pugh Classification (Child-Pugh) Prothrombin time, international normalized ratio (INR).",http://loinc.org/,LOINC,6301-6,C82515,C82515,Collection Date Time,datetime,
2025-09-23,"Child-Pugh - PT, Sec Prolonged",C121072,C121072,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,"CPS01-PT, Sec Prolonged;CPS0105A;Child-Pugh - PT, Sec Prolonged",Ordinal,"Child-Pugh Classification (Child-Pugh) Prothrombin time, sec prolonged.",http://loinc.org/,LOINC,5902-2,C46126,C46126,Ordinal Position,integer,1;2;3
2025-09-23,"Child-Pugh - PT, Sec Prolonged",C121072,C121072,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,"CPS01-PT, Sec Prolonged;CPS0105A;Child-Pugh - PT, Sec Prolonged",Ordinal,"Child-Pugh Classification (Child-Pugh) Prothrombin time, sec prolonged.",http://loinc.org/,LOINC,5902-2,C91106,C91106,Clinical or Research Assessment Answer,string,4 to 6;<4;>6
2025-09-23,"Child-Pugh - PT, Sec Prolonged",C121072,C121072,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,"CPS01-PT, Sec Prolonged;CPS0105A;Child-Pugh - PT, Sec Prolonged",Ordinal,"Child-Pugh Classification (Child-Pugh) Prothrombin time, sec prolonged.",http://loinc.org/,LOINC,5902-2,C25372,C25372,Category,string,CHILD-PUGH CLASSIFICATION
2025-09-23,"Child-Pugh - PT, Sec Prolonged",C121072,C121072,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,"CPS01-PT, Sec Prolonged;CPS0105A;Child-Pugh - PT, Sec Prolonged",Ordinal,"Child-Pugh Classification (Child-Pugh) Prothrombin time, sec prolonged.",http://loinc.org/,LOINC,5902-2,C42574,C42574,Unit of Time,string,s
2025-09-23,"Child-Pugh - PT, Sec Prolonged",C121072,C121072,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,"CPS01-PT, Sec Prolonged;CPS0105A;Child-Pugh - PT, Sec Prolonged",Ordinal,"Child-Pugh Classification (Child-Pugh) Prothrombin time, sec prolonged.",http://loinc.org/,LOINC,5902-2,C82515,C82515,Collection Date Time,datetime,
2025-09-23,"Child-Pugh - PT, Sec Prolonged",C121072,C121072,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,"CPS01-PT, Sec Prolonged;CPS0105A;Child-Pugh - PT, Sec Prolonged",Ordinal,"Child-Pugh Classification (Child-Pugh) Prothrombin time, sec prolonged.",http://loinc.org/,LOINC,5902-2,C51824,C51824,Evaluator,string,INVESTIGATOR
2025-09-23,Child-Pugh - Serum Albumin,C121071,C121071,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,CPS01-Serum Albumin;CPS0104;Child-Pugh - Serum Albumin,Ordinal,"Child-Pugh Classification (Child-Pugh) Serum albumin, g/dL.",http://loinc.org/,LOINC,1751-7,C46126,C46126,Ordinal Position,integer,1;2;3
2025-09-23,Child-Pugh - Serum Albumin,C121071,C121071,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,CPS01-Serum Albumin;CPS0104;Child-Pugh - Serum Albumin,Ordinal,"Child-Pugh Classification (Child-Pugh) Serum albumin, g/dL.",http://loinc.org/,LOINC,1751-7,C91106,C91106,Clinical or Research Assessment Answer,string,2.8 to 3.5;<2.8;>3.5
2025-09-23,Child-Pugh - Serum Albumin,C121071,C121071,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,CPS01-Serum Albumin;CPS0104;Child-Pugh - Serum Albumin,Ordinal,"Child-Pugh Classification (Child-Pugh) Serum albumin, g/dL.",http://loinc.org/,LOINC,1751-7,C51824,C51824,Evaluator,string,INVESTIGATOR
2025-09-23,Child-Pugh - Serum Albumin,C121071,C121071,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,CPS01-Serum Albumin;CPS0104;Child-Pugh - Serum Albumin,Ordinal,"Child-Pugh Classification (Child-Pugh) Serum albumin, g/dL.",http://loinc.org/,LOINC,1751-7,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Child-Pugh - Serum Albumin,C121071,C121071,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,CPS01-Serum Albumin;CPS0104;Child-Pugh - Serum Albumin,Ordinal,"Child-Pugh Classification (Child-Pugh) Serum albumin, g/dL.",http://loinc.org/,LOINC,1751-7,C48207,C48207,Unit of Concentration,string,g/dL
2025-09-23,Child-Pugh - Serum Albumin,C121071,C121071,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,CPS01-Serum Albumin;CPS0104;Child-Pugh - Serum Albumin,Ordinal,"Child-Pugh Classification (Child-Pugh) Serum albumin, g/dL.",http://loinc.org/,LOINC,1751-7,C25372,C25372,Category,string,CHILD-PUGH CLASSIFICATION
2025-09-23,Child-Pugh - Serum Bilirubin,C121070,C121070,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,CPS01-Serum Bilirubin;CPS0103;Child-Pugh - Serum Bilirubin,Ordinal,"Child-Pugh Classification (Child-Pugh) Serum bilirubin, mg/dL.",http://loinc.org/,LOINC,1975-2,C51824,C51824,Evaluator,string,INVESTIGATOR
2025-09-23,Child-Pugh - Serum Bilirubin,C121070,C121070,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,CPS01-Serum Bilirubin;CPS0103;Child-Pugh - Serum Bilirubin,Ordinal,"Child-Pugh Classification (Child-Pugh) Serum bilirubin, mg/dL.",http://loinc.org/,LOINC,1975-2,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Child-Pugh - Serum Bilirubin,C121070,C121070,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,CPS01-Serum Bilirubin;CPS0103;Child-Pugh - Serum Bilirubin,Ordinal,"Child-Pugh Classification (Child-Pugh) Serum bilirubin, mg/dL.",http://loinc.org/,LOINC,1975-2,C48207,C48207,Unit of Concentration,string,mg/dL
2025-09-23,Child-Pugh - Serum Bilirubin,C121070,C121070,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,CPS01-Serum Bilirubin;CPS0103;Child-Pugh - Serum Bilirubin,Ordinal,"Child-Pugh Classification (Child-Pugh) Serum bilirubin, mg/dL.",http://loinc.org/,LOINC,1975-2,C25372,C25372,Category,string,CHILD-PUGH CLASSIFICATION
2025-09-23,Child-Pugh - Serum Bilirubin,C121070,C121070,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,CPS01-Serum Bilirubin;CPS0103;Child-Pugh - Serum Bilirubin,Ordinal,"Child-Pugh Classification (Child-Pugh) Serum bilirubin, mg/dL.",http://loinc.org/,LOINC,1975-2,C46126,C46126,Ordinal Position,integer,1;2;3
2025-09-23,Child-Pugh - Serum Bilirubin,C121070,C121070,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,CPS01-Serum Bilirubin;CPS0103;Child-Pugh - Serum Bilirubin,Ordinal,"Child-Pugh Classification (Child-Pugh) Serum bilirubin, mg/dL.",http://loinc.org/,LOINC,1975-2,C91106,C91106,Clinical or Research Assessment Answer,string,2 to 3;<2;>3
2025-09-23,Child-Pugh - Total Score,C121074,C121074,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,CPS01-Total Score;CPS0106;Child-Pugh - Total Score,Ordinal,Child-Pugh Classification (Child-Pugh) Child-Pugh total score.,http://loinc.org/,LOINC,98152-2,C51824,C51824,Evaluator,string,INVESTIGATOR
2025-09-23,Child-Pugh - Total Score,C121074,C121074,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,CPS01-Total Score;CPS0106;Child-Pugh - Total Score,Ordinal,Child-Pugh Classification (Child-Pugh) Child-Pugh total score.,http://loinc.org/,LOINC,98152-2,C25372,C25372,Category,string,CHILD-PUGH CLASSIFICATION
2025-09-23,Child-Pugh - Total Score,C121074,C121074,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,CPS01-Total Score;CPS0106;Child-Pugh - Total Score,Ordinal,Child-Pugh Classification (Child-Pugh) Child-Pugh total score.,http://loinc.org/,LOINC,98152-2,C91106,C91106,Clinical or Research Assessment Answer,string,
2025-09-23,Child-Pugh - Total Score,C121074,C121074,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,CPS01-Total Score;CPS0106;Child-Pugh - Total Score,Ordinal,Child-Pugh Classification (Child-Pugh) Child-Pugh total score.,http://loinc.org/,LOINC,98152-2,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Child-Pugh - Total Score,C121074,C121074,C120996,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,CPS01-Total Score;CPS0106;Child-Pugh - Total Score,Ordinal,Child-Pugh Classification (Child-Pugh) Child-Pugh total score.,http://loinc.org/,LOINC,98152-2,C46126,C46126,Ordinal Position,integer,
2025-09-23,Child-Pugh Clinical Classification,C121007,C121007,C118969,QRS;Clinical or Research Assessment Classification;Child-Pugh Clinical Classification;CHILD-PUGH CLASSIFICATION;Child-Pugh;CPS01;Child-Pugh Clinical Classification Question,Child-Pugh;CHILD-PUGH CLASSIFICATION;Child-Pugh Classification;Child-Pugh Score;CPS01,,"A standardized rating scale used to assess the severity of liver cirrhosis and determine the prognosis, the required strength of treatment, and the necessity of liver transplantation. This instrument uses the following clinical and lab criteria: encephalopathy grade, ascites, bilirubin, albumin, and prothrombin index.",,,,,,,,
2025-09-23,Child-Pugh Clinical Classification Question,C120996,C120996,C211913,QRS Instrument Questions,,,A question associated with the Child-Pugh clinical classification.,,,,,,,,
2025-09-23,Circulating Tumor Cells Positive,C146691,C146691,,Diagnostic Procedures;Genetic Testing;Laboratory Tests;Blood Cell Counts;Tumor Results,CTC Positive;Circulating Tumor Cells Present,Ordinal,An indication that tumor cells have been detected in a peripheral blood sample.,,,,C25372,C25372,Category,string,
2025-09-23,Circulating Tumor Cells Positive,C146691,C146691,,Diagnostic Procedures;Genetic Testing;Laboratory Tests;Blood Cell Counts;Tumor Results,CTC Positive;Circulating Tumor Cells Present,Ordinal,An indication that tumor cells have been detected in a peripheral blood sample.,,,,C70856,C70856,Observation Result,boolean,Y;N
2025-09-23,Circulating Tumor Cells Positive,C146691,C146691,,Diagnostic Procedures;Genetic Testing;Laboratory Tests;Blood Cell Counts;Tumor Results,CTC Positive;Circulating Tumor Cells Present,Ordinal,An indication that tumor cells have been detected in a peripheral blood sample.,,,,C25692,C25692,Subcategory,string,
2025-09-23,Circulating Tumor Cells Positive,C146691,C146691,,Diagnostic Procedures;Genetic Testing;Laboratory Tests;Blood Cell Counts;Tumor Results,CTC Positive;Circulating Tumor Cells Present,Ordinal,An indication that tumor cells have been detected in a peripheral blood sample.,,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Overall Status
2025-09-23,Circulating Tumor Cells Positive,C146691,C146691,,Diagnostic Procedures;Genetic Testing;Laboratory Tests;Blood Cell Counts;Tumor Results,CTC Positive;Circulating Tumor Cells Present,Ordinal,An indication that tumor cells have been detected in a peripheral blood sample.,,,,C70713,C70713,Biospecimen Type,string,Blood
2025-09-23,Circulating Tumor Cells Positive,C146691,C146691,,Diagnostic Procedures;Genetic Testing;Laboratory Tests;Blood Cell Counts;Tumor Results,CTC Positive;Circulating Tumor Cells Present,Ordinal,An indication that tumor cells have been detected in a peripheral blood sample.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Circulating Tumor-Derived DNA Positive,C183130,C183130,,Diagnostic Procedures;Genetic Testing;Laboratory Tests;Blood Cell Counts;Tumor Results,Cell-Free Circulating Tumor DNA;Circulating Tumor DNA;Circulating Tumor-Derived DNA;ctDNA;ctdDNA,Ordinal,An indication that circulating tumor-derived DNA has been detected in a sample.,,,,C25692,C25692,Subcategory,string,
2025-09-23,Circulating Tumor-Derived DNA Positive,C183130,C183130,,Diagnostic Procedures;Genetic Testing;Laboratory Tests;Blood Cell Counts;Tumor Results,Cell-Free Circulating Tumor DNA;Circulating Tumor DNA;Circulating Tumor-Derived DNA;ctDNA;ctdDNA,Ordinal,An indication that circulating tumor-derived DNA has been detected in a sample.,,,,C25372,C25372,Category,string,
2025-09-23,Circulating Tumor-Derived DNA Positive,C183130,C183130,,Diagnostic Procedures;Genetic Testing;Laboratory Tests;Blood Cell Counts;Tumor Results,Cell-Free Circulating Tumor DNA;Circulating Tumor DNA;Circulating Tumor-Derived DNA;ctDNA;ctdDNA,Ordinal,An indication that circulating tumor-derived DNA has been detected in a sample.,,,,C70713,C70713,Biospecimen Type,string,Blood
2025-09-23,Circulating Tumor-Derived DNA Positive,C183130,C183130,,Diagnostic Procedures;Genetic Testing;Laboratory Tests;Blood Cell Counts;Tumor Results,Cell-Free Circulating Tumor DNA;Circulating Tumor DNA;Circulating Tumor-Derived DNA;ctDNA;ctdDNA,Ordinal,An indication that circulating tumor-derived DNA has been detected in a sample.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Circulating Tumor-Derived DNA Positive,C183130,C183130,,Diagnostic Procedures;Genetic Testing;Laboratory Tests;Blood Cell Counts;Tumor Results,Cell-Free Circulating Tumor DNA;Circulating Tumor DNA;Circulating Tumor-Derived DNA;ctDNA;ctdDNA,Ordinal,An indication that circulating tumor-derived DNA has been detected in a sample.,,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Overall Status
2025-09-23,Circulating Tumor-Derived DNA Positive,C183130,C183130,,Diagnostic Procedures;Genetic Testing;Laboratory Tests;Blood Cell Counts;Tumor Results,Cell-Free Circulating Tumor DNA;Circulating Tumor DNA;Circulating Tumor-Derived DNA;ctDNA;ctdDNA,Ordinal,An indication that circulating tumor-derived DNA has been detected in a sample.,,,,C70856,C70856,Observation Result,boolean,Y;N
2025-09-23,Clinical Global Impression Generic Modification Version Questionnaire,C135738,C135738,C91105,QRS;Clinical or Research Assessment Questionnaire;Clinical Global Impression Generic Modification Version Questionnaire;CGI02;CGI,CGI;CGI02,,A modified version of a standardized questionnaire published in 1976 by Guy et al. that was initially created to provide a clinician-determined summary measure of a patient's global functioning prior to and after initiating a study medication. It has been modified for use in any disease/condition concept use case.,,,,,,,,
2025-09-23,Combat Exposure Scale Questionnaire,C132532,C132532,C91105,QRS;Clinical or Research Assessment Questionnaire;Combat Exposure Scale Questionnaire;CES;CES01,CES;CES01,,"A standardized 7-item self-report scale that was developed by Keane et al in 1989 to measure combat exposure. The instrument is derived from Figley's combat scale (1980), with additional items included by consensus of a group of clinical psychologists with experience in the assessment and treatment of combat-related PTSD. The items are weighted according to the severity of the combat experience.",,,,,,,,
2025-09-23,Concomitant Medication Yes No Indicator,C83056,C83056,C82438,Event Occurrence Indicators;Concomitant Medication,CMYN,Nominal,An indication of whether concomitant medication usage has occurred.,,,,C83056,C83056,Concomitant Medication Yes No Indicator,string,N;Y
2025-09-23,Concomitant Medication Yes No Indicator,C83056,C83056,C82438,Event Occurrence Indicators;Concomitant Medication,CMYN,Nominal,An indication of whether concomitant medication usage has occurred.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Diagnostic Mammography,C79416,C79416,C16818,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures,Diagnostic Mammogram,Nominal,Mammography done after suspicious results on a screening mammogram or after other signs of possible breast cancer.,,,,C117511,C117511,Reported Name of Procedure,string,Diagnostic Mammography
2025-09-23,Diagnostic Mammography,C79416,C79416,C16818,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures,Diagnostic Mammogram,Nominal,Mammography done after suspicious results on a screening mammogram or after other signs of possible breast cancer.,,,,C25692,C25692,Subcategory,string,
2025-09-23,Diagnostic Mammography,C79416,C79416,C16818,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures,Diagnostic Mammogram,Nominal,Mammography done after suspicious results on a screening mammogram or after other signs of possible breast cancer.,,,,C171000,C171000,Prespecified Event or Intervention Indicator,boolean,Y;N
2025-09-23,Diagnostic Mammography,C79416,C79416,C16818,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures,Diagnostic Mammogram,Nominal,Mammography done after suspicious results on a screening mammogram or after other signs of possible breast cancer.,,,,C25372,C25372,Category,string,
2025-09-23,Diagnostic Mammography,C79416,C79416,C16818,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures,Diagnostic Mammogram,Nominal,Mammography done after suspicious results on a screening mammogram or after other signs of possible breast cancer.,,,,C117512,C117512,Standardized Name of Procedure,string,
2025-09-23,Diagnostic Mammography,C79416,C79416,C16818,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures,Diagnostic Mammogram,Nominal,Mammography done after suspicious results on a screening mammogram or after other signs of possible breast cancer.,,,,C54215,C54215,Directionality,string,
2025-09-23,Diagnostic Mammography,C79416,C79416,C16818,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures,Diagnostic Mammogram,Nominal,Mammography done after suspicious results on a screening mammogram or after other signs of possible breast cancer.,,,,C127786,C127786,Occurrence Indicator,boolean,Y;N
2025-09-23,Diagnostic Mammography,C79416,C79416,C16818,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures,Diagnostic Mammogram,Nominal,Mammography done after suspicious results on a screening mammogram or after other signs of possible breast cancer.,,,,C25185,C25185,Laterality,string,Left;Right;Bilateral
2025-09-23,Diagnostic Mammography,C79416,C79416,C16818,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures,Diagnostic Mammogram,Nominal,Mammography done after suspicious results on a screening mammogram or after other signs of possible breast cancer.,,,,C13717,C13717,Anatomic Site,string,Breast
2025-09-23,Diagnostic Mammography,C79416,C79416,C16818,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures,Diagnostic Mammogram,Nominal,Mammography done after suspicious results on a screening mammogram or after other signs of possible breast cancer.,,,,C117530,C117530,End Date and Time of Procedure,datetime,
2025-09-23,Diagnostic Mammography,C79416,C79416,C16818,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures,Diagnostic Mammogram,Nominal,Mammography done after suspicious results on a screening mammogram or after other signs of possible breast cancer.,,,,C117529,C117529,Start Date and Time of Procedure,datetime,
2025-09-23,Diagnostic Ultrasound,C19337,C19337,C17230,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures,Diagnostic Ultrasonography;Diagnosis (US);Ultrasound,Nominal,Use of ultrasound for imaging for diagnostic purposes.,,,,C171000,C171000,Prespecified Event or Intervention Indicator,boolean,Y;N
2025-09-23,Diagnostic Ultrasound,C19337,C19337,C17230,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures,Diagnostic Ultrasonography;Diagnosis (US);Ultrasound,Nominal,Use of ultrasound for imaging for diagnostic purposes.,,,,C13717,C13717,Anatomic Site,string,Abdomen;Pelvis;Heart;Breast
2025-09-23,Diagnostic Ultrasound,C19337,C19337,C17230,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures,Diagnostic Ultrasonography;Diagnosis (US);Ultrasound,Nominal,Use of ultrasound for imaging for diagnostic purposes.,,,,C127786,C127786,Occurrence Indicator,boolean,Y;N
2025-09-23,Diagnostic Ultrasound,C19337,C19337,C17230,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures,Diagnostic Ultrasonography;Diagnosis (US);Ultrasound,Nominal,Use of ultrasound for imaging for diagnostic purposes.,,,,C117529,C117529,Start Date and Time of Procedure,datetime,
2025-09-23,Diagnostic Ultrasound,C19337,C19337,C17230,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures,Diagnostic Ultrasonography;Diagnosis (US);Ultrasound,Nominal,Use of ultrasound for imaging for diagnostic purposes.,,,,C54215,C54215,Directionality,string,
2025-09-23,Diagnostic Ultrasound,C19337,C19337,C17230,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures,Diagnostic Ultrasonography;Diagnosis (US);Ultrasound,Nominal,Use of ultrasound for imaging for diagnostic purposes.,,,,C25185,C25185,Laterality,string,Left;Right;Bilateral
2025-09-23,Diagnostic Ultrasound,C19337,C19337,C17230,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures,Diagnostic Ultrasonography;Diagnosis (US);Ultrasound,Nominal,Use of ultrasound for imaging for diagnostic purposes.,,,,C117511,C117511,Reported Name of Procedure,string,Diagnostic Ultrasound
2025-09-23,Diagnostic Ultrasound,C19337,C19337,C17230,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures,Diagnostic Ultrasonography;Diagnosis (US);Ultrasound,Nominal,Use of ultrasound for imaging for diagnostic purposes.,,,,C25372,C25372,Category,string,
2025-09-23,Diagnostic Ultrasound,C19337,C19337,C17230,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures,Diagnostic Ultrasonography;Diagnosis (US);Ultrasound,Nominal,Use of ultrasound for imaging for diagnostic purposes.,,,,C25692,C25692,Subcategory,string,
2025-09-23,Diagnostic Ultrasound,C19337,C19337,C17230,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures,Diagnostic Ultrasonography;Diagnosis (US);Ultrasound,Nominal,Use of ultrasound for imaging for diagnostic purposes.,,,,C117530,C117530,End Date and Time of Procedure,datetime,
2025-09-23,Diagnostic Ultrasound,C19337,C19337,C17230,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures,Diagnostic Ultrasonography;Diagnosis (US);Ultrasound,Nominal,Use of ultrasound for imaging for diagnostic purposes.,,,,C117512,C117512,Standardized Name of Procedure,string,
2025-09-23,Disease-Free Survival,C17751,C17751,,Disease Response;Disease Response Criteria;Survival,Disease Free;Disease-Free Survival;DFS,Temporal,The length of time after treatment for a specific disease during which a patient survives with no sign of recurrence of the disease.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Disease-Free Survival,C17751,C17751,,Disease Response;Disease Response Criteria;Survival,Disease Free;Disease-Free Survival;DFS,Temporal,The length of time after treatment for a specific disease during which a patient survives with no sign of recurrence of the disease.,,,,C42574,C42574,Unit of Time,string,Days;Weeks;Months;Years
2025-09-23,Disease-Free Survival,C17751,C17751,,Disease Response;Disease Response Criteria;Survival,Disease Free;Disease-Free Survival;DFS,Temporal,The length of time after treatment for a specific disease during which a patient survives with no sign of recurrence of the disease.,,,,C25372,C25372,Category,string,
2025-09-23,Disease-Free Survival,C17751,C17751,,Disease Response;Disease Response Criteria;Survival,Disease Free;Disease-Free Survival;DFS,Temporal,The length of time after treatment for a specific disease during which a patient survives with no sign of recurrence of the disease.,,,,C70856,C70856,Observation Result,decimal,
2025-09-23,Disease-Free Survival,C17751,C17751,,Disease Response;Disease Response Criteria;Survival,Disease Free;Disease-Free Survival;DFS,Temporal,The length of time after treatment for a specific disease during which a patient survives with no sign of recurrence of the disease.,,,,C25692,C25692,Subcategory,string,
2025-09-23,ECOG - Performance Status,C102408,C102408,C101874,QRS;Clinical or Research Assessment Classification;Eastern Cooperative Oncology Group Performance Status Clinical Classification;ECOG;ECOG1;ECOG Clinical Classification Question,ECOG1-Performance Status;ECOG101;ECOG - Performance Status,Ordinal,Eastern Cooperative Oncology Group (ECOG) Performance status.,http://loinc.org/,LOINC,89247-1,C46126,C46126,Ordinal Position,integer,0;1;2;3;4;5
2025-09-23,ECOG - Performance Status,C102408,C102408,C101874,QRS;Clinical or Research Assessment Classification;Eastern Cooperative Oncology Group Performance Status Clinical Classification;ECOG;ECOG1;ECOG Clinical Classification Question,ECOG1-Performance Status;ECOG101;ECOG - Performance Status,Ordinal,Eastern Cooperative Oncology Group (ECOG) Performance status.,http://loinc.org/,LOINC,89247-1,C25372,C25372,Category,string,ECOG
2025-09-23,ECOG - Performance Status,C102408,C102408,C101874,QRS;Clinical or Research Assessment Classification;Eastern Cooperative Oncology Group Performance Status Clinical Classification;ECOG;ECOG1;ECOG Clinical Classification Question,ECOG1-Performance Status;ECOG101;ECOG - Performance Status,Ordinal,Eastern Cooperative Oncology Group (ECOG) Performance status.,http://loinc.org/,LOINC,89247-1,C91106,C91106,Clinical or Research Assessment Answer,string,"Fully active, able to carry on all pre-disease performance without restriction;Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work;Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours;Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours;Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair;Dead"
2025-09-23,ECOG - Performance Status,C102408,C102408,C101874,QRS;Clinical or Research Assessment Classification;Eastern Cooperative Oncology Group Performance Status Clinical Classification;ECOG;ECOG1;ECOG Clinical Classification Question,ECOG1-Performance Status;ECOG101;ECOG - Performance Status,Ordinal,Eastern Cooperative Oncology Group (ECOG) Performance status.,http://loinc.org/,LOINC,89247-1,C82515,C82515,Collection Date Time,datetime,
2025-09-23,ECOG Clinical Classification Question,C101874,C101874,C211913,QRS Instrument Questions,,,A question associated with the ECOG performance status questionnaire.,,,,,,,,
2025-09-23,EQ-5D-5L - Anxiety or Depression,C102071,C102071,C101875,QRS;EQ-5D-5L;EQ5D02;European Quality of Life Five Dimension Five Level Scale;EQ-5D-5L Questionnaire Questions,EQ5D02-Anxiety/Depression;EQ5D0205,Ordinal,The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Check the one box that best describes your health today: Anxiety or depression.,,,,C82534,C82534,Evaluation Interval,string,Today
2025-09-23,EQ-5D-5L - Anxiety or Depression,C102071,C102071,C101875,QRS;EQ-5D-5L;EQ5D02;European Quality of Life Five Dimension Five Level Scale;EQ-5D-5L Questionnaire Questions,EQ5D02-Anxiety/Depression;EQ5D0205,Ordinal,The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Check the one box that best describes your health today: Anxiety or depression.,,,,C46126,C46126,Ordinal Position,integer,1;2;3;4;5
2025-09-23,EQ-5D-5L - Anxiety or Depression,C102071,C102071,C101875,QRS;EQ-5D-5L;EQ5D02;European Quality of Life Five Dimension Five Level Scale;EQ-5D-5L Questionnaire Questions,EQ5D02-Anxiety/Depression;EQ5D0205,Ordinal,The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Check the one box that best describes your health today: Anxiety or depression.,,,,C25372,C25372,Category,string,EQ-5D-5L
2025-09-23,EQ-5D-5L - Anxiety or Depression,C102071,C102071,C101875,QRS;EQ-5D-5L;EQ5D02;European Quality of Life Five Dimension Five Level Scale;EQ-5D-5L Questionnaire Questions,EQ5D02-Anxiety/Depression;EQ5D0205,Ordinal,The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Check the one box that best describes your health today: Anxiety or depression.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,I am not anxious or depressed;I am slightly anxious or depressed;I am moderately anxious or depressed;I am severely anxious or depressed;I am extremely anxious or depressed
2025-09-23,EQ-5D-5L - Anxiety or Depression,C102071,C102071,C101875,QRS;EQ-5D-5L;EQ5D02;European Quality of Life Five Dimension Five Level Scale;EQ-5D-5L Questionnaire Questions,EQ5D02-Anxiety/Depression;EQ5D0205,Ordinal,The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Check the one box that best describes your health today: Anxiety or depression.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,EQ-5D-5L - EQ VAS Score,C102072,C102072,C101875,QRS;EQ-5D-5L;EQ5D02;European Quality of Life Five Dimension Five Level Scale;EQ-5D-5L Questionnaire Questions,EQ5D02-EQ VAS Score;EQ5D0206,Ordinal,The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Mark an X on the scale to indicate how your health is today and write the number you marked on the scale in the box below.,,,,C121935,C121935,High Reference Range in Text Format,string,The best health you can imagine
2025-09-23,EQ-5D-5L - EQ VAS Score,C102072,C102072,C101875,QRS;EQ-5D-5L;EQ5D02;European Quality of Life Five Dimension Five Level Scale;EQ-5D-5L Questionnaire Questions,EQ5D02-EQ VAS Score;EQ5D0206,Ordinal,The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Mark an X on the scale to indicate how your health is today and write the number you marked on the scale in the box below.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,EQ-5D-5L - EQ VAS Score,C102072,C102072,C101875,QRS;EQ-5D-5L;EQ5D02;European Quality of Life Five Dimension Five Level Scale;EQ-5D-5L Questionnaire Questions,EQ5D02-EQ VAS Score;EQ5D0206,Ordinal,The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Mark an X on the scale to indicate how your health is today and write the number you marked on the scale in the box below.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,The worst health you can imagine;The best health you can imagine
2025-09-23,EQ-5D-5L - EQ VAS Score,C102072,C102072,C101875,QRS;EQ-5D-5L;EQ5D02;European Quality of Life Five Dimension Five Level Scale;EQ-5D-5L Questionnaire Questions,EQ5D02-EQ VAS Score;EQ5D0206,Ordinal,The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Mark an X on the scale to indicate how your health is today and write the number you marked on the scale in the box below.,,,,C82535,C82535,Test Method,string,Visual Analog Scale (1-100)
2025-09-23,EQ-5D-5L - EQ VAS Score,C102072,C102072,C101875,QRS;EQ-5D-5L;EQ5D02;European Quality of Life Five Dimension Five Level Scale;EQ-5D-5L Questionnaire Questions,EQ5D02-EQ VAS Score;EQ5D0206,Ordinal,The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Mark an X on the scale to indicate how your health is today and write the number you marked on the scale in the box below.,,,,C25372,C25372,Category,string,EQ-5D-5L
2025-09-23,EQ-5D-5L - EQ VAS Score,C102072,C102072,C101875,QRS;EQ-5D-5L;EQ5D02;European Quality of Life Five Dimension Five Level Scale;EQ-5D-5L Questionnaire Questions,EQ5D02-EQ VAS Score;EQ5D0206,Ordinal,The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Mark an X on the scale to indicate how your health is today and write the number you marked on the scale in the box below.,,,,C70934,C70934,Low Test Reference Range,integer,0
2025-09-23,EQ-5D-5L - EQ VAS Score,C102072,C102072,C101875,QRS;EQ-5D-5L;EQ5D02;European Quality of Life Five Dimension Five Level Scale;EQ-5D-5L Questionnaire Questions,EQ5D02-EQ VAS Score;EQ5D0206,Ordinal,The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Mark an X on the scale to indicate how your health is today and write the number you marked on the scale in the box below.,,,,C121936,C121936,Low Reference Range in Text Format,string,The worst health you can imagine
2025-09-23,EQ-5D-5L - EQ VAS Score,C102072,C102072,C101875,QRS;EQ-5D-5L;EQ5D02;European Quality of Life Five Dimension Five Level Scale;EQ-5D-5L Questionnaire Questions,EQ5D02-EQ VAS Score;EQ5D0206,Ordinal,The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Mark an X on the scale to indicate how your health is today and write the number you marked on the scale in the box below.,,,,C70933,C70933,High Test Reference Range,integer,100
2025-09-23,EQ-5D-5L - EQ VAS Score,C102072,C102072,C101875,QRS;EQ-5D-5L;EQ5D02;European Quality of Life Five Dimension Five Level Scale;EQ-5D-5L Questionnaire Questions,EQ5D02-EQ VAS Score;EQ5D0206,Ordinal,The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Mark an X on the scale to indicate how your health is today and write the number you marked on the scale in the box below.,,,,C82534,C82534,Evaluation Interval,string,Today
2025-09-23,EQ-5D-5L - EQ VAS Score,C102072,C102072,C101875,QRS;EQ-5D-5L;EQ5D02;European Quality of Life Five Dimension Five Level Scale;EQ-5D-5L Questionnaire Questions,EQ5D02-EQ VAS Score;EQ5D0206,Ordinal,The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Mark an X on the scale to indicate how your health is today and write the number you marked on the scale in the box below.,,,,C46126,C46126,Ordinal Position,integer,0;1;2;3;4;5;6;7;8;9;10;11;12;13;14;15;16;17;18;19;20;21;22;23;24;25;26;27;28;29;30;31;32;33;34;35;36;37;38;39;40;41;42;43;44;45;46;47;48;49;50;51;52;53;54;55;56;57;58;59;60;61;62;63;64;65;66;67;68;69;70;71;72;73;74;75;76;77;78;79;80;81;82;83;84;85;86;87;88;89;90;91;92;93;94;95;96;97;98;99;100
2025-09-23,EQ-5D-5L - Mobility,C102067,C102067,C101875,QRS;EQ-5D-5L;EQ5D02;European Quality of Life Five Dimension Five Level Scale;EQ-5D-5L Questionnaire Questions,EQ5D02-Mobility;EQ5D0201,Ordinal,The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Check the one box that best describes your health today: Mobility.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,EQ-5D-5L - Mobility,C102067,C102067,C101875,QRS;EQ-5D-5L;EQ5D02;European Quality of Life Five Dimension Five Level Scale;EQ-5D-5L Questionnaire Questions,EQ5D02-Mobility;EQ5D0201,Ordinal,The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Check the one box that best describes your health today: Mobility.,,,,C46126,C46126,Ordinal Position,integer,1;2;3;4;5
2025-09-23,EQ-5D-5L - Mobility,C102067,C102067,C101875,QRS;EQ-5D-5L;EQ5D02;European Quality of Life Five Dimension Five Level Scale;EQ-5D-5L Questionnaire Questions,EQ5D02-Mobility;EQ5D0201,Ordinal,The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Check the one box that best describes your health today: Mobility.,,,,C25372,C25372,Category,string,EQ-5D-5L
2025-09-23,EQ-5D-5L - Mobility,C102067,C102067,C101875,QRS;EQ-5D-5L;EQ5D02;European Quality of Life Five Dimension Five Level Scale;EQ-5D-5L Questionnaire Questions,EQ5D02-Mobility;EQ5D0201,Ordinal,The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Check the one box that best describes your health today: Mobility.,,,,C82534,C82534,Evaluation Interval,string,Today
2025-09-23,EQ-5D-5L - Mobility,C102067,C102067,C101875,QRS;EQ-5D-5L;EQ5D02;European Quality of Life Five Dimension Five Level Scale;EQ-5D-5L Questionnaire Questions,EQ5D02-Mobility;EQ5D0201,Ordinal,The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Check the one box that best describes your health today: Mobility.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,I have no problems walking;I have slight problems walking;I have moderate problems walking;I have severe problems walking;I am unable to walk
2025-09-23,EQ-5D-5L - Pain or Discomfort,C102070,C102070,C101875,QRS;EQ-5D-5L;EQ5D02;European Quality of Life Five Dimension Five Level Scale;EQ-5D-5L Questionnaire Questions,EQ5D02-Pain/Discomfort;EQ5D0204,Ordinal,The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Check the one box that best describes your health today: Pain or discomfort.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,EQ-5D-5L - Pain or Discomfort,C102070,C102070,C101875,QRS;EQ-5D-5L;EQ5D02;European Quality of Life Five Dimension Five Level Scale;EQ-5D-5L Questionnaire Questions,EQ5D02-Pain/Discomfort;EQ5D0204,Ordinal,The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Check the one box that best describes your health today: Pain or discomfort.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,I have no pain or discomfort;I have slight pain or discomfort;I have moderate pain or discomfort;I have severe pain or discomfort;I have extreme pain or discomfort
2025-09-23,EQ-5D-5L - Pain or Discomfort,C102070,C102070,C101875,QRS;EQ-5D-5L;EQ5D02;European Quality of Life Five Dimension Five Level Scale;EQ-5D-5L Questionnaire Questions,EQ5D02-Pain/Discomfort;EQ5D0204,Ordinal,The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Check the one box that best describes your health today: Pain or discomfort.,,,,C25372,C25372,Category,string,EQ-5D-5L
2025-09-23,EQ-5D-5L - Pain or Discomfort,C102070,C102070,C101875,QRS;EQ-5D-5L;EQ5D02;European Quality of Life Five Dimension Five Level Scale;EQ-5D-5L Questionnaire Questions,EQ5D02-Pain/Discomfort;EQ5D0204,Ordinal,The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Check the one box that best describes your health today: Pain or discomfort.,,,,C82534,C82534,Evaluation Interval,string,Today
2025-09-23,EQ-5D-5L - Pain or Discomfort,C102070,C102070,C101875,QRS;EQ-5D-5L;EQ5D02;European Quality of Life Five Dimension Five Level Scale;EQ-5D-5L Questionnaire Questions,EQ5D02-Pain/Discomfort;EQ5D0204,Ordinal,The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Check the one box that best describes your health today: Pain or discomfort.,,,,C46126,C46126,Ordinal Position,integer,1;2;3;4;5
2025-09-23,EQ-5D-5L - Self-Care,C102068,C102068,C101875,QRS;EQ-5D-5L;EQ5D02;European Quality of Life Five Dimension Five Level Scale;EQ-5D-5L Questionnaire Questions,EQ5D02-Self-Care;EQ5D0202,Ordinal,The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Check the one box that best describes your health today: Self-care.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,I have no problems washing or dressing myself;I have slight problems washing or dressing myself;I have moderate problems washing or dressing myself;I have severe problems washing or dressing myself;I am unable to wash or dress myself
2025-09-23,EQ-5D-5L - Self-Care,C102068,C102068,C101875,QRS;EQ-5D-5L;EQ5D02;European Quality of Life Five Dimension Five Level Scale;EQ-5D-5L Questionnaire Questions,EQ5D02-Self-Care;EQ5D0202,Ordinal,The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Check the one box that best describes your health today: Self-care.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,EQ-5D-5L - Self-Care,C102068,C102068,C101875,QRS;EQ-5D-5L;EQ5D02;European Quality of Life Five Dimension Five Level Scale;EQ-5D-5L Questionnaire Questions,EQ5D02-Self-Care;EQ5D0202,Ordinal,The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Check the one box that best describes your health today: Self-care.,,,,C46126,C46126,Ordinal Position,integer,1;2;3;4;5
2025-09-23,EQ-5D-5L - Self-Care,C102068,C102068,C101875,QRS;EQ-5D-5L;EQ5D02;European Quality of Life Five Dimension Five Level Scale;EQ-5D-5L Questionnaire Questions,EQ5D02-Self-Care;EQ5D0202,Ordinal,The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Check the one box that best describes your health today: Self-care.,,,,C25372,C25372,Category,string,EQ-5D-5L
2025-09-23,EQ-5D-5L - Self-Care,C102068,C102068,C101875,QRS;EQ-5D-5L;EQ5D02;European Quality of Life Five Dimension Five Level Scale;EQ-5D-5L Questionnaire Questions,EQ5D02-Self-Care;EQ5D0202,Ordinal,The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Check the one box that best describes your health today: Self-care.,,,,C82534,C82534,Evaluation Interval,string,Today
2025-09-23,EQ-5D-5L - Usual Activities,C102069,C102069,C101875,QRS;EQ-5D-5L;EQ5D02;European Quality of Life Five Dimension Five Level Scale;EQ-5D-5L Questionnaire Questions,EQ5D02-Usual Activities;EQ5D0203,Ordinal,The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Check the one box that best describes your health today: Usual activities.,,,,C25372,C25372,Category,string,EQ-5D-5L
2025-09-23,EQ-5D-5L - Usual Activities,C102069,C102069,C101875,QRS;EQ-5D-5L;EQ5D02;European Quality of Life Five Dimension Five Level Scale;EQ-5D-5L Questionnaire Questions,EQ5D02-Usual Activities;EQ5D0203,Ordinal,The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Check the one box that best describes your health today: Usual activities.,,,,C46126,C46126,Ordinal Position,integer,1;2;3;4;5
2025-09-23,EQ-5D-5L - Usual Activities,C102069,C102069,C101875,QRS;EQ-5D-5L;EQ5D02;European Quality of Life Five Dimension Five Level Scale;EQ-5D-5L Questionnaire Questions,EQ5D02-Usual Activities;EQ5D0203,Ordinal,The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Check the one box that best describes your health today: Usual activities.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,I have no problems doing my usual activities;I have slight problems doing my usual activities;I have moderate problems doing my usual activities;I have severe problems doing my usual activities;I am unable to do my usual activities
2025-09-23,EQ-5D-5L - Usual Activities,C102069,C102069,C101875,QRS;EQ-5D-5L;EQ5D02;European Quality of Life Five Dimension Five Level Scale;EQ-5D-5L Questionnaire Questions,EQ5D02-Usual Activities;EQ5D0203,Ordinal,The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Check the one box that best describes your health today: Usual activities.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,EQ-5D-5L - Usual Activities,C102069,C102069,C101875,QRS;EQ-5D-5L;EQ5D02;European Quality of Life Five Dimension Five Level Scale;EQ-5D-5L Questionnaire Questions,EQ5D02-Usual Activities;EQ5D0203,Ordinal,The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Check the one box that best describes your health today: Usual activities.,,,,C82534,C82534,Evaluation Interval,string,Today
2025-09-23,Eastern Cooperative Oncology Group Performance Status Clinical Classification,C102116,C102116,C118969,QRS;Clinical or Research Assessment Classification;Eastern Cooperative Oncology Group Performance Status Clinical Classification;ECOG;ECOG1,,,"A standardized classification scale, published by Oken et al. in 1982 for the Eastern Cooperative Oncology Group (ECOG), that utilizes a six point rating scale to assess a patient's functional status.",,,,,,,,
2025-09-23,Education Level,C17953,C17953,C17468,Subject Characteristics;Socioeconomic Factors;Socioeconomic Status;Education,EDULEVEL;Education Level Completed;Education,Nominal,"An indication of the years of schooling completed in graded public, private, or parochial schools, and in colleges, universities, or professional schools.",,,,C70856,C70856,Observation Result,string,8th Grade Completion;High School Completion;College Completion;Bachelor's Degree Completion;Master's Degree Completion
2025-09-23,Education Level,C17953,C17953,C17468,Subject Characteristics;Socioeconomic Factors;Socioeconomic Status;Education,EDULEVEL;Education Level Completed;Education,Nominal,"An indication of the years of schooling completed in graded public, private, or parochial schools, and in colleges, universities, or professional schools.",,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Estrogen Receptor Measurement,C112274,C112274,C64430,Laboratory Tests;Chemistry Tests;Protein or Enzyme Type Measurements;Endocrine Tests;Hormone Measurements,ESTRCPT;ESR;ER;Estrogen Receptor;Oestrogen Receptor,Nominal;Quantitative,The determination of the amount of estrogen receptor present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Tissue
2025-09-23,Estrogen Receptor Measurement,C112274,C112274,C64430,Laboratory Tests;Chemistry Tests;Protein or Enzyme Type Measurements;Endocrine Tests;Hormone Measurements,ESTRCPT;ESR;ER;Estrogen Receptor;Oestrogen Receptor,Nominal;Quantitative,The determination of the amount of estrogen receptor present in a sample.,,,,C82535,C82535,Test Method,string,Immunohistochemistry
2025-09-23,Estrogen Receptor Measurement,C112274,C112274,C64430,Laboratory Tests;Chemistry Tests;Protein or Enzyme Type Measurements;Endocrine Tests;Hormone Measurements,ESTRCPT;ESR;ER;Estrogen Receptor;Oestrogen Receptor,Nominal;Quantitative,The determination of the amount of estrogen receptor present in a sample.,,,,C170500,C170500,Result Anatomical Location,string,Breast
2025-09-23,Estrogen Receptor Measurement,C112274,C112274,C64430,Laboratory Tests;Chemistry Tests;Protein or Enzyme Type Measurements;Endocrine Tests;Hormone Measurements,ESTRCPT;ESR;ER;Estrogen Receptor;Oestrogen Receptor,Nominal;Quantitative,The determination of the amount of estrogen receptor present in a sample.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Estrogen Receptor Measurement,C112274,C112274,C64430,Laboratory Tests;Chemistry Tests;Protein or Enzyme Type Measurements;Endocrine Tests;Hormone Measurements,ESTRCPT;ESR;ER;Estrogen Receptor;Oestrogen Receptor,Nominal;Quantitative,The determination of the amount of estrogen receptor present in a sample.,,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Allred Proportion Positive Score;Allred  Staining Intensity Score;Allred Total Score
2025-09-23,Estrogen Receptor Measurement,C112274,C112274,C64430,Laboratory Tests;Chemistry Tests;Protein or Enzyme Type Measurements;Endocrine Tests;Hormone Measurements,ESTRCPT;ESR;ER;Estrogen Receptor;Oestrogen Receptor,Nominal;Quantitative,The determination of the amount of estrogen receptor present in a sample.,,,,C70856,C70856,Observation Result,string,
2025-09-23,Estrogen Receptor Positive,C15492,C15492,C16150,Laboratory Tests;Chemistry Tests;Protein or Enzyme Type Measurements;Endocrine Tests;Hormone Measurements,ER Alpha Positive;ER Positive;ER-Alpha Positive;ER +;ERA Positive;Positive Estrogen Receptor;ERS1 Positive,Ordinal,An indication that estrogen receptor alpha expression has been detected in a sample.,,,,C25372,C25372,Category,string,Hormone Receptor
2025-09-23,Estrogen Receptor Positive,C15492,C15492,C16150,Laboratory Tests;Chemistry Tests;Protein or Enzyme Type Measurements;Endocrine Tests;Hormone Measurements,ER Alpha Positive;ER Positive;ER-Alpha Positive;ER +;ERA Positive;Positive Estrogen Receptor;ERS1 Positive,Ordinal,An indication that estrogen receptor alpha expression has been detected in a sample.,,,,C25692,C25692,Subcategory,string,Nuclear Receptor
2025-09-23,Estrogen Receptor Positive,C15492,C15492,C16150,Laboratory Tests;Chemistry Tests;Protein or Enzyme Type Measurements;Endocrine Tests;Hormone Measurements,ER Alpha Positive;ER Positive;ER-Alpha Positive;ER +;ERA Positive;Positive Estrogen Receptor;ERS1 Positive,Ordinal,An indication that estrogen receptor alpha expression has been detected in a sample.,,,,C70856,C70856,Observation Result,boolean,Y;N
2025-09-23,Estrogen Receptor Positive,C15492,C15492,C16150,Laboratory Tests;Chemistry Tests;Protein or Enzyme Type Measurements;Endocrine Tests;Hormone Measurements,ER Alpha Positive;ER Positive;ER-Alpha Positive;ER +;ERA Positive;Positive Estrogen Receptor;ERS1 Positive,Ordinal,An indication that estrogen receptor alpha expression has been detected in a sample.,,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Overall Status
2025-09-23,Estrogen Receptor Positive,C15492,C15492,C16150,Laboratory Tests;Chemistry Tests;Protein or Enzyme Type Measurements;Endocrine Tests;Hormone Measurements,ER Alpha Positive;ER Positive;ER-Alpha Positive;ER +;ERA Positive;Positive Estrogen Receptor;ERS1 Positive,Ordinal,An indication that estrogen receptor alpha expression has been detected in a sample.,,,,C171435,C171435,Specimen Anatomic Site,string,
2025-09-23,Estrogen Receptor Positive,C15492,C15492,C16150,Laboratory Tests;Chemistry Tests;Protein or Enzyme Type Measurements;Endocrine Tests;Hormone Measurements,ER Alpha Positive;ER Positive;ER-Alpha Positive;ER +;ERA Positive;Positive Estrogen Receptor;ERS1 Positive,Ordinal,An indication that estrogen receptor alpha expression has been detected in a sample.,,,,C70713,C70713,Biospecimen Type,string,
2025-09-23,Estrogen Receptor Positive,C15492,C15492,C16150,Laboratory Tests;Chemistry Tests;Protein or Enzyme Type Measurements;Endocrine Tests;Hormone Measurements,ER Alpha Positive;ER Positive;ER-Alpha Positive;ER +;ERA Positive;Positive Estrogen Receptor;ERS1 Positive,Ordinal,An indication that estrogen receptor alpha expression has been detected in a sample.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Estrogen Receptor Status,C16150,C16150,C188928,Laboratory Tests;Chemistry Tests;Protein or Enzyme Type Measurements;Endocrine Tests;Hormone Measurements,ER Alpha Status;ER Status;ERA Status;ESR Status;ESR1 Status;ESRA Status;Estrogen Receptor 1 Status;Estrogen Receptor Alpha Status;ESTRR Status;NR3A1 Status;Nuclear Receptor Subfamily 3 Group A Member 1 Status,Ordinal,"The estrogen receptor level measured in a primary tumor or in metastases.  There are essentially two distinct forms of breast cancer, one that tends to have an early onset and is characterized by an ER- status, and one that tends to have a late onset and is characterized by an ER+ status.  However, these two variants tend to overlap with respect to age, so it is possible for a young woman to have a ""late-onset"" form of breast cancer and for an older woman to have an ""early-onset"" variant of the disease.",,,,C25372,C25372,Category,string,
2025-09-23,Estrogen Receptor Status,C16150,C16150,C188928,Laboratory Tests;Chemistry Tests;Protein or Enzyme Type Measurements;Endocrine Tests;Hormone Measurements,ER Alpha Status;ER Status;ERA Status;ESR Status;ESR1 Status;ESRA Status;Estrogen Receptor 1 Status;Estrogen Receptor Alpha Status;ESTRR Status;NR3A1 Status;Nuclear Receptor Subfamily 3 Group A Member 1 Status,Ordinal,"The estrogen receptor level measured in a primary tumor or in metastases.  There are essentially two distinct forms of breast cancer, one that tends to have an early onset and is characterized by an ER- status, and one that tends to have a late onset and is characterized by an ER+ status.  However, these two variants tend to overlap with respect to age, so it is possible for a young woman to have a ""late-onset"" form of breast cancer and for an older woman to have an ""early-onset"" variant of the disease.",,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Overall Status
2025-09-23,Estrogen Receptor Status,C16150,C16150,C188928,Laboratory Tests;Chemistry Tests;Protein or Enzyme Type Measurements;Endocrine Tests;Hormone Measurements,ER Alpha Status;ER Status;ERA Status;ESR Status;ESR1 Status;ESRA Status;Estrogen Receptor 1 Status;Estrogen Receptor Alpha Status;ESTRR Status;NR3A1 Status;Nuclear Receptor Subfamily 3 Group A Member 1 Status,Ordinal,"The estrogen receptor level measured in a primary tumor or in metastases.  There are essentially two distinct forms of breast cancer, one that tends to have an early onset and is characterized by an ER- status, and one that tends to have a late onset and is characterized by an ER+ status.  However, these two variants tend to overlap with respect to age, so it is possible for a young woman to have a ""late-onset"" form of breast cancer and for an older woman to have an ""early-onset"" variant of the disease.",,,,C171435,C171435,Specimen Anatomic Site,string,
2025-09-23,Estrogen Receptor Status,C16150,C16150,C188928,Laboratory Tests;Chemistry Tests;Protein or Enzyme Type Measurements;Endocrine Tests;Hormone Measurements,ER Alpha Status;ER Status;ERA Status;ESR Status;ESR1 Status;ESRA Status;Estrogen Receptor 1 Status;Estrogen Receptor Alpha Status;ESTRR Status;NR3A1 Status;Nuclear Receptor Subfamily 3 Group A Member 1 Status,Ordinal,"The estrogen receptor level measured in a primary tumor or in metastases.  There are essentially two distinct forms of breast cancer, one that tends to have an early onset and is characterized by an ER- status, and one that tends to have a late onset and is characterized by an ER+ status.  However, these two variants tend to overlap with respect to age, so it is possible for a young woman to have a ""late-onset"" form of breast cancer and for an older woman to have an ""early-onset"" variant of the disease.",,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Estrogen Receptor Status,C16150,C16150,C188928,Laboratory Tests;Chemistry Tests;Protein or Enzyme Type Measurements;Endocrine Tests;Hormone Measurements,ER Alpha Status;ER Status;ERA Status;ESR Status;ESR1 Status;ESRA Status;Estrogen Receptor 1 Status;Estrogen Receptor Alpha Status;ESTRR Status;NR3A1 Status;Nuclear Receptor Subfamily 3 Group A Member 1 Status,Ordinal,"The estrogen receptor level measured in a primary tumor or in metastases.  There are essentially two distinct forms of breast cancer, one that tends to have an early onset and is characterized by an ER- status, and one that tends to have a late onset and is characterized by an ER+ status.  However, these two variants tend to overlap with respect to age, so it is possible for a young woman to have a ""late-onset"" form of breast cancer and for an older woman to have an ""early-onset"" variant of the disease.",,,,C70713,C70713,Biospecimen Type,string,
2025-09-23,Estrogen Receptor Status,C16150,C16150,C188928,Laboratory Tests;Chemistry Tests;Protein or Enzyme Type Measurements;Endocrine Tests;Hormone Measurements,ER Alpha Status;ER Status;ERA Status;ESR Status;ESR1 Status;ESRA Status;Estrogen Receptor 1 Status;Estrogen Receptor Alpha Status;ESTRR Status;NR3A1 Status;Nuclear Receptor Subfamily 3 Group A Member 1 Status,Ordinal,"The estrogen receptor level measured in a primary tumor or in metastases.  There are essentially two distinct forms of breast cancer, one that tends to have an early onset and is characterized by an ER- status, and one that tends to have a late onset and is characterized by an ER+ status.  However, these two variants tend to overlap with respect to age, so it is possible for a young woman to have a ""late-onset"" form of breast cancer and for an older woman to have an ""early-onset"" variant of the disease.",,,,C70856,C70856,Observation Result,string,Positive;Negative
2025-09-23,Estrogen Receptor Status,C16150,C16150,C188928,Laboratory Tests;Chemistry Tests;Protein or Enzyme Type Measurements;Endocrine Tests;Hormone Measurements,ER Alpha Status;ER Status;ERA Status;ESR Status;ESR1 Status;ESRA Status;Estrogen Receptor 1 Status;Estrogen Receptor Alpha Status;ESTRR Status;NR3A1 Status;Nuclear Receptor Subfamily 3 Group A Member 1 Status,Ordinal,"The estrogen receptor level measured in a primary tumor or in metastases.  There are essentially two distinct forms of breast cancer, one that tends to have an early onset and is characterized by an ER- status, and one that tends to have a late onset and is characterized by an ER+ status.  However, these two variants tend to overlap with respect to age, so it is possible for a young woman to have a ""late-onset"" form of breast cancer and for an older woman to have an ""early-onset"" variant of the disease.",,,,C25692,C25692,Subcategory,string,
2025-09-23,European Quality of Life Five Dimension Five Level Scale Questionnaire,C102117,C102117,C91105,QRS;Research or Clinical Assessment Tools;Clinical or Research Assessment Questionnaires,EQ5D02;EQ-5D-5L;European Quality of Life Five Dimension Five Level Scale Questionnaire,,"A standardized rating scale which is used as a measure of health outcome. This instrument is a descriptive system consisting of 5 dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. Each dimension has 5 levels ranging from no problem to extreme problem or incapable, which are assessed by the patient.",,,,C25372,C25372,Category,string,EQ-5D-5L
2025-09-23,European Quality of Life Five Dimension Five Level Scale Questionnaire,C102117,C102117,C91105,QRS;Research or Clinical Assessment Tools;Clinical or Research Assessment Questionnaires,EQ5D02;EQ-5D-5L;European Quality of Life Five Dimension Five Level Scale Questionnaire,,"A standardized rating scale which is used as a measure of health outcome. This instrument is a descriptive system consisting of 5 dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. Each dimension has 5 levels ranging from no problem to extreme problem or incapable, which are assessed by the patient.",,,,C82525,C82525,Test Occurrence,string,N;Y
2025-09-23,European Quality of Life Five Dimension Five Level Scale Questionnaire,C102117,C102117,C91105,QRS;Research or Clinical Assessment Tools;Clinical or Research Assessment Questionnaires,EQ5D02;EQ-5D-5L;European Quality of Life Five Dimension Five Level Scale Questionnaire,,"A standardized rating scale which is used as a measure of health outcome. This instrument is a descriptive system consisting of 5 dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. Each dimension has 5 levels ranging from no problem to extreme problem or incapable, which are assessed by the patient.",,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,European Quality of Life Five Dimension Five Level Scale Questionnaire,C102117,C102117,C91105,QRS;Research or Clinical Assessment Tools;Clinical or Research Assessment Questionnaires,EQ5D02;EQ-5D-5L;European Quality of Life Five Dimension Five Level Scale Questionnaire,,"A standardized rating scale which is used as a measure of health outcome. This instrument is a descriptive system consisting of 5 dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. Each dimension has 5 levels ranging from no problem to extreme problem or incapable, which are assessed by the patient.",,,,C82534,C82534,Evaluation Interval,string,Today
2025-09-23,Expression Positive,C177692,C177692,,Laboratory Tests;Immunology Tests;Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis,,Ordinal,"An indication that the expression of a gene, transcript or protein has been detected in a sample.",,,,C70713,C70713,Biospecimen Type,string,Tissue;Blood
2025-09-23,Expression Positive,C177692,C177692,,Laboratory Tests;Immunology Tests;Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis,,Ordinal,"An indication that the expression of a gene, transcript or protein has been detected in a sample.",,,,C171435,C171435,Specimen Anatomic Site,string,
2025-09-23,Expression Positive,C177692,C177692,,Laboratory Tests;Immunology Tests;Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis,,Ordinal,"An indication that the expression of a gene, transcript or protein has been detected in a sample.",,,,C70856,C70856,Observation Result,string,Positive;Negative
2025-09-23,Expression Positive,C177692,C177692,,Laboratory Tests;Immunology Tests;Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis,,Ordinal,"An indication that the expression of a gene, transcript or protein has been detected in a sample.",,,,C25692,C25692,Subcategory,string,
2025-09-23,Expression Positive,C177692,C177692,,Laboratory Tests;Immunology Tests;Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis,,Ordinal,"An indication that the expression of a gene, transcript or protein has been detected in a sample.",,,,C25372,C25372,Category,string,
2025-09-23,Expression Positive,C177692,C177692,,Laboratory Tests;Immunology Tests;Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis,,Ordinal,"An indication that the expression of a gene, transcript or protein has been detected in a sample.",,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Expression Positive,C177692,C177692,,Laboratory Tests;Immunology Tests;Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis,,Ordinal,"An indication that the expression of a gene, transcript or protein has been detected in a sample.",,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Overall Status
2025-09-23,Fanconi Anemia Complementation Group Gene Mutation,C159204,C159204,,Genetic Testing;Gene Expression Analysis;Molecular Analysis;Molecular Genetic Variation;Gene Abnormality,BRCA2 and FANC Gene Mutations;Fanconi Anemia Group Gene Mutation,,A change in the nucleotide sequence for a gene that is a member of the Fanconi anemia complementation group.,,,,,,,,
2025-09-23,Genetic Testing,C15709,C15709,C19770,Molecular Analysis;Genetic Variation Analysis;Gene Expression Analysis;Oncology Standards,Genetic Analysis;Genetic Examination,Narrative;Ordinal;Nominal,The process of isolating and testing the DNA of an embryo or a person to detect the presence of genetic alterations or defects that may predispose to the future development of a disease or disorder.,,,,C171435,C171435,Specimen Anatomic Site,string,
2025-09-23,Genetic Testing,C15709,C15709,C19770,Molecular Analysis;Genetic Variation Analysis;Gene Expression Analysis;Oncology Standards,Genetic Analysis;Genetic Examination,Narrative;Ordinal;Nominal,The process of isolating and testing the DNA of an embryo or a person to detect the presence of genetic alterations or defects that may predispose to the future development of a disease or disorder.,,,,C70713,C70713,Biospecimen Type,string,Tissue;Blood
2025-09-23,Genetic Testing,C15709,C15709,C19770,Molecular Analysis;Genetic Variation Analysis;Gene Expression Analysis;Oncology Standards,Genetic Analysis;Genetic Examination,Narrative;Ordinal;Nominal,The process of isolating and testing the DNA of an embryo or a person to detect the presence of genetic alterations or defects that may predispose to the future development of a disease or disorder.,,,,C25372,C25372,Category,string,Genetic Variation;Gene Expression
2025-09-23,Genetic Testing,C15709,C15709,C19770,Molecular Analysis;Genetic Variation Analysis;Gene Expression Analysis;Oncology Standards,Genetic Analysis;Genetic Examination,Narrative;Ordinal;Nominal,The process of isolating and testing the DNA of an embryo or a person to detect the presence of genetic alterations or defects that may predispose to the future development of a disease or disorder.,,,,C70856,C70856,Observation Result,string,Positive;Negative;Variant of Unknown Significance
2025-09-23,Genetic Testing,C15709,C15709,C19770,Molecular Analysis;Genetic Variation Analysis;Gene Expression Analysis;Oncology Standards,Genetic Analysis;Genetic Examination,Narrative;Ordinal;Nominal,The process of isolating and testing the DNA of an embryo or a person to detect the presence of genetic alterations or defects that may predispose to the future development of a disease or disorder.,,,,C25692,C25692,Subcategory,string,Single Nucleotide Polymorphism;Copy Number Variation
2025-09-23,Genetic Testing,C15709,C15709,C19770,Molecular Analysis;Genetic Variation Analysis;Gene Expression Analysis;Oncology Standards,Genetic Analysis;Genetic Examination,Narrative;Ordinal;Nominal,The process of isolating and testing the DNA of an embryo or a person to detect the presence of genetic alterations or defects that may predispose to the future development of a disease or disorder.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Genetic Variation Analysis,C18302,C18302,,Genomics Findings;Genetic Variation Analysis;Oncology Standards;Genetic Testing;Gene Expression Analysis;Molecular Analysis;Laboratory Procedures,Mutation Analysis,,The identification of genetic variation in a biological sample.,,,,,,,,
2025-09-23,Genomic Profile,C94411,C94411,C19770,Genetic Testing;Gene Expression Analysis;Genetic Variation;Genetic Variation Analysis,Genomic Profiling;Genomic Test;Genomic Testing,Narrative,"An analysis of all the genes in an organism or cell type; this includes assays that identify variants, examine gene expression and determine the interactions of genes with each other and with the environment.",,,,C171435,C171435,Specimen Anatomic Site,string,
2025-09-23,Genomic Profile,C94411,C94411,C19770,Genetic Testing;Gene Expression Analysis;Genetic Variation;Genetic Variation Analysis,Genomic Profiling;Genomic Test;Genomic Testing,Narrative,"An analysis of all the genes in an organism or cell type; this includes assays that identify variants, examine gene expression and determine the interactions of genes with each other and with the environment.",,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Genomic Profile,C94411,C94411,C19770,Genetic Testing;Gene Expression Analysis;Genetic Variation;Genetic Variation Analysis,Genomic Profiling;Genomic Test;Genomic Testing,Narrative,"An analysis of all the genes in an organism or cell type; this includes assays that identify variants, examine gene expression and determine the interactions of genes with each other and with the environment.",,,,C70856,C70856,Observation Result,string,
2025-09-23,Genomic Profile,C94411,C94411,C19770,Genetic Testing;Gene Expression Analysis;Genetic Variation;Genetic Variation Analysis,Genomic Profiling;Genomic Test;Genomic Testing,Narrative,"An analysis of all the genes in an organism or cell type; this includes assays that identify variants, examine gene expression and determine the interactions of genes with each other and with the environment.",,,,C25372,C25372,Category,string,
2025-09-23,Genomic Profile,C94411,C94411,C19770,Genetic Testing;Gene Expression Analysis;Genetic Variation;Genetic Variation Analysis,Genomic Profiling;Genomic Test;Genomic Testing,Narrative,"An analysis of all the genes in an organism or cell type; this includes assays that identify variants, examine gene expression and determine the interactions of genes with each other and with the environment.",,,,C70713,C70713,Biospecimen Type,string,
2025-09-23,Genomic Profile,C94411,C94411,C19770,Genetic Testing;Gene Expression Analysis;Genetic Variation;Genetic Variation Analysis,Genomic Profiling;Genomic Test;Genomic Testing,Narrative,"An analysis of all the genes in an organism or cell type; this includes assays that identify variants, examine gene expression and determine the interactions of genes with each other and with the environment.",,,,C25692,C25692,Subcategory,string,
2025-09-23,Glucose Measurement,C105585,C105585,C49237,Laboratory Tests;Chemistry Tests,Glucose,Quantitative;Ordinal,The determination of the amount of glucose present in a sample.,,,,C70856,C70856,Observation Result,string,
2025-09-23,Glucose Measurement,C105585,C105585,C49237,Laboratory Tests;Chemistry Tests,Glucose,Quantitative;Ordinal,The determination of the amount of glucose present in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-09-23,Glucose Measurement,C105585,C105585,C49237,Laboratory Tests;Chemistry Tests,Glucose,Quantitative;Ordinal,The determination of the amount of glucose present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Blood;Plasma;Serum;Urine
2025-09-23,Glucose Measurement,C105585,C105585,C49237,Laboratory Tests;Chemistry Tests,Glucose,Quantitative;Ordinal,The determination of the amount of glucose present in a sample.,,,,C215501,C215501,Medical Device Identifier,string,
2025-09-23,Glucose Measurement,C105585,C105585,C49237,Laboratory Tests;Chemistry Tests,Glucose,Quantitative;Ordinal,The determination of the amount of glucose present in a sample.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Glucose Measurement,C105585,C105585,C49237,Laboratory Tests;Chemistry Tests,Glucose,Quantitative;Ordinal,The determination of the amount of glucose present in a sample.,,,,C48207,C48207,Unit of Concentration,string,mg/dL;g/L;mmol/L
2025-09-23,Glucose Measurement,C105585,C105585,C49237,Laboratory Tests;Chemistry Tests,Glucose,Quantitative;Ordinal,The determination of the amount of glucose present in a sample.,,,,C82535,C82535,Test Method,string,
2025-09-23,HBI - Abdominal Mass,C191047,C191047,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Abdominal Mass;HBI0104;HBI - Abdominal Mass,Ordinal,Harvey-Bradshaw Index (HBI) Abdominal mass.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,HBI - Abdominal Mass,C191047,C191047,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Abdominal Mass;HBI0104;HBI - Abdominal Mass,Ordinal,Harvey-Bradshaw Index (HBI) Abdominal mass.,,,,C46126,C46126,Ordinal Position,integer,0;1;2;3
2025-09-23,HBI - Abdominal Mass,C191047,C191047,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Abdominal Mass;HBI0104;HBI - Abdominal Mass,Ordinal,Harvey-Bradshaw Index (HBI) Abdominal mass.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,definite and tender;definite;dubious;none
2025-09-23,HBI - Abdominal Mass,C191047,C191047,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Abdominal Mass;HBI0104;HBI - Abdominal Mass,Ordinal,Harvey-Bradshaw Index (HBI) Abdominal mass.,,,,C25372,C25372,Category,string,HBI
2025-09-23,HBI - Abdominal Pain,C191045,C191045,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Abdominal Pain;HBI0102;HBI - Abdominal Pain,Ordinal,Harvey-Bradshaw Index (HBI) Abdominal pain (for the previous day).,,,,C25372,C25372,Category,string,HBI
2025-09-23,HBI - Abdominal Pain,C191045,C191045,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Abdominal Pain;HBI0102;HBI - Abdominal Pain,Ordinal,Harvey-Bradshaw Index (HBI) Abdominal pain (for the previous day).,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,HBI - Abdominal Pain,C191045,C191045,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Abdominal Pain;HBI0102;HBI - Abdominal Pain,Ordinal,Harvey-Bradshaw Index (HBI) Abdominal pain (for the previous day).,,,,C91106,C91106,Clinical or Research Assessment Answer,string,mild;moderate;none;severe
2025-09-23,HBI - Abdominal Pain,C191045,C191045,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Abdominal Pain;HBI0102;HBI - Abdominal Pain,Ordinal,Harvey-Bradshaw Index (HBI) Abdominal pain (for the previous day).,,,,C46126,C46126,Ordinal Position,integer,0;1;2;3
2025-09-23,HBI - Abdominal Pain,C191045,C191045,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Abdominal Pain;HBI0102;HBI - Abdominal Pain,Ordinal,Harvey-Bradshaw Index (HBI) Abdominal pain (for the previous day).,,,,C82534,C82534,Evaluation Interval,string,-P1D
2025-09-23,HBI - Complication: Abscess,C191055,C191055,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Complication: Abscess;HBI0105H;HBI - Complication: Abscess,Ordinal,Harvey-Bradshaw Index (HBI) Complication: Abscess.,,,,C46126,C46126,Ordinal Position,integer,0;1
2025-09-23,HBI - Complication: Abscess,C191055,C191055,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Complication: Abscess;HBI0105H;HBI - Complication: Abscess,Ordinal,Harvey-Bradshaw Index (HBI) Complication: Abscess.,,,,C25372,C25372,Category,string,HBI
2025-09-23,HBI - Complication: Abscess,C191055,C191055,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Complication: Abscess;HBI0105H;HBI - Complication: Abscess,Ordinal,Harvey-Bradshaw Index (HBI) Complication: Abscess.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,HBI - Complication: Abscess,C191055,C191055,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Complication: Abscess;HBI0105H;HBI - Complication: Abscess,Ordinal,Harvey-Bradshaw Index (HBI) Complication: Abscess.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,no;yes
2025-09-23,HBI - Complication: Anal Fissures,C191053,C191053,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI - Complication: Anal Fissures;HBI01-Complication: Anal Fissures;HBI0105F,Ordinal,Harvey-Bradshaw Index (HBI) Complication: Anal fissures.,,,,C46126,C46126,Ordinal Position,integer,0;1
2025-09-23,HBI - Complication: Anal Fissures,C191053,C191053,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI - Complication: Anal Fissures;HBI01-Complication: Anal Fissures;HBI0105F,Ordinal,Harvey-Bradshaw Index (HBI) Complication: Anal fissures.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,no;yes
2025-09-23,HBI - Complication: Anal Fissures,C191053,C191053,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI - Complication: Anal Fissures;HBI01-Complication: Anal Fissures;HBI0105F,Ordinal,Harvey-Bradshaw Index (HBI) Complication: Anal fissures.,,,,C25372,C25372,Category,string,HBI
2025-09-23,HBI - Complication: Anal Fissures,C191053,C191053,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI - Complication: Anal Fissures;HBI01-Complication: Anal Fissures;HBI0105F,Ordinal,Harvey-Bradshaw Index (HBI) Complication: Anal fissures.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,HBI - Complication: Aphthous Ulcers,C191051,C191051,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Complication: Aphthous Ulcers;HBI0105D;HBI - Complication: Aphthous Ulcers,Ordinal,Harvey-Bradshaw Index (HBI) Complication: Aphthous ulcers.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,HBI - Complication: Aphthous Ulcers,C191051,C191051,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Complication: Aphthous Ulcers;HBI0105D;HBI - Complication: Aphthous Ulcers,Ordinal,Harvey-Bradshaw Index (HBI) Complication: Aphthous ulcers.,,,,C25372,C25372,Category,string,HBI
2025-09-23,HBI - Complication: Aphthous Ulcers,C191051,C191051,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Complication: Aphthous Ulcers;HBI0105D;HBI - Complication: Aphthous Ulcers,Ordinal,Harvey-Bradshaw Index (HBI) Complication: Aphthous ulcers.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,no;yes
2025-09-23,HBI - Complication: Aphthous Ulcers,C191051,C191051,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Complication: Aphthous Ulcers;HBI0105D;HBI - Complication: Aphthous Ulcers,Ordinal,Harvey-Bradshaw Index (HBI) Complication: Aphthous ulcers.,,,,C46126,C46126,Ordinal Position,integer,0;1
2025-09-23,HBI - Complication: Arthralgia,C191048,C191048,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Complication: Arthralgia;HBI0105A;HBI - Complication: Arthralgia,Ordinal,Harvey-Bradshaw Index (HBI) Complication: Arthralgia.,,,,C46126,C46126,Ordinal Position,integer,0;1
2025-09-23,HBI - Complication: Arthralgia,C191048,C191048,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Complication: Arthralgia;HBI0105A;HBI - Complication: Arthralgia,Ordinal,Harvey-Bradshaw Index (HBI) Complication: Arthralgia.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,no;yes
2025-09-23,HBI - Complication: Arthralgia,C191048,C191048,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Complication: Arthralgia;HBI0105A;HBI - Complication: Arthralgia,Ordinal,Harvey-Bradshaw Index (HBI) Complication: Arthralgia.,,,,C25372,C25372,Category,string,HBI
2025-09-23,HBI - Complication: Arthralgia,C191048,C191048,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Complication: Arthralgia;HBI0105A;HBI - Complication: Arthralgia,Ordinal,Harvey-Bradshaw Index (HBI) Complication: Arthralgia.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,HBI - Complication: Erythema Nodosum,C191050,C191050,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Complication: Erythema Nodosum;HBI0105C;HBI - Complication: Erythema Nodosum,Ordinal,Harvey-Bradshaw Index (HBI) Complication: Erythema nodosum.,,,,C46126,C46126,Ordinal Position,integer,0;1
2025-09-23,HBI - Complication: Erythema Nodosum,C191050,C191050,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Complication: Erythema Nodosum;HBI0105C;HBI - Complication: Erythema Nodosum,Ordinal,Harvey-Bradshaw Index (HBI) Complication: Erythema nodosum.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,no;yes
2025-09-23,HBI - Complication: Erythema Nodosum,C191050,C191050,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Complication: Erythema Nodosum;HBI0105C;HBI - Complication: Erythema Nodosum,Ordinal,Harvey-Bradshaw Index (HBI) Complication: Erythema nodosum.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,HBI - Complication: Erythema Nodosum,C191050,C191050,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Complication: Erythema Nodosum;HBI0105C;HBI - Complication: Erythema Nodosum,Ordinal,Harvey-Bradshaw Index (HBI) Complication: Erythema nodosum.,,,,C25372,C25372,Category,string,HBI
2025-09-23,HBI - Complication: New Fistula,C191054,C191054,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Complication: New Fistula;HBI0105G;HBI - Complication: New Fistula,Ordinal,Harvey-Bradshaw Index (HBI) Complication: New fistula.,,,,C46126,C46126,Ordinal Position,integer,0;1
2025-09-23,HBI - Complication: New Fistula,C191054,C191054,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Complication: New Fistula;HBI0105G;HBI - Complication: New Fistula,Ordinal,Harvey-Bradshaw Index (HBI) Complication: New fistula.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,HBI - Complication: New Fistula,C191054,C191054,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Complication: New Fistula;HBI0105G;HBI - Complication: New Fistula,Ordinal,Harvey-Bradshaw Index (HBI) Complication: New fistula.,,,,C25372,C25372,Category,string,HBI
2025-09-23,HBI - Complication: New Fistula,C191054,C191054,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Complication: New Fistula;HBI0105G;HBI - Complication: New Fistula,Ordinal,Harvey-Bradshaw Index (HBI) Complication: New fistula.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,no;yes
2025-09-23,HBI - Complication: Pyoderma Gangrenosum,C191052,C191052,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Complication: Pyoderma Gangrenosum;HBI0105E;HBI - Complication: Pyoderma Gangrenosum,Ordinal,Harvey-Bradshaw Index (HBI) Complication: Pyoderma gangrenosum.,,,,C46126,C46126,Ordinal Position,integer,0;1
2025-09-23,HBI - Complication: Pyoderma Gangrenosum,C191052,C191052,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Complication: Pyoderma Gangrenosum;HBI0105E;HBI - Complication: Pyoderma Gangrenosum,Ordinal,Harvey-Bradshaw Index (HBI) Complication: Pyoderma gangrenosum.,,,,C25372,C25372,Category,string,HBI
2025-09-23,HBI - Complication: Pyoderma Gangrenosum,C191052,C191052,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Complication: Pyoderma Gangrenosum;HBI0105E;HBI - Complication: Pyoderma Gangrenosum,Ordinal,Harvey-Bradshaw Index (HBI) Complication: Pyoderma gangrenosum.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,HBI - Complication: Pyoderma Gangrenosum,C191052,C191052,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Complication: Pyoderma Gangrenosum;HBI0105E;HBI - Complication: Pyoderma Gangrenosum,Ordinal,Harvey-Bradshaw Index (HBI) Complication: Pyoderma gangrenosum.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,no;yes
2025-09-23,HBI - Complication: Uveitis,C191049,C191049,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Complication: Uveitis;HBI0105B;HBI - Complication: Uveitis,Ordinal,Harvey-Bradshaw Index (HBI) Complication: Uveitis.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,HBI - Complication: Uveitis,C191049,C191049,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Complication: Uveitis;HBI0105B;HBI - Complication: Uveitis,Ordinal,Harvey-Bradshaw Index (HBI) Complication: Uveitis.,,,,C25372,C25372,Category,string,HBI
2025-09-23,HBI - Complication: Uveitis,C191049,C191049,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Complication: Uveitis;HBI0105B;HBI - Complication: Uveitis,Ordinal,Harvey-Bradshaw Index (HBI) Complication: Uveitis.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,no;yes
2025-09-23,HBI - Complication: Uveitis,C191049,C191049,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Complication: Uveitis;HBI0105B;HBI - Complication: Uveitis,Ordinal,Harvey-Bradshaw Index (HBI) Complication: Uveitis.,,,,C46126,C46126,Ordinal Position,integer,0;1
2025-09-23,HBI - General Well-being,C191044,C191044,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-General Well-being;HBI0101;HBI - General Well-being,Ordinal,Harvey-Bradshaw Index (HBI) Patient's general well-being (for the previous day).,,,,C91106,C91106,Clinical or Research Assessment Answer,string,poor;slightly below par;terrible;very poor;very well
2025-09-23,HBI - General Well-being,C191044,C191044,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-General Well-being;HBI0101;HBI - General Well-being,Ordinal,Harvey-Bradshaw Index (HBI) Patient's general well-being (for the previous day).,,,,C25372,C25372,Category,string,HBI
2025-09-23,HBI - General Well-being,C191044,C191044,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-General Well-being;HBI0101;HBI - General Well-being,Ordinal,Harvey-Bradshaw Index (HBI) Patient's general well-being (for the previous day).,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,HBI - General Well-being,C191044,C191044,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-General Well-being;HBI0101;HBI - General Well-being,Ordinal,Harvey-Bradshaw Index (HBI) Patient's general well-being (for the previous day).,,,,C82534,C82534,Evaluation Interval,string,-P1D
2025-09-23,HBI - General Well-being,C191044,C191044,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-General Well-being;HBI0101;HBI - General Well-being,Ordinal,Harvey-Bradshaw Index (HBI) Patient's general well-being (for the previous day).,,,,C46126,C46126,Ordinal Position,integer,0;1;2;3;4
2025-09-23,HBI - Number Liquid Stools,C191046,C191046,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Number Liquid Stools;HBI0103;HBI - Number Liquid Stools,Ordinal,Harvey-Bradshaw Index (HBI) Number of liquid stools (for the previous day).,,,,C91106,C91106,Clinical or Research Assessment Answer,string,
2025-09-23,HBI - Number Liquid Stools,C191046,C191046,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Number Liquid Stools;HBI0103;HBI - Number Liquid Stools,Ordinal,Harvey-Bradshaw Index (HBI) Number of liquid stools (for the previous day).,,,,C25372,C25372,Category,string,HBI
2025-09-23,HBI - Number Liquid Stools,C191046,C191046,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Number Liquid Stools;HBI0103;HBI - Number Liquid Stools,Ordinal,Harvey-Bradshaw Index (HBI) Number of liquid stools (for the previous day).,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,HBI - Number Liquid Stools,C191046,C191046,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Number Liquid Stools;HBI0103;HBI - Number Liquid Stools,Ordinal,Harvey-Bradshaw Index (HBI) Number of liquid stools (for the previous day).,,,,C82534,C82534,Evaluation Interval,string,-P1D
2025-09-23,HBI - Number Liquid Stools,C191046,C191046,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Number Liquid Stools;HBI0103;HBI - Number Liquid Stools,Ordinal,Harvey-Bradshaw Index (HBI) Number of liquid stools (for the previous day).,,,,C46126,C46126,Ordinal Position,integer,
2025-09-23,HBI - Total Score,C191056,C191056,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Total Score;HBI0106;HBI - Total Score,Ordinal,Harvey-Bradshaw Index (HBI) Total score.,,,,C46126,C46126,Ordinal Position,integer,
2025-09-23,HBI - Total Score,C191056,C191056,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Total Score;HBI0106;HBI - Total Score,Ordinal,Harvey-Bradshaw Index (HBI) Total score.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,
2025-09-23,HBI - Total Score,C191056,C191056,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Total Score;HBI0106;HBI - Total Score,Ordinal,Harvey-Bradshaw Index (HBI) Total score.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,HBI - Total Score,C191056,C191056,C190943,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01-Total Score;HBI0106;HBI - Total Score,Ordinal,Harvey-Bradshaw Index (HBI) Total score.,,,,C25372,C25372,Category,string,HBI
2025-09-23,HER2-Positive Breast Carcinoma,C53556,C53556,,Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Cancer Biomarkers,ERBB2 Overexpressing Subtype of Breast Carcinoma;HER2 Overexpressing Breast Carcinoma;HER2 Overexpressing Subtype of Breast Carcinoma,Quantitative;Ordinal,"A biologic subset of breast carcinoma defined by high expression of HER2, GRB7, and TRAP100, and by lack of expression of estrogen receptor (ER).",,,,C70856,C70856,Observation Result,boolean,Y;N
2025-09-23,HER2-Positive Breast Carcinoma,C53556,C53556,,Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Cancer Biomarkers,ERBB2 Overexpressing Subtype of Breast Carcinoma;HER2 Overexpressing Breast Carcinoma;HER2 Overexpressing Subtype of Breast Carcinoma,Quantitative;Ordinal,"A biologic subset of breast carcinoma defined by high expression of HER2, GRB7, and TRAP100, and by lack of expression of estrogen receptor (ER).",,,,C171435,C171435,Specimen Anatomic Site,string,Breast
2025-09-23,HER2-Positive Breast Carcinoma,C53556,C53556,,Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Cancer Biomarkers,ERBB2 Overexpressing Subtype of Breast Carcinoma;HER2 Overexpressing Breast Carcinoma;HER2 Overexpressing Subtype of Breast Carcinoma,Quantitative;Ordinal,"A biologic subset of breast carcinoma defined by high expression of HER2, GRB7, and TRAP100, and by lack of expression of estrogen receptor (ER).",,,,C25372,C25372,Category,string,
2025-09-23,HER2-Positive Breast Carcinoma,C53556,C53556,,Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Cancer Biomarkers,ERBB2 Overexpressing Subtype of Breast Carcinoma;HER2 Overexpressing Breast Carcinoma;HER2 Overexpressing Subtype of Breast Carcinoma,Quantitative;Ordinal,"A biologic subset of breast carcinoma defined by high expression of HER2, GRB7, and TRAP100, and by lack of expression of estrogen receptor (ER).",,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Overall Status
2025-09-23,HER2-Positive Breast Carcinoma,C53556,C53556,,Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Cancer Biomarkers,ERBB2 Overexpressing Subtype of Breast Carcinoma;HER2 Overexpressing Breast Carcinoma;HER2 Overexpressing Subtype of Breast Carcinoma,Quantitative;Ordinal,"A biologic subset of breast carcinoma defined by high expression of HER2, GRB7, and TRAP100, and by lack of expression of estrogen receptor (ER).",,,,C25692,C25692,Subcategory,string,
2025-09-23,HER2-Positive Breast Carcinoma,C53556,C53556,,Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Cancer Biomarkers,ERBB2 Overexpressing Subtype of Breast Carcinoma;HER2 Overexpressing Breast Carcinoma;HER2 Overexpressing Subtype of Breast Carcinoma,Quantitative;Ordinal,"A biologic subset of breast carcinoma defined by high expression of HER2, GRB7, and TRAP100, and by lack of expression of estrogen receptor (ER).",,,,C70713,C70713,Biospecimen Type,string,Tissue;Tumor tissue
2025-09-23,HER2/Neu Positive,C68748,C68748,C16152,Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Cancer Biomarkers,ERBB2 Positive;HER-2 Positive;HER2 Positive,Quantitative;Ordinal,A laboratory test result indicating the presence of HER2/Neu in a tissue sample.,,,,C70856,C70856,Observation Result,boolean,Y;N
2025-09-23,HER2/Neu Positive,C68748,C68748,C16152,Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Cancer Biomarkers,ERBB2 Positive;HER-2 Positive;HER2 Positive,Quantitative;Ordinal,A laboratory test result indicating the presence of HER2/Neu in a tissue sample.,,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Overall Status
2025-09-23,HER2/Neu Positive,C68748,C68748,C16152,Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Cancer Biomarkers,ERBB2 Positive;HER-2 Positive;HER2 Positive,Quantitative;Ordinal,A laboratory test result indicating the presence of HER2/Neu in a tissue sample.,,,,C70713,C70713,Biospecimen Type,string,Tissue
2025-09-23,HER2/Neu Positive,C68748,C68748,C16152,Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Cancer Biomarkers,ERBB2 Positive;HER-2 Positive;HER2 Positive,Quantitative;Ordinal,A laboratory test result indicating the presence of HER2/Neu in a tissue sample.,,,,C171435,C171435,Specimen Anatomic Site,string,
2025-09-23,HER2/Neu Positive,C68748,C68748,C16152,Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Cancer Biomarkers,ERBB2 Positive;HER-2 Positive;HER2 Positive,Quantitative;Ordinal,A laboratory test result indicating the presence of HER2/Neu in a tissue sample.,,,,C25372,C25372,Category,string,
2025-09-23,HER2/Neu Positive,C68748,C68748,C16152,Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Cancer Biomarkers,ERBB2 Positive;HER-2 Positive;HER2 Positive,Quantitative;Ordinal,A laboratory test result indicating the presence of HER2/Neu in a tissue sample.,,,,C25692,C25692,Subcategory,string,
2025-09-23,HER2/Neu Status,C16152,C16152,C94299,Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Cancer Biomarkers,ERBB2 Status;HER2/Her2/Neu Value;HER2/neu,Ordinal,The presence or absence of Her2/Neu on a tissue sample.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,HER2/Neu Status,C16152,C16152,C94299,Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Cancer Biomarkers,ERBB2 Status;HER2/Her2/Neu Value;HER2/neu,Ordinal,The presence or absence of Her2/Neu on a tissue sample.,,,,C25372,C25372,Category,string,
2025-09-23,HER2/Neu Status,C16152,C16152,C94299,Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Cancer Biomarkers,ERBB2 Status;HER2/Her2/Neu Value;HER2/neu,Ordinal,The presence or absence of Her2/Neu on a tissue sample.,,,,C70713,C70713,Biospecimen Type,string,Tissue
2025-09-23,HER2/Neu Status,C16152,C16152,C94299,Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Cancer Biomarkers,ERBB2 Status;HER2/Her2/Neu Value;HER2/neu,Ordinal,The presence or absence of Her2/Neu on a tissue sample.,,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Overall Status
2025-09-23,HER2/Neu Status,C16152,C16152,C94299,Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Cancer Biomarkers,ERBB2 Status;HER2/Her2/Neu Value;HER2/neu,Ordinal,The presence or absence of Her2/Neu on a tissue sample.,,,,C171435,C171435,Specimen Anatomic Site,string,
2025-09-23,HER2/Neu Status,C16152,C16152,C94299,Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Cancer Biomarkers,ERBB2 Status;HER2/Her2/Neu Value;HER2/neu,Ordinal,The presence or absence of Her2/Neu on a tissue sample.,,,,C70856,C70856,Observation Result,string,Positive;Negative
2025-09-23,HER2/Neu Status,C16152,C16152,C94299,Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Cancer Biomarkers,ERBB2 Status;HER2/Her2/Neu Value;HER2/neu,Ordinal,The presence or absence of Her2/Neu on a tissue sample.,,,,C25692,C25692,Subcategory,string,
2025-09-23,Harvey-Bradshaw Index Clinical Classification,C191036,C191036,C118969,QRS;Clinical or Research Assessment Classification;Harvey-Bradshaw Index Clinical Classification;HBI;HBI01;Harvey-Bradshaw Index Clinical Classification Question,HBI01;HBI,,"A standardized clinical tool, published in 1980 by Harvey et al. as a simplified version of the Crohn Disease Activity Index (CDAI), that assesses and scores five patient parameters (well-being, abdominal pain, number of liquid or soft stools, abdominal mass, and complications) to stratify Crohn's disease severity.",,,,,,,,
2025-09-23,Harvey-Bradshaw Index Clinical Classification Question,C190943,C190943,C211913,QRS Instrument Questions,,,A question associated with the Harvey-Bradshaw Index clinical classification.,,,,,,,,
2025-09-23,Hormone Receptor Status,C188928,C188928,C94299,Laboratory Tests;Chemistry Tests;Hormone Measurements;Endocrine Tests;Protein or Enzyme Type Measurements,HR Status,Ordinal;Quantitative,An indication of the presence or absence of detection of hormone receptor expression in a sample.,,,,C70713,C70713,Biospecimen Type,string,
2025-09-23,Hormone Receptor Status,C188928,C188928,C94299,Laboratory Tests;Chemistry Tests;Hormone Measurements;Endocrine Tests;Protein or Enzyme Type Measurements,HR Status,Ordinal;Quantitative,An indication of the presence or absence of detection of hormone receptor expression in a sample.,,,,C70856,C70856,Observation Result,string,Positive;Negative
2025-09-23,Hormone Receptor Status,C188928,C188928,C94299,Laboratory Tests;Chemistry Tests;Hormone Measurements;Endocrine Tests;Protein or Enzyme Type Measurements,HR Status,Ordinal;Quantitative,An indication of the presence or absence of detection of hormone receptor expression in a sample.,,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Overall Status
2025-09-23,Hormone Receptor Status,C188928,C188928,C94299,Laboratory Tests;Chemistry Tests;Hormone Measurements;Endocrine Tests;Protein or Enzyme Type Measurements,HR Status,Ordinal;Quantitative,An indication of the presence or absence of detection of hormone receptor expression in a sample.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Hormone Receptor Status,C188928,C188928,C94299,Laboratory Tests;Chemistry Tests;Hormone Measurements;Endocrine Tests;Protein or Enzyme Type Measurements,HR Status,Ordinal;Quantitative,An indication of the presence or absence of detection of hormone receptor expression in a sample.,,,,C171435,C171435,Specimen Anatomic Site,string,
2025-09-23,Hormone Receptor Status,C188928,C188928,C94299,Laboratory Tests;Chemistry Tests;Hormone Measurements;Endocrine Tests;Protein or Enzyme Type Measurements,HR Status,Ordinal;Quantitative,An indication of the presence or absence of detection of hormone receptor expression in a sample.,,,,C25692,C25692,Subcategory,string,Estrogen Receptor;Progesterone Receptor
2025-09-23,Hormone Receptor Status,C188928,C188928,C94299,Laboratory Tests;Chemistry Tests;Hormone Measurements;Endocrine Tests;Protein or Enzyme Type Measurements,HR Status,Ordinal;Quantitative,An indication of the presence or absence of detection of hormone receptor expression in a sample.,,,,C25372,C25372,Category,string,Breast Cancer;Prostate Cancer
2025-09-23,Hormone Resistance,C147564,C147564,C36285,Laboratory Tests;Hormone Measurements;Endocrine Tests;Protein or Enzyme Type Measurement,Endocrine Resistance;Hormone Therapy Resistance,Ordinal,A finding indicating decreased tissue sensitivity to a hormone.,,,,C70856,C70856,Observation Result,string,Present;Absent
2025-09-23,Hormone Resistance,C147564,C147564,C36285,Laboratory Tests;Hormone Measurements;Endocrine Tests;Protein or Enzyme Type Measurement,Endocrine Resistance;Hormone Therapy Resistance,Ordinal,A finding indicating decreased tissue sensitivity to a hormone.,,,,C171435,C171435,Specimen Anatomic Site,string,
2025-09-23,Hormone Resistance,C147564,C147564,C36285,Laboratory Tests;Hormone Measurements;Endocrine Tests;Protein or Enzyme Type Measurement,Endocrine Resistance;Hormone Therapy Resistance,Ordinal,A finding indicating decreased tissue sensitivity to a hormone.,,,,C25372,C25372,Category,string,
2025-09-23,Hormone Resistance,C147564,C147564,C36285,Laboratory Tests;Hormone Measurements;Endocrine Tests;Protein or Enzyme Type Measurement,Endocrine Resistance;Hormone Therapy Resistance,Ordinal,A finding indicating decreased tissue sensitivity to a hormone.,,,,C25692,C25692,Subcategory,string,
2025-09-23,Hormone Resistance,C147564,C147564,C36285,Laboratory Tests;Hormone Measurements;Endocrine Tests;Protein or Enzyme Type Measurement,Endocrine Resistance;Hormone Therapy Resistance,Ordinal,A finding indicating decreased tissue sensitivity to a hormone.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Hormone Resistance,C147564,C147564,C36285,Laboratory Tests;Hormone Measurements;Endocrine Tests;Protein or Enzyme Type Measurement,Endocrine Resistance;Hormone Therapy Resistance,Ordinal,A finding indicating decreased tissue sensitivity to a hormone.,,,,C70713,C70713,Biospecimen Type,string,
2025-09-23,Human Epidermal Growth Factor Receptor 2 Measurement,C112312,C112312,C64430,Laboratory Tests;Chemistry Tests;Protein or Enzyme Type Measurements;Endocrine Tests;Hormone Measurements,ERBB2;HER2;HER2/NEU;Receptor Tyrosine-Protein Kinase erbB-2 Measurement,Quantitative,The determination of the amount of human epidermal growth factor receptor 2 present in a sample.,,,,C82498,C82498,Result Category,string,Positive;Negative
2025-09-23,Human Epidermal Growth Factor Receptor 2 Measurement,C112312,C112312,C64430,Laboratory Tests;Chemistry Tests;Protein or Enzyme Type Measurements;Endocrine Tests;Hormone Measurements,ERBB2;HER2;HER2/NEU;Receptor Tyrosine-Protein Kinase erbB-2 Measurement,Quantitative,The determination of the amount of human epidermal growth factor receptor 2 present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Tissue
2025-09-23,Human Epidermal Growth Factor Receptor 2 Measurement,C112312,C112312,C64430,Laboratory Tests;Chemistry Tests;Protein or Enzyme Type Measurements;Endocrine Tests;Hormone Measurements,ERBB2;HER2;HER2/NEU;Receptor Tyrosine-Protein Kinase erbB-2 Measurement,Quantitative,The determination of the amount of human epidermal growth factor receptor 2 present in a sample.,,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Staining Intensity
2025-09-23,Human Epidermal Growth Factor Receptor 2 Measurement,C112312,C112312,C64430,Laboratory Tests;Chemistry Tests;Protein or Enzyme Type Measurements;Endocrine Tests;Hormone Measurements,ERBB2;HER2;HER2/NEU;Receptor Tyrosine-Protein Kinase erbB-2 Measurement,Quantitative,The determination of the amount of human epidermal growth factor receptor 2 present in a sample.,,,,C170500,C170500,Result Anatomical Location,string,Breast
2025-09-23,Human Epidermal Growth Factor Receptor 2 Measurement,C112312,C112312,C64430,Laboratory Tests;Chemistry Tests;Protein or Enzyme Type Measurements;Endocrine Tests;Hormone Measurements,ERBB2;HER2;HER2/NEU;Receptor Tyrosine-Protein Kinase erbB-2 Measurement,Quantitative,The determination of the amount of human epidermal growth factor receptor 2 present in a sample.,,,,C82535,C82535,Test Method,string,Immunohistochemistry
2025-09-23,Human Epidermal Growth Factor Receptor 2 Measurement,C112312,C112312,C64430,Laboratory Tests;Chemistry Tests;Protein or Enzyme Type Measurements;Endocrine Tests;Hormone Measurements,ERBB2;HER2;HER2/NEU;Receptor Tyrosine-Protein Kinase erbB-2 Measurement,Quantitative,The determination of the amount of human epidermal growth factor receptor 2 present in a sample.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Human Epidermal Growth Factor Receptor 2 Measurement,C112312,C112312,C64430,Laboratory Tests;Chemistry Tests;Protein or Enzyme Type Measurements;Endocrine Tests;Hormone Measurements,ERBB2;HER2;HER2/NEU;Receptor Tyrosine-Protein Kinase erbB-2 Measurement,Quantitative,The determination of the amount of human epidermal growth factor receptor 2 present in a sample.,,,,C70856,C70856,Observation Result,string,
2025-09-23,IgM Autoantibody Measurement,C198280,C198280,C181397,Laboratory Tests;Immunogenicity Specimen Assessments;Autoantibody Measurement,ATIGMAB;IgM Autoantibody,Quantitative;Nominal,The determination of the amount of IgM autoantibody present in a sample.,,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Staining Pattern
2025-09-23,IgM Autoantibody Measurement,C198280,C198280,C181397,Laboratory Tests;Immunogenicity Specimen Assessments;Autoantibody Measurement,ATIGMAB;IgM Autoantibody,Quantitative;Nominal,The determination of the amount of IgM autoantibody present in a sample.,,,,C70856,C70856,Observation Result,string,Speckled Pattern;Nucleolar Pattern;Homogeneous Pattern;Centromere Pattern
2025-09-23,IgM Autoantibody Measurement,C198280,C198280,C181397,Laboratory Tests;Immunogenicity Specimen Assessments;Autoantibody Measurement,ATIGMAB;IgM Autoantibody,Quantitative;Nominal,The determination of the amount of IgM autoantibody present in a sample.,,,,C218437,C218437,Immunogenicity Specimen Test Operational Objective,string,Screen;Confirm;Quantify;Overall Subject Status
2025-09-23,IgM Autoantibody Measurement,C198280,C198280,C181397,Laboratory Tests;Immunogenicity Specimen Assessments;Autoantibody Measurement,ATIGMAB;IgM Autoantibody,Quantitative;Nominal,The determination of the amount of IgM autoantibody present in a sample.,,,,C42647,C42647,Binder Excipient,string,Liver Kidney Microsomal Type 1 Antigen;Beta-2 Glycoprotein 1;Cardiolipin;Phosphatidylserine;Phospholipid;Tissue Transglutaminase
2025-09-23,IgM Autoantibody Measurement,C198280,C198280,C181397,Laboratory Tests;Immunogenicity Specimen Assessments;Autoantibody Measurement,ATIGMAB;IgM Autoantibody,Quantitative;Nominal,The determination of the amount of IgM autoantibody present in a sample.,,,,C25692,C25692,Subcategory,string,
2025-09-23,IgM Autoantibody Measurement,C198280,C198280,C181397,Laboratory Tests;Immunogenicity Specimen Assessments;Autoantibody Measurement,ATIGMAB;IgM Autoantibody,Quantitative;Nominal,The determination of the amount of IgM autoantibody present in a sample.,,,,C25372,C25372,Category,string,
2025-09-23,IgM Autoantibody Measurement,C198280,C198280,C181397,Laboratory Tests;Immunogenicity Specimen Assessments;Autoantibody Measurement,ATIGMAB;IgM Autoantibody,Quantitative;Nominal,The determination of the amount of IgM autoantibody present in a sample.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,IgM Autoantibody Measurement,C198280,C198280,C181397,Laboratory Tests;Immunogenicity Specimen Assessments;Autoantibody Measurement,ATIGMAB;IgM Autoantibody,Quantitative;Nominal,The determination of the amount of IgM autoantibody present in a sample.,,,,C82535,C82535,Test Method,string,Fluorescent Immunoassay;Immunoassay;Enzyme-linked Immunosorbent Assay
2025-09-23,IgM Autoantibody Measurement,C198280,C198280,C181397,Laboratory Tests;Immunogenicity Specimen Assessments;Autoantibody Measurement,ATIGMAB;IgM Autoantibody,Quantitative;Nominal,The determination of the amount of IgM autoantibody present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Serum;Plasma
2025-09-23,IgM Autoantibody Measurement,C198280,C198280,C181397,Laboratory Tests;Immunogenicity Specimen Assessments;Autoantibody Measurement,ATIGMAB;IgM Autoantibody,Quantitative;Nominal,The determination of the amount of IgM autoantibody present in a sample.,,,,C48207,C48207,Unit of Concentration,string,mmol/L;g/L;mg/dL;mg/mL;umol/L;titer;U/mL
2025-09-23,Imaging Procedure,C17369,C17369,,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures,,,"Any technology or method that aids in the visualization of any biological process, cell, tissue or organ for use in screening, diagnosis, surgical procedures or therapy.",,,,,,,,
2025-09-23,Immunoglobulin A Measurement,C81969,C81969,,Immunoglobulin A Measurement,,,The determination of the amount of immunoglobulin A present in a sample.,,,,,,,,
2025-09-23,KPS Scale - Karnofsky Performance Status,C100417,C100417,C100116,QRS;KPS Scale Questionnaire Question;Karnofsky Performance Status Scale Clinical Classification;KPSS01;KPS SCALE,KPSS01-Karnofsky Performance Status;KPSS0101;KPS Scale - Karnofsky Performance Status,Ordinal,Karnofsky Performance Status Scale (KPS Scale) Karnofsky Performance Status.,http://loinc.org/,LOINC,89243-0,C46126,C46126,Ordinal Position,integer,100;90;80;70;60;50;40;30;20;10;0
2025-09-23,KPS Scale - Karnofsky Performance Status,C100417,C100417,C100116,QRS;KPS Scale Questionnaire Question;Karnofsky Performance Status Scale Clinical Classification;KPSS01;KPS SCALE,KPSS01-Karnofsky Performance Status;KPSS0101;KPS Scale - Karnofsky Performance Status,Ordinal,Karnofsky Performance Status Scale (KPS Scale) Karnofsky Performance Status.,http://loinc.org/,LOINC,89243-0,C82515,C82515,Collection Date Time,datetime,
2025-09-23,KPS Scale - Karnofsky Performance Status,C100417,C100417,C100116,QRS;KPS Scale Questionnaire Question;Karnofsky Performance Status Scale Clinical Classification;KPSS01;KPS SCALE,KPSS01-Karnofsky Performance Status;KPSS0101;KPS Scale - Karnofsky Performance Status,Ordinal,Karnofsky Performance Status Scale (KPS Scale) Karnofsky Performance Status.,http://loinc.org/,LOINC,89243-0,C91106,C91106,Clinical or Research Assessment Answer,string,"Normal no complaints, no evidence of disease.;Able to carry on normal activity, minor signs or symptoms of disease.;Normal activity with effort, some signs or symptoms of disease.;Cares for self, unable to carry on normal activity or to do active work.;Requires occasional assistance, but is able to care for most of his personal needs.;Requires considerable assistance and frequent medical care.;Disabled, requires special care and assistance.;Severely disabled, hospital admission is indicated although death not imminent.;Very sick, hospital admission necessary, active supportive treatment necessary.;Moribund, fatal processes progressing rapidly.;Dead"
2025-09-23,KPS Scale - Karnofsky Performance Status,C100417,C100417,C100116,QRS;KPS Scale Questionnaire Question;Karnofsky Performance Status Scale Clinical Classification;KPSS01;KPS SCALE,KPSS01-Karnofsky Performance Status;KPSS0101;KPS Scale - Karnofsky Performance Status,Ordinal,Karnofsky Performance Status Scale (KPS Scale) Karnofsky Performance Status.,http://loinc.org/,LOINC,89243-0,C25372,C25372,Category,string,KPS SCALE
2025-09-23,Ki-67 Labeling Index,C157250,C157250,C28042,Cancer Biomarkers;Molecular Measurements,Ki-67;Ki-67Anti-KI67 Labeling Index;Anti-Ki-67 Labeling Index;Anti-MKI67 Labeling Index;Ki-67 Labeling Index;Ki-67 MIB1 Labeling Index;MIB-1 Antibody Labeling Index;MIB-1 Labeling Index;MIB1 Antibody Labeling Index;MIB1 Labeling Index,Quantitative,The percentage of cells in a sample that are dividing that is determined by immunohistochemical staining techniques using MIB-1 antibody (anti-Ki-67 protein antibody).,,,,C70713,C70713,Biospecimen Type,string,Tissue
2025-09-23,Ki-67 Labeling Index,C157250,C157250,C28042,Cancer Biomarkers;Molecular Measurements,Ki-67;Ki-67Anti-KI67 Labeling Index;Anti-Ki-67 Labeling Index;Anti-MKI67 Labeling Index;Ki-67 Labeling Index;Ki-67 MIB1 Labeling Index;MIB-1 Antibody Labeling Index;MIB-1 Labeling Index;MIB1 Antibody Labeling Index;MIB1 Labeling Index,Quantitative,The percentage of cells in a sample that are dividing that is determined by immunohistochemical staining techniques using MIB-1 antibody (anti-Ki-67 protein antibody).,,,,C82535,C82535,Test Method,string,Immunohistochemistry
2025-09-23,Ki-67 Labeling Index,C157250,C157250,C28042,Cancer Biomarkers;Molecular Measurements,Ki-67;Ki-67Anti-KI67 Labeling Index;Anti-Ki-67 Labeling Index;Anti-MKI67 Labeling Index;Ki-67 Labeling Index;Ki-67 MIB1 Labeling Index;MIB-1 Antibody Labeling Index;MIB-1 Labeling Index;MIB1 Antibody Labeling Index;MIB1 Labeling Index,Quantitative,The percentage of cells in a sample that are dividing that is determined by immunohistochemical staining techniques using MIB-1 antibody (anti-Ki-67 protein antibody).,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Ki-67 Labeling Index,C157250,C157250,C28042,Cancer Biomarkers;Molecular Measurements,Ki-67;Ki-67Anti-KI67 Labeling Index;Anti-Ki-67 Labeling Index;Anti-MKI67 Labeling Index;Ki-67 Labeling Index;Ki-67 MIB1 Labeling Index;MIB-1 Antibody Labeling Index;MIB-1 Labeling Index;MIB1 Antibody Labeling Index;MIB1 Labeling Index,Quantitative,The percentage of cells in a sample that are dividing that is determined by immunohistochemical staining techniques using MIB-1 antibody (anti-Ki-67 protein antibody).,,,,C70856,C70856,Observation Result,integer,
2025-09-23,Ki-67 Labeling Index,C157250,C157250,C28042,Cancer Biomarkers;Molecular Measurements,Ki-67;Ki-67Anti-KI67 Labeling Index;Anti-Ki-67 Labeling Index;Anti-MKI67 Labeling Index;Ki-67 Labeling Index;Ki-67 MIB1 Labeling Index;MIB-1 Antibody Labeling Index;MIB-1 Labeling Index;MIB1 Antibody Labeling Index;MIB1 Labeling Index,Quantitative,The percentage of cells in a sample that are dividing that is determined by immunohistochemical staining techniques using MIB-1 antibody (anti-Ki-67 protein antibody).,,,,C25372,C25372,Category,string,
2025-09-23,Ki-67 Labeling Index,C157250,C157250,C28042,Cancer Biomarkers;Molecular Measurements,Ki-67;Ki-67Anti-KI67 Labeling Index;Anti-Ki-67 Labeling Index;Anti-MKI67 Labeling Index;Ki-67 Labeling Index;Ki-67 MIB1 Labeling Index;MIB-1 Antibody Labeling Index;MIB-1 Labeling Index;MIB1 Antibody Labeling Index;MIB1 Labeling Index,Quantitative,The percentage of cells in a sample that are dividing that is determined by immunohistochemical staining techniques using MIB-1 antibody (anti-Ki-67 protein antibody).,,,,C171435,C171435,Specimen Anatomic Site,string,
2025-09-23,Ki-67 Labeling Index,C157250,C157250,C28042,Cancer Biomarkers;Molecular Measurements,Ki-67;Ki-67Anti-KI67 Labeling Index;Anti-Ki-67 Labeling Index;Anti-MKI67 Labeling Index;Ki-67 Labeling Index;Ki-67 MIB1 Labeling Index;MIB-1 Antibody Labeling Index;MIB-1 Labeling Index;MIB1 Antibody Labeling Index;MIB1 Labeling Index,Quantitative,The percentage of cells in a sample that are dividing that is determined by immunohistochemical staining techniques using MIB-1 antibody (anti-Ki-67 protein antibody).,,,,C25692,C25692,Subcategory,string,
2025-09-23,Ki-67 Labeling Index,C157250,C157250,C28042,Cancer Biomarkers;Molecular Measurements,Ki-67;Ki-67Anti-KI67 Labeling Index;Anti-Ki-67 Labeling Index;Anti-MKI67 Labeling Index;Ki-67 Labeling Index;Ki-67 MIB1 Labeling Index;MIB-1 Antibody Labeling Index;MIB-1 Labeling Index;MIB1 Antibody Labeling Index;MIB1 Labeling Index,Quantitative,The percentage of cells in a sample that are dividing that is determined by immunohistochemical staining techniques using MIB-1 antibody (anti-Ki-67 protein antibody).,,,,C48570,C48570,Percent Unit,string,%
2025-09-23,Ki-67 Labeling Index,C157250,C157250,C28042,Cancer Biomarkers;Molecular Measurements,Ki-67;Ki-67Anti-KI67 Labeling Index;Anti-Ki-67 Labeling Index;Anti-MKI67 Labeling Index;Ki-67 Labeling Index;Ki-67 MIB1 Labeling Index;MIB-1 Antibody Labeling Index;MIB-1 Labeling Index;MIB1 Antibody Labeling Index;MIB1 Labeling Index,Quantitative,The percentage of cells in a sample that are dividing that is determined by immunohistochemical staining techniques using MIB-1 antibody (anti-Ki-67 protein antibody).,,,,C117062,C117062,"Measurement, Test or Examination Detail",string,
2025-09-23,Liquid Biopsy,C135727,C135727,C15189,Diagnostic Procedure;Blood Cell Counts,Plasma Biopsy,Nominal;Ordinal,"Sampling and analysis of non-solid biological material (primarily blood), usually to determine if cancer cells or circulating-free cancer DNA is present.",,,,C25372,C25372,Category,string,
2025-09-23,Liquid Biopsy,C135727,C135727,C15189,Diagnostic Procedure;Blood Cell Counts,Plasma Biopsy,Nominal;Ordinal,"Sampling and analysis of non-solid biological material (primarily blood), usually to determine if cancer cells or circulating-free cancer DNA is present.",,,,C25692,C25692,Subcategory,string,
2025-09-23,Liquid Biopsy,C135727,C135727,C15189,Diagnostic Procedure;Blood Cell Counts,Plasma Biopsy,Nominal;Ordinal,"Sampling and analysis of non-solid biological material (primarily blood), usually to determine if cancer cells or circulating-free cancer DNA is present.",,,,C70713,C70713,Biospecimen Type,string,Blood;Plasma
2025-09-23,Liquid Biopsy,C135727,C135727,C15189,Diagnostic Procedure;Blood Cell Counts,Plasma Biopsy,Nominal;Ordinal,"Sampling and analysis of non-solid biological material (primarily blood), usually to determine if cancer cells or circulating-free cancer DNA is present.",,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Liquid Biopsy,C135727,C135727,C15189,Diagnostic Procedure;Blood Cell Counts,Plasma Biopsy,Nominal;Ordinal,"Sampling and analysis of non-solid biological material (primarily blood), usually to determine if cancer cells or circulating-free cancer DNA is present.",,,,C70856,C70856,Observation Result,string,Positive;Negative;Variant Detection
2025-09-23,Locally Recurrent Disease,C176551,C176551,C38155,Disease Response;Recurrence,Local Recurrence,Ordinal,The return of a disease after a period of remission at the site in which it initially manifested or adjacent to it.,,,,C25372,C25372,Category,string,
2025-09-23,Locally Recurrent Disease,C176551,C176551,C38155,Disease Response;Recurrence,Local Recurrence,Ordinal,The return of a disease after a period of remission at the site in which it initially manifested or adjacent to it.,,,,C25692,C25692,Subcategory,string,
2025-09-23,Locally Recurrent Disease,C176551,C176551,C38155,Disease Response;Recurrence,Local Recurrence,Ordinal,The return of a disease after a period of remission at the site in which it initially manifested or adjacent to it.,,,,C70856,C70856,Observation Result,string,Positive;Negative;Absent Present
2025-09-23,Locally Recurrent Disease,C176551,C176551,C38155,Disease Response;Recurrence,Local Recurrence,Ordinal,The return of a disease after a period of remission at the site in which it initially manifested or adjacent to it.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Lumpectomy,C15755,C15755,C15280,Surgeries;Breast Cancer Procedures,Lumpectomy;Lumpectomy of Breast;Partial Mastectomy;lumpectomy;partial mastectomy,Nominal,The surgical removal of a discrete mass.,,,,C25692,C25692,Subcategory,string,
2025-09-23,Lumpectomy,C15755,C15755,C15280,Surgeries;Breast Cancer Procedures,Lumpectomy;Lumpectomy of Breast;Partial Mastectomy;lumpectomy;partial mastectomy,Nominal,The surgical removal of a discrete mass.,,,,C117529,C117529,Start Date and Time of Procedure,datetime,
2025-09-23,Lumpectomy,C15755,C15755,C15280,Surgeries;Breast Cancer Procedures,Lumpectomy;Lumpectomy of Breast;Partial Mastectomy;lumpectomy;partial mastectomy,Nominal,The surgical removal of a discrete mass.,,,,C117511,C117511,Reported Name of Procedure,string,Lumpectomy
2025-09-23,Lumpectomy,C15755,C15755,C15280,Surgeries;Breast Cancer Procedures,Lumpectomy;Lumpectomy of Breast;Partial Mastectomy;lumpectomy;partial mastectomy,Nominal,The surgical removal of a discrete mass.,,,,C117530,C117530,End Date and Time of Procedure,datetime,
2025-09-23,Lumpectomy,C15755,C15755,C15280,Surgeries;Breast Cancer Procedures,Lumpectomy;Lumpectomy of Breast;Partial Mastectomy;lumpectomy;partial mastectomy,Nominal,The surgical removal of a discrete mass.,,,,C117512,C117512,Standardized Name of Procedure,string,
2025-09-23,Lumpectomy,C15755,C15755,C15280,Surgeries;Breast Cancer Procedures,Lumpectomy;Lumpectomy of Breast;Partial Mastectomy;lumpectomy;partial mastectomy,Nominal,The surgical removal of a discrete mass.,,,,C54215,C54215,Directionality,string,
2025-09-23,Lumpectomy,C15755,C15755,C15280,Surgeries;Breast Cancer Procedures,Lumpectomy;Lumpectomy of Breast;Partial Mastectomy;lumpectomy;partial mastectomy,Nominal,The surgical removal of a discrete mass.,,,,C25185,C25185,Laterality,string,Left;Right;Bilateral
2025-09-23,Lumpectomy,C15755,C15755,C15280,Surgeries;Breast Cancer Procedures,Lumpectomy;Lumpectomy of Breast;Partial Mastectomy;lumpectomy;partial mastectomy,Nominal,The surgical removal of a discrete mass.,,,,C13717,C13717,Anatomic Site,string,Breast
2025-09-23,Lumpectomy,C15755,C15755,C15280,Surgeries;Breast Cancer Procedures,Lumpectomy;Lumpectomy of Breast;Partial Mastectomy;lumpectomy;partial mastectomy,Nominal,The surgical removal of a discrete mass.,,,,C25372,C25372,Category,string,
2025-09-23,Lumpectomy,C15755,C15755,C15280,Surgeries;Breast Cancer Procedures,Lumpectomy;Lumpectomy of Breast;Partial Mastectomy;lumpectomy;partial mastectomy,Nominal,The surgical removal of a discrete mass.,,,,C171000,C171000,Prespecified Event or Intervention Indicator,boolean,Y;N
2025-09-23,Lumpectomy,C15755,C15755,C15280,Surgeries;Breast Cancer Procedures,Lumpectomy;Lumpectomy of Breast;Partial Mastectomy;lumpectomy;partial mastectomy,Nominal,The surgical removal of a discrete mass.,,,,C127786,C127786,Occurrence Indicator,boolean,Y;N
2025-09-23,Lymph Node Biopsy,C51900,C51900,C217124,Diagnostic Procedures;Biopsies,Biopsy of Lymph Node,Nominal,A test in which a lymph node or a piece of a lymph node is removed for examination under a microscope for signs of infection or disease such as cancer.,,,,C171435,C171435,Specimen Anatomic Site,string,
2025-09-23,Lymph Node Biopsy,C51900,C51900,C217124,Diagnostic Procedures;Biopsies,Biopsy of Lymph Node,Nominal,A test in which a lymph node or a piece of a lymph node is removed for examination under a microscope for signs of infection or disease such as cancer.,,,,C117512,C117512,Standardized Name of Procedure,string,
2025-09-23,Lymph Node Biopsy,C51900,C51900,C217124,Diagnostic Procedures;Biopsies,Biopsy of Lymph Node,Nominal,A test in which a lymph node or a piece of a lymph node is removed for examination under a microscope for signs of infection or disease such as cancer.,,,,C54215,C54215,Directionality,string,
2025-09-23,Lymph Node Biopsy,C51900,C51900,C217124,Diagnostic Procedures;Biopsies,Biopsy of Lymph Node,Nominal,A test in which a lymph node or a piece of a lymph node is removed for examination under a microscope for signs of infection or disease such as cancer.,,,,C25372,C25372,Category,string,
2025-09-23,Lymph Node Biopsy,C51900,C51900,C217124,Diagnostic Procedures;Biopsies,Biopsy of Lymph Node,Nominal,A test in which a lymph node or a piece of a lymph node is removed for examination under a microscope for signs of infection or disease such as cancer.,,,,C25692,C25692,Subcategory,string,
2025-09-23,Lymph Node Biopsy,C51900,C51900,C217124,Diagnostic Procedures;Biopsies,Biopsy of Lymph Node,Nominal,A test in which a lymph node or a piece of a lymph node is removed for examination under a microscope for signs of infection or disease such as cancer.,,,,C171000,C171000,Prespecified Event or Intervention Indicator,boolean,Y;N
2025-09-23,Lymph Node Biopsy,C51900,C51900,C217124,Diagnostic Procedures;Biopsies,Biopsy of Lymph Node,Nominal,A test in which a lymph node or a piece of a lymph node is removed for examination under a microscope for signs of infection or disease such as cancer.,,,,C127786,C127786,Occurrence Indicator,boolean,Y;N
2025-09-23,Lymph Node Biopsy,C51900,C51900,C217124,Diagnostic Procedures;Biopsies,Biopsy of Lymph Node,Nominal,A test in which a lymph node or a piece of a lymph node is removed for examination under a microscope for signs of infection or disease such as cancer.,,,,C117530,C117530,End Date and Time of Procedure,datetime,
2025-09-23,Lymph Node Biopsy,C51900,C51900,C217124,Diagnostic Procedures;Biopsies,Biopsy of Lymph Node,Nominal,A test in which a lymph node or a piece of a lymph node is removed for examination under a microscope for signs of infection or disease such as cancer.,,,,C117529,C117529,Start Date and Time of Procedure,datetime,
2025-09-23,Lymph Node Biopsy,C51900,C51900,C217124,Diagnostic Procedures;Biopsies,Biopsy of Lymph Node,Nominal,A test in which a lymph node or a piece of a lymph node is removed for examination under a microscope for signs of infection or disease such as cancer.,,,,C117511,C117511,Reported Name of Procedure,string,Lymph Node Biopsy
2025-09-23,Lymph Node Biopsy,C51900,C51900,C217124,Diagnostic Procedures;Biopsies,Biopsy of Lymph Node,Nominal,A test in which a lymph node or a piece of a lymph node is removed for examination under a microscope for signs of infection or disease such as cancer.,,,,C25185,C25185,Laterality,string,Left;Right;Bilateral
2025-09-23,Lymphadenectomy,C15275,C15275,,Diagnostic Procedures;Biopsies,Lymph Node Dissection;Lymph Node Excision;Excision of the Lymph Node,Nominal,"Surgical removal of lymph nodes, usually done to assess the spread of cancer.",,,,C54215,C54215,Directionality,string,
2025-09-23,Lymphadenectomy,C15275,C15275,,Diagnostic Procedures;Biopsies,Lymph Node Dissection;Lymph Node Excision;Excision of the Lymph Node,Nominal,"Surgical removal of lymph nodes, usually done to assess the spread of cancer.",,,,C171000,C171000,Prespecified Event or Intervention Indicator,boolean,Y;N
2025-09-23,Lymphadenectomy,C15275,C15275,,Diagnostic Procedures;Biopsies,Lymph Node Dissection;Lymph Node Excision;Excision of the Lymph Node,Nominal,"Surgical removal of lymph nodes, usually done to assess the spread of cancer.",,,,C25692,C25692,Subcategory,string,
2025-09-23,Lymphadenectomy,C15275,C15275,,Diagnostic Procedures;Biopsies,Lymph Node Dissection;Lymph Node Excision;Excision of the Lymph Node,Nominal,"Surgical removal of lymph nodes, usually done to assess the spread of cancer.",,,,C25372,C25372,Category,string,
2025-09-23,Lymphadenectomy,C15275,C15275,,Diagnostic Procedures;Biopsies,Lymph Node Dissection;Lymph Node Excision;Excision of the Lymph Node,Nominal,"Surgical removal of lymph nodes, usually done to assess the spread of cancer.",,,,C117530,C117530,End Date and Time of Procedure,datetime,
2025-09-23,Lymphadenectomy,C15275,C15275,,Diagnostic Procedures;Biopsies,Lymph Node Dissection;Lymph Node Excision;Excision of the Lymph Node,Nominal,"Surgical removal of lymph nodes, usually done to assess the spread of cancer.",,,,C117511,C117511,Reported Name of Procedure,string,Lymphadenectomy
2025-09-23,Lymphadenectomy,C15275,C15275,,Diagnostic Procedures;Biopsies,Lymph Node Dissection;Lymph Node Excision;Excision of the Lymph Node,Nominal,"Surgical removal of lymph nodes, usually done to assess the spread of cancer.",,,,C117529,C117529,Start Date and Time of Procedure,datetime,
2025-09-23,Lymphadenectomy,C15275,C15275,,Diagnostic Procedures;Biopsies,Lymph Node Dissection;Lymph Node Excision;Excision of the Lymph Node,Nominal,"Surgical removal of lymph nodes, usually done to assess the spread of cancer.",,,,C117512,C117512,Standardized Name of Procedure,string,
2025-09-23,Lymphadenectomy,C15275,C15275,,Diagnostic Procedures;Biopsies,Lymph Node Dissection;Lymph Node Excision;Excision of the Lymph Node,Nominal,"Surgical removal of lymph nodes, usually done to assess the spread of cancer.",,,,C25185,C25185,Laterality,string,Left;Right;Bilateral
2025-09-23,Lymphadenectomy,C15275,C15275,,Diagnostic Procedures;Biopsies,Lymph Node Dissection;Lymph Node Excision;Excision of the Lymph Node,Nominal,"Surgical removal of lymph nodes, usually done to assess the spread of cancer.",,,,C13717,C13717,Anatomic Site,string,Axillary Lymph Node
2025-09-23,Lymphadenectomy,C15275,C15275,,Diagnostic Procedures;Biopsies,Lymph Node Dissection;Lymph Node Excision;Excision of the Lymph Node,Nominal,"Surgical removal of lymph nodes, usually done to assess the spread of cancer.",,,,C127786,C127786,Occurrence Indicator,boolean,Y;N
2025-09-23,MammaPrint Index,C199199,C199199,C190808,Diagnostic Tests;Diagnostic Procedures;Gene Expression Analysis,MammaPrint Index Score;MPI,Quantitative;Nominal,A predictive score for breast cancer reoccurrence based on the expression activity of 70 genes. The results are presented as a score between -1 and 1 with negative scores correlating with low risk of reoccurrence and positive scores correlating with high risk of reoccurrence.,,,,C25372,C25372,Category,string,
2025-09-23,MammaPrint Index,C199199,C199199,C190808,Diagnostic Tests;Diagnostic Procedures;Gene Expression Analysis,MammaPrint Index Score;MPI,Quantitative;Nominal,A predictive score for breast cancer reoccurrence based on the expression activity of 70 genes. The results are presented as a score between -1 and 1 with negative scores correlating with low risk of reoccurrence and positive scores correlating with high risk of reoccurrence.,,,,C70856,C70856,Observation Result,string,Low Risk;High Risk;-1.0-+1.0
2025-09-23,MammaPrint Index,C199199,C199199,C190808,Diagnostic Tests;Diagnostic Procedures;Gene Expression Analysis,MammaPrint Index Score;MPI,Quantitative;Nominal,A predictive score for breast cancer reoccurrence based on the expression activity of 70 genes. The results are presented as a score between -1 and 1 with negative scores correlating with low risk of reoccurrence and positive scores correlating with high risk of reoccurrence.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,MammaPrint Index,C199199,C199199,C190808,Diagnostic Tests;Diagnostic Procedures;Gene Expression Analysis,MammaPrint Index Score;MPI,Quantitative;Nominal,A predictive score for breast cancer reoccurrence based on the expression activity of 70 genes. The results are presented as a score between -1 and 1 with negative scores correlating with low risk of reoccurrence and positive scores correlating with high risk of reoccurrence.,,,,C82535,C82535,Test Method,string,Gene Expression Profiling
2025-09-23,MammaPrint Index,C199199,C199199,C190808,Diagnostic Tests;Diagnostic Procedures;Gene Expression Analysis,MammaPrint Index Score;MPI,Quantitative;Nominal,A predictive score for breast cancer reoccurrence based on the expression activity of 70 genes. The results are presented as a score between -1 and 1 with negative scores correlating with low risk of reoccurrence and positive scores correlating with high risk of reoccurrence.,,,,C171435,C171435,Specimen Anatomic Site,string,Breast
2025-09-23,MammaPrint Index,C199199,C199199,C190808,Diagnostic Tests;Diagnostic Procedures;Gene Expression Analysis,MammaPrint Index Score;MPI,Quantitative;Nominal,A predictive score for breast cancer reoccurrence based on the expression activity of 70 genes. The results are presented as a score between -1 and 1 with negative scores correlating with low risk of reoccurrence and positive scores correlating with high risk of reoccurrence.,,,,C25692,C25692,Subcategory,string,
2025-09-23,MammaPrint Index,C199199,C199199,C190808,Diagnostic Tests;Diagnostic Procedures;Gene Expression Analysis,MammaPrint Index Score;MPI,Quantitative;Nominal,A predictive score for breast cancer reoccurrence based on the expression activity of 70 genes. The results are presented as a score between -1 and 1 with negative scores correlating with low risk of reoccurrence and positive scores correlating with high risk of reoccurrence.,,,,C70713,C70713,Biospecimen Type,string,Tissue
2025-09-23,Mammography,C16818,C16818,C16502,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures,MG,Nominal,"A type of radiography used specifically to examine breast tissue. The procedure utilizes a low-dose of x-rays or radiation to generate an image. A mammography exam or mammogram, is used as a screening tool to detect early breast cancer in women experiencing no symptoms and to detect and diagnose breast disease.",,,,C25372,C25372,Category,string,
2025-09-23,Mammography,C16818,C16818,C16502,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures,MG,Nominal,"A type of radiography used specifically to examine breast tissue. The procedure utilizes a low-dose of x-rays or radiation to generate an image. A mammography exam or mammogram, is used as a screening tool to detect early breast cancer in women experiencing no symptoms and to detect and diagnose breast disease.",,,,C171000,C171000,Prespecified Event or Intervention Indicator,boolean,Y;N
2025-09-23,Mammography,C16818,C16818,C16502,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures,MG,Nominal,"A type of radiography used specifically to examine breast tissue. The procedure utilizes a low-dose of x-rays or radiation to generate an image. A mammography exam or mammogram, is used as a screening tool to detect early breast cancer in women experiencing no symptoms and to detect and diagnose breast disease.",,,,C25692,C25692,Subcategory,string,
2025-09-23,Mammography,C16818,C16818,C16502,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures,MG,Nominal,"A type of radiography used specifically to examine breast tissue. The procedure utilizes a low-dose of x-rays or radiation to generate an image. A mammography exam or mammogram, is used as a screening tool to detect early breast cancer in women experiencing no symptoms and to detect and diagnose breast disease.",,,,C117530,C117530,End Date and Time of Procedure,datetime,
2025-09-23,Mammography,C16818,C16818,C16502,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures,MG,Nominal,"A type of radiography used specifically to examine breast tissue. The procedure utilizes a low-dose of x-rays or radiation to generate an image. A mammography exam or mammogram, is used as a screening tool to detect early breast cancer in women experiencing no symptoms and to detect and diagnose breast disease.",,,,C117512,C117512,Standardized Name of Procedure,string,
2025-09-23,Mammography,C16818,C16818,C16502,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures,MG,Nominal,"A type of radiography used specifically to examine breast tissue. The procedure utilizes a low-dose of x-rays or radiation to generate an image. A mammography exam or mammogram, is used as a screening tool to detect early breast cancer in women experiencing no symptoms and to detect and diagnose breast disease.",,,,C117511,C117511,Reported Name of Procedure,string,Mammography
2025-09-23,Mammography,C16818,C16818,C16502,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures,MG,Nominal,"A type of radiography used specifically to examine breast tissue. The procedure utilizes a low-dose of x-rays or radiation to generate an image. A mammography exam or mammogram, is used as a screening tool to detect early breast cancer in women experiencing no symptoms and to detect and diagnose breast disease.",,,,C117529,C117529,Start Date and Time of Procedure,datetime,
2025-09-23,Mammography,C16818,C16818,C16502,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures,MG,Nominal,"A type of radiography used specifically to examine breast tissue. The procedure utilizes a low-dose of x-rays or radiation to generate an image. A mammography exam or mammogram, is used as a screening tool to detect early breast cancer in women experiencing no symptoms and to detect and diagnose breast disease.",,,,C54215,C54215,Directionality,string,
2025-09-23,Mammography,C16818,C16818,C16502,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures,MG,Nominal,"A type of radiography used specifically to examine breast tissue. The procedure utilizes a low-dose of x-rays or radiation to generate an image. A mammography exam or mammogram, is used as a screening tool to detect early breast cancer in women experiencing no symptoms and to detect and diagnose breast disease.",,,,C25185,C25185,Laterality,string,Left;Right;Bilateral
2025-09-23,Mammography,C16818,C16818,C16502,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures,MG,Nominal,"A type of radiography used specifically to examine breast tissue. The procedure utilizes a low-dose of x-rays or radiation to generate an image. A mammography exam or mammogram, is used as a screening tool to detect early breast cancer in women experiencing no symptoms and to detect and diagnose breast disease.",,,,C13717,C13717,Anatomic Site,string,Breast
2025-09-23,Mammography,C16818,C16818,C16502,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures,MG,Nominal,"A type of radiography used specifically to examine breast tissue. The procedure utilizes a low-dose of x-rays or radiation to generate an image. A mammography exam or mammogram, is used as a screening tool to detect early breast cancer in women experiencing no symptoms and to detect and diagnose breast disease.",,,,C127786,C127786,Occurrence Indicator,boolean,Y;N
2025-09-23,Mastectomy,C15277,C15277,C157802,Surgeries;Breast Cancer Procedures,Mammectomy;Mastectomy;Partial Mastectomy,Nominal,Surgical removal of the breast.,,,,C171000,C171000,Prespecified Event or Intervention Indicator,boolean,Y;N
2025-09-23,Mastectomy,C15277,C15277,C157802,Surgeries;Breast Cancer Procedures,Mammectomy;Mastectomy;Partial Mastectomy,Nominal,Surgical removal of the breast.,,,,C25185,C25185,Laterality,string,Left;Right;Bilateral
2025-09-23,Mastectomy,C15277,C15277,C157802,Surgeries;Breast Cancer Procedures,Mammectomy;Mastectomy;Partial Mastectomy,Nominal,Surgical removal of the breast.,,,,C127786,C127786,Occurrence Indicator,boolean,Y;N
2025-09-23,Mastectomy,C15277,C15277,C157802,Surgeries;Breast Cancer Procedures,Mammectomy;Mastectomy;Partial Mastectomy,Nominal,Surgical removal of the breast.,,,,C117530,C117530,End Date and Time of Procedure,datetime,
2025-09-23,Mastectomy,C15277,C15277,C157802,Surgeries;Breast Cancer Procedures,Mammectomy;Mastectomy;Partial Mastectomy,Nominal,Surgical removal of the breast.,,,,C117511,C117511,Reported Name of Procedure,string,Mastectomy
2025-09-23,Mastectomy,C15277,C15277,C157802,Surgeries;Breast Cancer Procedures,Mammectomy;Mastectomy;Partial Mastectomy,Nominal,Surgical removal of the breast.,,,,C117529,C117529,Start Date and Time of Procedure,datetime,
2025-09-23,Mastectomy,C15277,C15277,C157802,Surgeries;Breast Cancer Procedures,Mammectomy;Mastectomy;Partial Mastectomy,Nominal,Surgical removal of the breast.,,,,C25692,C25692,Subcategory,string,
2025-09-23,Mastectomy,C15277,C15277,C157802,Surgeries;Breast Cancer Procedures,Mammectomy;Mastectomy;Partial Mastectomy,Nominal,Surgical removal of the breast.,,,,C13717,C13717,Anatomic Site,string,Breast
2025-09-23,Mastectomy,C15277,C15277,C157802,Surgeries;Breast Cancer Procedures,Mammectomy;Mastectomy;Partial Mastectomy,Nominal,Surgical removal of the breast.,,,,C25372,C25372,Category,string,
2025-09-23,Mastectomy,C15277,C15277,C157802,Surgeries;Breast Cancer Procedures,Mammectomy;Mastectomy;Partial Mastectomy,Nominal,Surgical removal of the breast.,,,,C117512,C117512,Standardized Name of Procedure,string,
2025-09-23,Medical Procedure Yes No Indicator,C219640,C219640,C82438,Event Occurrence Indicators;Medical Procedure,PRYN,Nominal,An indication of whether a medical procedure has taken place.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Medical Procedure Yes No Indicator,C219640,C219640,C82438,Event Occurrence Indicators;Medical Procedure,PRYN,Nominal,An indication of whether a medical procedure has taken place.,,,,C219640,C219640,Medical Procedure Yes No Indicator,string,N;Y
2025-09-23,Microarray Analysis,C18477,C18477,C19770,Genetic Testing;Gene Expression Analysis;Molecular Analysis;Genetic Molecular Analysis;Laboratory Procedures,Gene Expression Profiling;Gene Expression Profile,Ordinal;Narrative,"Analysis using microarray technology (e.g., cDNA arrays to see gene expression or protein microarrays to profile the pattern of proteins).",,,,C171435,C171435,Specimen Anatomic Site,string,
2025-09-23,Microarray Analysis,C18477,C18477,C19770,Genetic Testing;Gene Expression Analysis;Molecular Analysis;Genetic Molecular Analysis;Laboratory Procedures,Gene Expression Profiling;Gene Expression Profile,Ordinal;Narrative,"Analysis using microarray technology (e.g., cDNA arrays to see gene expression or protein microarrays to profile the pattern of proteins).",,,,C70713,C70713,Biospecimen Type,string,Blood;Saliva;Tissue
2025-09-23,Microarray Analysis,C18477,C18477,C19770,Genetic Testing;Gene Expression Analysis;Molecular Analysis;Genetic Molecular Analysis;Laboratory Procedures,Gene Expression Profiling;Gene Expression Profile,Ordinal;Narrative,"Analysis using microarray technology (e.g., cDNA arrays to see gene expression or protein microarrays to profile the pattern of proteins).",,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Microarray Analysis,C18477,C18477,C19770,Genetic Testing;Gene Expression Analysis;Molecular Analysis;Genetic Molecular Analysis;Laboratory Procedures,Gene Expression Profiling;Gene Expression Profile,Ordinal;Narrative,"Analysis using microarray technology (e.g., cDNA arrays to see gene expression or protein microarrays to profile the pattern of proteins).",,,,C117062,C117062,"Measurement, Test or Examination Detail",string,
2025-09-23,Microarray Analysis,C18477,C18477,C19770,Genetic Testing;Gene Expression Analysis;Molecular Analysis;Genetic Molecular Analysis;Laboratory Procedures,Gene Expression Profiling;Gene Expression Profile,Ordinal;Narrative,"Analysis using microarray technology (e.g., cDNA arrays to see gene expression or protein microarrays to profile the pattern of proteins).",,,,C70856,C70856,Observation Result,string,
2025-09-23,Microarray Analysis,C18477,C18477,C19770,Genetic Testing;Gene Expression Analysis;Molecular Analysis;Genetic Molecular Analysis;Laboratory Procedures,Gene Expression Profiling;Gene Expression Profile,Ordinal;Narrative,"Analysis using microarray technology (e.g., cDNA arrays to see gene expression or protein microarrays to profile the pattern of proteins).",,,,C25372,C25372,Category,string,
2025-09-23,Microarray Analysis,C18477,C18477,C19770,Genetic Testing;Gene Expression Analysis;Molecular Analysis;Genetic Molecular Analysis;Laboratory Procedures,Gene Expression Profiling;Gene Expression Profile,Ordinal;Narrative,"Analysis using microarray technology (e.g., cDNA arrays to see gene expression or protein microarrays to profile the pattern of proteins).",,,,C25692,C25692,Subcategory,string,
2025-09-23,Microbial-induced Antibody Measurement,C187780,C187780,,Laboratory Tests;Immunogenicity Specimen Assessments;Microbial-induced Antibody Measurement,,,The determination of the amount of total microbial-induced antibody in a sample.,,,,,,,,
2025-09-23,Microbial-induced IgM Antibody Measurement,C187786,C187786,C187780,Laboratory Tests;Immunogenicity Specimen Assessments;Microbial-induced Antibody Measurement,MBIMAB;Microbial-induced IgM Antibody,Quantitative;Ordinal,The determination of the amount of microbial-induced IgM antibody in a sample.,,,,C70713,C70713,Biospecimen Type,string,Serum;Plasma;Cerebral Spinal Fluid
2025-09-23,Microbial-induced IgM Antibody Measurement,C187786,C187786,C187780,Laboratory Tests;Immunogenicity Specimen Assessments;Microbial-induced Antibody Measurement,MBIMAB;Microbial-induced IgM Antibody,Quantitative;Ordinal,The determination of the amount of microbial-induced IgM antibody in a sample.,,,,C82535,C82535,Test Method,string,Immunoassay;Immunofluorescence
2025-09-23,Microbial-induced IgM Antibody Measurement,C187786,C187786,C187780,Laboratory Tests;Immunogenicity Specimen Assessments;Microbial-induced Antibody Measurement,MBIMAB;Microbial-induced IgM Antibody,Quantitative;Ordinal,The determination of the amount of microbial-induced IgM antibody in a sample.,,,,C70856,C70856,Observation Result,string,
2025-09-23,Microbial-induced IgM Antibody Measurement,C187786,C187786,C187780,Laboratory Tests;Immunogenicity Specimen Assessments;Microbial-induced Antibody Measurement,MBIMAB;Microbial-induced IgM Antibody,Quantitative;Ordinal,The determination of the amount of microbial-induced IgM antibody in a sample.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Microbial-induced IgM Antibody Measurement,C187786,C187786,C187780,Laboratory Tests;Immunogenicity Specimen Assessments;Microbial-induced Antibody Measurement,MBIMAB;Microbial-induced IgM Antibody,Quantitative;Ordinal,The determination of the amount of microbial-induced IgM antibody in a sample.,,,,C25372,C25372,Category,string,
2025-09-23,Microbial-induced IgM Antibody Measurement,C187786,C187786,C187780,Laboratory Tests;Immunogenicity Specimen Assessments;Microbial-induced Antibody Measurement,MBIMAB;Microbial-induced IgM Antibody,Quantitative;Ordinal,The determination of the amount of microbial-induced IgM antibody in a sample.,,,,C25692,C25692,Subcategory,string,
2025-09-23,Microbial-induced IgM Antibody Measurement,C187786,C187786,C187780,Laboratory Tests;Immunogenicity Specimen Assessments;Microbial-induced Antibody Measurement,MBIMAB;Microbial-induced IgM Antibody,Quantitative;Ordinal,The determination of the amount of microbial-induced IgM antibody in a sample.,,,,C42647,C42647,Binder Excipient,string,Borrelia Burgdorferi;Chlamydophila Pneumoniae;Chlamydia Trachomatis;Cytomegalovirus;Ebola Virus;Epstein-Barr Virus Capsid Antigen;Hepatitis A Virus;Hepatitis B Virus Core Antigen;Hepatitis D Virus;Hepatitis E Virus;Human Herpesvirus 1;Herpes Simplex Viruses;Human Herpesvirus 2;Legionella Pneumophila;Human Parvovirus B19;Measles Morbillivirus;Toxoplasma Gondii;Varicella Zoster Virus;Adenoviridae;Coccidioides;Mumps Rubulavirus;Mycoplasma Pneumoniae;Norovirus Genogroup Ii.4;Rubella Virus;Severe Acute Respiratory Syndrome Coronavirus 2;Dengue Virus
2025-09-23,Microbial-induced IgM Antibody Measurement,C187786,C187786,C187780,Laboratory Tests;Immunogenicity Specimen Assessments;Microbial-induced Antibody Measurement,MBIMAB;Microbial-induced IgM Antibody,Quantitative;Ordinal,The determination of the amount of microbial-induced IgM antibody in a sample.,,,,C218437,C218437,Immunogenicity Specimen Test Operational Objective,string,Screen;Confirm;Quantify;Overall Subject Status
2025-09-23,Microbial-induced IgM Antibody Measurement,C187786,C187786,C187780,Laboratory Tests;Immunogenicity Specimen Assessments;Microbial-induced Antibody Measurement,MBIMAB;Microbial-induced IgM Antibody,Quantitative;Ordinal,The determination of the amount of microbial-induced IgM antibody in a sample.,,,,C48207,C48207,Unit of Concentration,string,mmol/L;g/L;mg/dL;mg/mL;umol/L;titer;U/mL
2025-09-23,Micrometastasis Present Indicator,C202140,C202140,C181043,Morphologic Findings;Metastasis,Micrometastasis Indicator;Micrometastasis Present,Ordinal,An indication of whether micrometastases were present in a sample.,,,,C25692,C25692,Subcategory,string,
2025-09-23,Micrometastasis Present Indicator,C202140,C202140,C181043,Morphologic Findings;Metastasis,Micrometastasis Indicator;Micrometastasis Present,Ordinal,An indication of whether micrometastases were present in a sample.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Micrometastasis Present Indicator,C202140,C202140,C181043,Morphologic Findings;Metastasis,Micrometastasis Indicator;Micrometastasis Present,Ordinal,An indication of whether micrometastases were present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Tissue
2025-09-23,Micrometastasis Present Indicator,C202140,C202140,C181043,Morphologic Findings;Metastasis,Micrometastasis Indicator;Micrometastasis Present,Ordinal,An indication of whether micrometastases were present in a sample.,,,,C25372,C25372,Category,string,
2025-09-23,Micrometastasis Present Indicator,C202140,C202140,C181043,Morphologic Findings;Metastasis,Micrometastasis Indicator;Micrometastasis Present,Ordinal,An indication of whether micrometastases were present in a sample.,,,,C171435,C171435,Specimen Anatomic Site,string,
2025-09-23,Micrometastasis Present Indicator,C202140,C202140,C181043,Morphologic Findings;Metastasis,Micrometastasis Indicator;Micrometastasis Present,Ordinal,An indication of whether micrometastases were present in a sample.,,,,C70856,C70856,Observation Result,string,Absent;Present
2025-09-23,Needle Biopsy,C15190,C15190,C15189,Diagnostic Procedures;Biopsies,Aspiration Biopsy;Needle Biopsy;Puncture Biopsy;needle biopsy,Nominal,"The removal of a tissue sample using a needle, for microscopic examination.",,,,C171000,C171000,Prespecified Event or Intervention Indicator,boolean,Y;N
2025-09-23,Needle Biopsy,C15190,C15190,C15189,Diagnostic Procedures;Biopsies,Aspiration Biopsy;Needle Biopsy;Puncture Biopsy;needle biopsy,Nominal,"The removal of a tissue sample using a needle, for microscopic examination.",,,,C25692,C25692,Subcategory,string,
2025-09-23,Needle Biopsy,C15190,C15190,C15189,Diagnostic Procedures;Biopsies,Aspiration Biopsy;Needle Biopsy;Puncture Biopsy;needle biopsy,Nominal,"The removal of a tissue sample using a needle, for microscopic examination.",,,,C117512,C117512,Standardized Name of Procedure,string,
2025-09-23,Needle Biopsy,C15190,C15190,C15189,Diagnostic Procedures;Biopsies,Aspiration Biopsy;Needle Biopsy;Puncture Biopsy;needle biopsy,Nominal,"The removal of a tissue sample using a needle, for microscopic examination.",,,,C117511,C117511,Reported Name of Procedure,string,Needle Biopsy
2025-09-23,Needle Biopsy,C15190,C15190,C15189,Diagnostic Procedures;Biopsies,Aspiration Biopsy;Needle Biopsy;Puncture Biopsy;needle biopsy,Nominal,"The removal of a tissue sample using a needle, for microscopic examination.",,,,C127786,C127786,Occurrence Indicator,boolean,Y;N
2025-09-23,Needle Biopsy,C15190,C15190,C15189,Diagnostic Procedures;Biopsies,Aspiration Biopsy;Needle Biopsy;Puncture Biopsy;needle biopsy,Nominal,"The removal of a tissue sample using a needle, for microscopic examination.",,,,C171435,C171435,Specimen Anatomic Site,string,Liver;Lung;Breast
2025-09-23,Needle Biopsy,C15190,C15190,C15189,Diagnostic Procedures;Biopsies,Aspiration Biopsy;Needle Biopsy;Puncture Biopsy;needle biopsy,Nominal,"The removal of a tissue sample using a needle, for microscopic examination.",,,,C25185,C25185,Laterality,string,Left;Right;Bilateral
2025-09-23,Needle Biopsy,C15190,C15190,C15189,Diagnostic Procedures;Biopsies,Aspiration Biopsy;Needle Biopsy;Puncture Biopsy;needle biopsy,Nominal,"The removal of a tissue sample using a needle, for microscopic examination.",,,,C54215,C54215,Directionality,string,
2025-09-23,Needle Biopsy,C15190,C15190,C15189,Diagnostic Procedures;Biopsies,Aspiration Biopsy;Needle Biopsy;Puncture Biopsy;needle biopsy,Nominal,"The removal of a tissue sample using a needle, for microscopic examination.",,,,C117529,C117529,Start Date and Time of Procedure,datetime,
2025-09-23,Needle Biopsy,C15190,C15190,C15189,Diagnostic Procedures;Biopsies,Aspiration Biopsy;Needle Biopsy;Puncture Biopsy;needle biopsy,Nominal,"The removal of a tissue sample using a needle, for microscopic examination.",,,,C117530,C117530,End Date and Time of Procedure,datetime,
2025-09-23,Needle Biopsy,C15190,C15190,C15189,Diagnostic Procedures;Biopsies,Aspiration Biopsy;Needle Biopsy;Puncture Biopsy;needle biopsy,Nominal,"The removal of a tissue sample using a needle, for microscopic examination.",,,,C25372,C25372,Category,string,
2025-09-23,Number of Years of Education,C122393,C122393,C17468,Subject Characteristics;Socioeconomic Factors;Socioeconomic Status;Education,EDUYRNUM;Education,Quantitative,The number of education years that a subject has competed.,,,,C42574,C42574,Unit of Time,string,Years
2025-09-23,Number of Years of Education,C122393,C122393,C17468,Subject Characteristics;Socioeconomic Factors;Socioeconomic Status;Education,EDUYRNUM;Education,Quantitative,The number of education years that a subject has competed.,,,,C70856,C70856,Observation Result,decimal,
2025-09-23,Number of Years of Education,C122393,C122393,C17468,Subject Characteristics;Socioeconomic Factors;Socioeconomic Status;Education,EDUYRNUM;Education,Quantitative,The number of education years that a subject has competed.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Oncotype DX Breast Cancer Assay,C52159,C52159,C18194,Diagnostic Tests;Diagnostic Assays;Diagnostic Procedures;Gene Expression Analysis;Assays,Oncotype DX,Quantitative;Narrative,"A diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early stage breast cancer. In addition to predicting distant disease recurrence, Oncotype DX also assesses the benefit from certain types of chemotherapy. The assay, performed using formalin-fixed, paraffin-embedded tumor tissue, analyzes the expression of a panel of 21 genes and the results are provided as a Recurrence Score (0-100). The gene panel was selected and the Recurrence Score calculation was derived through extensive laboratory testing and multiple independent clinical development studies. Oncotype DX is validated for use in breast cancer patients whose disease is newly diagnosed, stage I or II, node-negative, estrogen receptor-positive and who will be treated with tamoxifen.",,,,C25372,C25372,Category,string,
2025-09-23,Oncotype DX Breast Cancer Assay,C52159,C52159,C18194,Diagnostic Tests;Diagnostic Assays;Diagnostic Procedures;Gene Expression Analysis;Assays,Oncotype DX,Quantitative;Narrative,"A diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early stage breast cancer. In addition to predicting distant disease recurrence, Oncotype DX also assesses the benefit from certain types of chemotherapy. The assay, performed using formalin-fixed, paraffin-embedded tumor tissue, analyzes the expression of a panel of 21 genes and the results are provided as a Recurrence Score (0-100). The gene panel was selected and the Recurrence Score calculation was derived through extensive laboratory testing and multiple independent clinical development studies. Oncotype DX is validated for use in breast cancer patients whose disease is newly diagnosed, stage I or II, node-negative, estrogen receptor-positive and who will be treated with tamoxifen.",,,,C70856,C70856,Observation Result,integer,0-100
2025-09-23,Oncotype DX Breast Cancer Assay,C52159,C52159,C18194,Diagnostic Tests;Diagnostic Assays;Diagnostic Procedures;Gene Expression Analysis;Assays,Oncotype DX,Quantitative;Narrative,"A diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early stage breast cancer. In addition to predicting distant disease recurrence, Oncotype DX also assesses the benefit from certain types of chemotherapy. The assay, performed using formalin-fixed, paraffin-embedded tumor tissue, analyzes the expression of a panel of 21 genes and the results are provided as a Recurrence Score (0-100). The gene panel was selected and the Recurrence Score calculation was derived through extensive laboratory testing and multiple independent clinical development studies. Oncotype DX is validated for use in breast cancer patients whose disease is newly diagnosed, stage I or II, node-negative, estrogen receptor-positive and who will be treated with tamoxifen.",,,,C70713,C70713,Biospecimen Type,string,Tissue
2025-09-23,Oncotype DX Breast Cancer Assay,C52159,C52159,C18194,Diagnostic Tests;Diagnostic Assays;Diagnostic Procedures;Gene Expression Analysis;Assays,Oncotype DX,Quantitative;Narrative,"A diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early stage breast cancer. In addition to predicting distant disease recurrence, Oncotype DX also assesses the benefit from certain types of chemotherapy. The assay, performed using formalin-fixed, paraffin-embedded tumor tissue, analyzes the expression of a panel of 21 genes and the results are provided as a Recurrence Score (0-100). The gene panel was selected and the Recurrence Score calculation was derived through extensive laboratory testing and multiple independent clinical development studies. Oncotype DX is validated for use in breast cancer patients whose disease is newly diagnosed, stage I or II, node-negative, estrogen receptor-positive and who will be treated with tamoxifen.",,,,C171435,C171435,Specimen Anatomic Site,string,Breast
2025-09-23,Oncotype DX Breast Cancer Assay,C52159,C52159,C18194,Diagnostic Tests;Diagnostic Assays;Diagnostic Procedures;Gene Expression Analysis;Assays,Oncotype DX,Quantitative;Narrative,"A diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early stage breast cancer. In addition to predicting distant disease recurrence, Oncotype DX also assesses the benefit from certain types of chemotherapy. The assay, performed using formalin-fixed, paraffin-embedded tumor tissue, analyzes the expression of a panel of 21 genes and the results are provided as a Recurrence Score (0-100). The gene panel was selected and the Recurrence Score calculation was derived through extensive laboratory testing and multiple independent clinical development studies. Oncotype DX is validated for use in breast cancer patients whose disease is newly diagnosed, stage I or II, node-negative, estrogen receptor-positive and who will be treated with tamoxifen.",,,,C82535,C82535,Test Method,string,RT-PCR
2025-09-23,Oncotype DX Breast Cancer Assay,C52159,C52159,C18194,Diagnostic Tests;Diagnostic Assays;Diagnostic Procedures;Gene Expression Analysis;Assays,Oncotype DX,Quantitative;Narrative,"A diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early stage breast cancer. In addition to predicting distant disease recurrence, Oncotype DX also assesses the benefit from certain types of chemotherapy. The assay, performed using formalin-fixed, paraffin-embedded tumor tissue, analyzes the expression of a panel of 21 genes and the results are provided as a Recurrence Score (0-100). The gene panel was selected and the Recurrence Score calculation was derived through extensive laboratory testing and multiple independent clinical development studies. Oncotype DX is validated for use in breast cancer patients whose disease is newly diagnosed, stage I or II, node-negative, estrogen receptor-positive and who will be treated with tamoxifen.",,,,C25692,C25692,Subcategory,string,
2025-09-23,Overall Survival,C125201,C125201,,Disease Response;Disease Response Criteria;Survival,Overall Survival Time,Temporal,A measure of the time until death from any cause.,,,,C25692,C25692,Subcategory,string,
2025-09-23,Overall Survival,C125201,C125201,,Disease Response;Disease Response Criteria;Survival,Overall Survival Time,Temporal,A measure of the time until death from any cause.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Overall Survival,C125201,C125201,,Disease Response;Disease Response Criteria;Survival,Overall Survival Time,Temporal,A measure of the time until death from any cause.,,,,C25372,C25372,Category,string,
2025-09-23,Overall Survival,C125201,C125201,,Disease Response;Disease Response Criteria;Survival,Overall Survival Time,Temporal,A measure of the time until death from any cause.,,,,C70856,C70856,Observation Result,decimal,
2025-09-23,Overall Survival,C125201,C125201,,Disease Response;Disease Response Criteria;Survival,Overall Survival Time,Temporal,A measure of the time until death from any cause.,,,,C42574,C42574,Unit of Time,string,Days;Weeks;Months;Years
2025-09-23,PD-L1 Positive,C128554,C128554,C177692,Laboratory Tests;Immunology Tests;Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis,B7 Homolog 1 Positive;B7-H Positive;B7H1 Positive;CD274 Antigen Positive;CD274 Molecule Positive;CD274 Positive;Expression of PD-L1;PD-L1 Positive;PD-L1+;PDCD1L1 Positive;PDCD1LG1 Positive;PDL1 Positive;Positive;Programmed Cell Death 1 Ligand 1 Positive,Ordinal,An immunohistochemical test result that indicates expression of PD-L1 in a tissue sample of a primary or metastatic malignant neoplasm.,,,,C70713,C70713,Biospecimen Type,string,Tissue;Blood
2025-09-23,PD-L1 Positive,C128554,C128554,C177692,Laboratory Tests;Immunology Tests;Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis,B7 Homolog 1 Positive;B7-H Positive;B7H1 Positive;CD274 Antigen Positive;CD274 Molecule Positive;CD274 Positive;Expression of PD-L1;PD-L1 Positive;PD-L1+;PDCD1L1 Positive;PDCD1LG1 Positive;PDL1 Positive;Positive;Programmed Cell Death 1 Ligand 1 Positive,Ordinal,An immunohistochemical test result that indicates expression of PD-L1 in a tissue sample of a primary or metastatic malignant neoplasm.,,,,C25692,C25692,Subcategory,string,
2025-09-23,PD-L1 Positive,C128554,C128554,C177692,Laboratory Tests;Immunology Tests;Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis,B7 Homolog 1 Positive;B7-H Positive;B7H1 Positive;CD274 Antigen Positive;CD274 Molecule Positive;CD274 Positive;Expression of PD-L1;PD-L1 Positive;PD-L1+;PDCD1L1 Positive;PDCD1LG1 Positive;PDL1 Positive;Positive;Programmed Cell Death 1 Ligand 1 Positive,Ordinal,An immunohistochemical test result that indicates expression of PD-L1 in a tissue sample of a primary or metastatic malignant neoplasm.,,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Overall Status
2025-09-23,PD-L1 Positive,C128554,C128554,C177692,Laboratory Tests;Immunology Tests;Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis,B7 Homolog 1 Positive;B7-H Positive;B7H1 Positive;CD274 Antigen Positive;CD274 Molecule Positive;CD274 Positive;Expression of PD-L1;PD-L1 Positive;PD-L1+;PDCD1L1 Positive;PDCD1LG1 Positive;PDL1 Positive;Positive;Programmed Cell Death 1 Ligand 1 Positive,Ordinal,An immunohistochemical test result that indicates expression of PD-L1 in a tissue sample of a primary or metastatic malignant neoplasm.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,PD-L1 Positive,C128554,C128554,C177692,Laboratory Tests;Immunology Tests;Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis,B7 Homolog 1 Positive;B7-H Positive;B7H1 Positive;CD274 Antigen Positive;CD274 Molecule Positive;CD274 Positive;Expression of PD-L1;PD-L1 Positive;PD-L1+;PDCD1L1 Positive;PDCD1LG1 Positive;PDL1 Positive;Positive;Programmed Cell Death 1 Ligand 1 Positive,Ordinal,An immunohistochemical test result that indicates expression of PD-L1 in a tissue sample of a primary or metastatic malignant neoplasm.,,,,C70856,C70856,Observation Result,string,Positive;Negative
2025-09-23,PD-L1 Positive,C128554,C128554,C177692,Laboratory Tests;Immunology Tests;Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis,B7 Homolog 1 Positive;B7-H Positive;B7H1 Positive;CD274 Antigen Positive;CD274 Molecule Positive;CD274 Positive;Expression of PD-L1;PD-L1 Positive;PD-L1+;PDCD1L1 Positive;PDCD1LG1 Positive;PDL1 Positive;Positive;Programmed Cell Death 1 Ligand 1 Positive,Ordinal,An immunohistochemical test result that indicates expression of PD-L1 in a tissue sample of a primary or metastatic malignant neoplasm.,,,,C171435,C171435,Specimen Anatomic Site,string,
2025-09-23,PD-L1 Positive,C128554,C128554,C177692,Laboratory Tests;Immunology Tests;Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis,B7 Homolog 1 Positive;B7-H Positive;B7H1 Positive;CD274 Antigen Positive;CD274 Molecule Positive;CD274 Positive;Expression of PD-L1;PD-L1 Positive;PD-L1+;PDCD1L1 Positive;PDCD1LG1 Positive;PDL1 Positive;Positive;Programmed Cell Death 1 Ligand 1 Positive,Ordinal,An immunohistochemical test result that indicates expression of PD-L1 in a tissue sample of a primary or metastatic malignant neoplasm.,,,,C25372,C25372,Category,string,
2025-09-23,PGI Generic Modification Version - Change,C135818,C135818,C135706,QRS;Clinical or Research Assessment Questionnaire;Patient Global Impression Generic Modification Version Questionnaire;PGI;PGI01;PGI Generic Modification Version Questionnaire Question,PGI01-Change;PGI0102;PGI Generic Modification Version - Change,Ordinal,Patient Global Impression Generic Modification Version (PGI Generic Modification Version) Compared to <previously assessed protocol specified time point> how much has your condition changed?,,,,C46126,C46126,Ordinal Position,integer,1;2;3;4;5;6;7
2025-09-23,PGI Generic Modification Version - Change,C135818,C135818,C135706,QRS;Clinical or Research Assessment Questionnaire;Patient Global Impression Generic Modification Version Questionnaire;PGI;PGI01;PGI Generic Modification Version Questionnaire Question,PGI01-Change;PGI0102;PGI Generic Modification Version - Change,Ordinal,Patient Global Impression Generic Modification Version (PGI Generic Modification Version) Compared to <previously assessed protocol specified time point> how much has your condition changed?,,,,C91106,C91106,Clinical or Research Assessment Answer,string,Very much improved;Much improved;Minimally improved;No change;Minimally worse;Much worse;Very much worse
2025-09-23,PGI Generic Modification Version - Change,C135818,C135818,C135706,QRS;Clinical or Research Assessment Questionnaire;Patient Global Impression Generic Modification Version Questionnaire;PGI;PGI01;PGI Generic Modification Version Questionnaire Question,PGI01-Change;PGI0102;PGI Generic Modification Version - Change,Ordinal,Patient Global Impression Generic Modification Version (PGI Generic Modification Version) Compared to <previously assessed protocol specified time point> how much has your condition changed?,,,,C25372,C25372,Category,string,PGI
2025-09-23,PGI Generic Modification Version - Change,C135818,C135818,C135706,QRS;Clinical or Research Assessment Questionnaire;Patient Global Impression Generic Modification Version Questionnaire;PGI;PGI01;PGI Generic Modification Version Questionnaire Question,PGI01-Change;PGI0102;PGI Generic Modification Version - Change,Ordinal,Patient Global Impression Generic Modification Version (PGI Generic Modification Version) Compared to <previously assessed protocol specified time point> how much has your condition changed?,,,,C82535,C82535,Test Method,string,VERBAL RATING SCALE 4-POINT;VERBAL RATING SCALE 7-POINT;LIKERT SCALE 4-POINT;LIKERT SCALE 7-POINT
2025-09-23,PGI Generic Modification Version - Change,C135818,C135818,C135706,QRS;Clinical or Research Assessment Questionnaire;Patient Global Impression Generic Modification Version Questionnaire;PGI;PGI01;PGI Generic Modification Version Questionnaire Question,PGI01-Change;PGI0102;PGI Generic Modification Version - Change,Ordinal,Patient Global Impression Generic Modification Version (PGI Generic Modification Version) Compared to <previously assessed protocol specified time point> how much has your condition changed?,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,PGI Generic Modification Version - Improvement,C135819,C135819,C135706,QRS;Clinical or Research Assessment Questionnaire;Patient Global Impression Generic Modification Version Questionnaire;PGI;PGI01;PGI Generic Modification Version Questionnaire Question,PGI01-Improvement;PGI0103;PGI Generic Modification Version - Improvement,Ordinal,Patient Global Impression Generic Modification Version (PGI Generic Modification Version) Compared to <previously assessed protocol specified time point> how much has your condition improved?,,,,C91106,C91106,Clinical or Research Assessment Answer,string,No change;Almost the same;A little better;Somewhat better;Moderately better;Much better;A great deal better
2025-09-23,PGI Generic Modification Version - Improvement,C135819,C135819,C135706,QRS;Clinical or Research Assessment Questionnaire;Patient Global Impression Generic Modification Version Questionnaire;PGI;PGI01;PGI Generic Modification Version Questionnaire Question,PGI01-Improvement;PGI0103;PGI Generic Modification Version - Improvement,Ordinal,Patient Global Impression Generic Modification Version (PGI Generic Modification Version) Compared to <previously assessed protocol specified time point> how much has your condition improved?,,,,C46126,C46126,Ordinal Position,integer,1;2;3;4;5;6;7
2025-09-23,PGI Generic Modification Version - Improvement,C135819,C135819,C135706,QRS;Clinical or Research Assessment Questionnaire;Patient Global Impression Generic Modification Version Questionnaire;PGI;PGI01;PGI Generic Modification Version Questionnaire Question,PGI01-Improvement;PGI0103;PGI Generic Modification Version - Improvement,Ordinal,Patient Global Impression Generic Modification Version (PGI Generic Modification Version) Compared to <previously assessed protocol specified time point> how much has your condition improved?,,,,C25372,C25372,Category,string,PGI
2025-09-23,PGI Generic Modification Version - Improvement,C135819,C135819,C135706,QRS;Clinical or Research Assessment Questionnaire;Patient Global Impression Generic Modification Version Questionnaire;PGI;PGI01;PGI Generic Modification Version Questionnaire Question,PGI01-Improvement;PGI0103;PGI Generic Modification Version - Improvement,Ordinal,Patient Global Impression Generic Modification Version (PGI Generic Modification Version) Compared to <previously assessed protocol specified time point> how much has your condition improved?,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,PGI Generic Modification Version - Improvement,C135819,C135819,C135706,QRS;Clinical or Research Assessment Questionnaire;Patient Global Impression Generic Modification Version Questionnaire;PGI;PGI01;PGI Generic Modification Version Questionnaire Question,PGI01-Improvement;PGI0103;PGI Generic Modification Version - Improvement,Ordinal,Patient Global Impression Generic Modification Version (PGI Generic Modification Version) Compared to <previously assessed protocol specified time point> how much has your condition improved?,,,,C82535,C82535,Test Method,string,VERBAL RATING SCALE 4-POINT;VERBAL RATING SCALE 7-POINT;LIKERT SCALE 4-POINT;LIKERT SCALE 7-POINT
2025-09-23,PGI Generic Modification Version - Severity,C135817,C135817,C135706,QRS;Clinical or Research Assessment Questionnaire;Patient Global Impression Generic Modification Version Questionnaire;PGI;PGI01;PGI Generic Modification Version Questionnaire Question,PGI01-Severity;PGI0101;PGI Generic Modification Version - Severity,Ordinal,"Patient Global Impression Generic Modification Version (PGI Generic Modification Version) Considering all the ways your condition impacts you, how severe is your condition at this time?",,,,C82535,C82535,Test Method,string,VERBAL RATING SCALE 4-POINT;VERBAL RATING SCALE 7-POINT;LIKERT SCALE 4-POINT;LIKERT SCALE 7-POINT
2025-09-23,PGI Generic Modification Version - Severity,C135817,C135817,C135706,QRS;Clinical or Research Assessment Questionnaire;Patient Global Impression Generic Modification Version Questionnaire;PGI;PGI01;PGI Generic Modification Version Questionnaire Question,PGI01-Severity;PGI0101;PGI Generic Modification Version - Severity,Ordinal,"Patient Global Impression Generic Modification Version (PGI Generic Modification Version) Considering all the ways your condition impacts you, how severe is your condition at this time?",,,,C25372,C25372,Category,string,PGI
2025-09-23,PGI Generic Modification Version - Severity,C135817,C135817,C135706,QRS;Clinical or Research Assessment Questionnaire;Patient Global Impression Generic Modification Version Questionnaire;PGI;PGI01;PGI Generic Modification Version Questionnaire Question,PGI01-Severity;PGI0101;PGI Generic Modification Version - Severity,Ordinal,"Patient Global Impression Generic Modification Version (PGI Generic Modification Version) Considering all the ways your condition impacts you, how severe is your condition at this time?",,,,C91106,C91106,Clinical or Research Assessment Answer,string,Normal;Mild;Moderate;Severe
2025-09-23,PGI Generic Modification Version - Severity,C135817,C135817,C135706,QRS;Clinical or Research Assessment Questionnaire;Patient Global Impression Generic Modification Version Questionnaire;PGI;PGI01;PGI Generic Modification Version Questionnaire Question,PGI01-Severity;PGI0101;PGI Generic Modification Version - Severity,Ordinal,"Patient Global Impression Generic Modification Version (PGI Generic Modification Version) Considering all the ways your condition impacts you, how severe is your condition at this time?",,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,PGI Generic Modification Version - Severity,C135817,C135817,C135706,QRS;Clinical or Research Assessment Questionnaire;Patient Global Impression Generic Modification Version Questionnaire;PGI;PGI01;PGI Generic Modification Version Questionnaire Question,PGI01-Severity;PGI0101;PGI Generic Modification Version - Severity,Ordinal,"Patient Global Impression Generic Modification Version (PGI Generic Modification Version) Considering all the ways your condition impacts you, how severe is your condition at this time?",,,,C46126,C46126,Ordinal Position,integer,1;2;3;4;5;6;7
2025-09-23,PGI Generic Modification Version Questionnaire Question,C135706,C135706,C211913,QRS Instrument Questions,,,A question associated with the PGI Generic Modification Version questionnaire.,,,,,,,,
2025-09-23,Patient Global Impression Generic Modification Version Questionnaire,C135739,C135739,C91105,QRS;Clinical or Research Assessment Questionnaire;Patient Global Impression Generic Modification Version Questionnaire;PGI;PGI01,PGI;PGI01;PGI Generic Modification Version,,"A modified, generic version of a standardized questionnaire, developed as a patient reported outcomes counterpart for the Clinical Global Impressions scale published by Guy et al. in 1976, that assesses a patient's perception of their condition.",,,,,,,,
2025-09-23,Percentage of in situ Carcinoma,C123559,C123559,C35867,Disease Response;Tumor Results;Tumor Measurements,PCTISCA,Quantitative,A relative measurement (percentage) of in situ component present in a carcinoma compared to the entire malignant cellular proliferation.,,,,C48570,C48570,Percent Unit,string,%
2025-09-23,Percentage of in situ Carcinoma,C123559,C123559,C35867,Disease Response;Tumor Results;Tumor Measurements,PCTISCA,Quantitative,A relative measurement (percentage) of in situ component present in a carcinoma compared to the entire malignant cellular proliferation.,,,,C25692,C25692,Subcategory,string,
2025-09-23,Percentage of in situ Carcinoma,C123559,C123559,C35867,Disease Response;Tumor Results;Tumor Measurements,PCTISCA,Quantitative,A relative measurement (percentage) of in situ component present in a carcinoma compared to the entire malignant cellular proliferation.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Percentage of in situ Carcinoma,C123559,C123559,C35867,Disease Response;Tumor Results;Tumor Measurements,PCTISCA,Quantitative,A relative measurement (percentage) of in situ component present in a carcinoma compared to the entire malignant cellular proliferation.,,,,C70713,C70713,Biospecimen Type,string,Tissue;Tumor tissue
2025-09-23,Percentage of in situ Carcinoma,C123559,C123559,C35867,Disease Response;Tumor Results;Tumor Measurements,PCTISCA,Quantitative,A relative measurement (percentage) of in situ component present in a carcinoma compared to the entire malignant cellular proliferation.,,,,C171435,C171435,Specimen Anatomic Site,string,
2025-09-23,Percentage of in situ Carcinoma,C123559,C123559,C35867,Disease Response;Tumor Results;Tumor Measurements,PCTISCA,Quantitative,A relative measurement (percentage) of in situ component present in a carcinoma compared to the entire malignant cellular proliferation.,,,,C70856,C70856,Observation Result,integer,
2025-09-23,Percentage of in situ Carcinoma,C123559,C123559,C35867,Disease Response;Tumor Results;Tumor Measurements,PCTISCA,Quantitative,A relative measurement (percentage) of in situ component present in a carcinoma compared to the entire malignant cellular proliferation.,,,,C25372,C25372,Category,string,
2025-09-23,Positron Emission Tomography,C17007,C17007,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures,Medical Imaging;PET;PET SCAN;PET Scan;PET scan;PT;Pet Scan;Positron Emission Tomography Scan;Positron emission tomography (procedure);Positron-Emission Tomography;positron emission tomography scan;proton magnetic resonance spectroscopic imaging,Nominal,"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.",,,,C117530,C117530,End Date and Time of Procedure,datetime,
2025-09-23,Positron Emission Tomography,C17007,C17007,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures,Medical Imaging;PET;PET SCAN;PET Scan;PET scan;PT;Pet Scan;Positron Emission Tomography Scan;Positron emission tomography (procedure);Positron-Emission Tomography;positron emission tomography scan;proton magnetic resonance spectroscopic imaging,Nominal,"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.",,,,C117511,C117511,Reported Name of Procedure,string,Positron Emission Tomography
2025-09-23,Positron Emission Tomography,C17007,C17007,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures,Medical Imaging;PET;PET SCAN;PET Scan;PET scan;PT;Pet Scan;Positron Emission Tomography Scan;Positron emission tomography (procedure);Positron-Emission Tomography;positron emission tomography scan;proton magnetic resonance spectroscopic imaging,Nominal,"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.",,,,C171000,C171000,Prespecified Event or Intervention Indicator,boolean,Y;N
2025-09-23,Positron Emission Tomography,C17007,C17007,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures,Medical Imaging;PET;PET SCAN;PET Scan;PET scan;PT;Pet Scan;Positron Emission Tomography Scan;Positron emission tomography (procedure);Positron-Emission Tomography;positron emission tomography scan;proton magnetic resonance spectroscopic imaging,Nominal,"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.",,,,C54215,C54215,Directionality,string,
2025-09-23,Positron Emission Tomography,C17007,C17007,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures,Medical Imaging;PET;PET SCAN;PET Scan;PET scan;PT;Pet Scan;Positron Emission Tomography Scan;Positron emission tomography (procedure);Positron-Emission Tomography;positron emission tomography scan;proton magnetic resonance spectroscopic imaging,Nominal,"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.",,,,C25185,C25185,Laterality,string,Left;Right;Bilateral
2025-09-23,Positron Emission Tomography,C17007,C17007,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures,Medical Imaging;PET;PET SCAN;PET Scan;PET scan;PT;Pet Scan;Positron Emission Tomography Scan;Positron emission tomography (procedure);Positron-Emission Tomography;positron emission tomography scan;proton magnetic resonance spectroscopic imaging,Nominal,"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.",,,,C13717,C13717,Anatomic Site,string,Brain;Heart;Lung
2025-09-23,Positron Emission Tomography,C17007,C17007,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures,Medical Imaging;PET;PET SCAN;PET Scan;PET scan;PT;Pet Scan;Positron Emission Tomography Scan;Positron emission tomography (procedure);Positron-Emission Tomography;positron emission tomography scan;proton magnetic resonance spectroscopic imaging,Nominal,"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.",,,,C25372,C25372,Category,string,
2025-09-23,Positron Emission Tomography,C17007,C17007,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures,Medical Imaging;PET;PET SCAN;PET Scan;PET scan;PT;Pet Scan;Positron Emission Tomography Scan;Positron emission tomography (procedure);Positron-Emission Tomography;positron emission tomography scan;proton magnetic resonance spectroscopic imaging,Nominal,"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.",,,,C117529,C117529,Start Date and Time of Procedure,datetime,
2025-09-23,Positron Emission Tomography,C17007,C17007,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures,Medical Imaging;PET;PET SCAN;PET Scan;PET scan;PT;Pet Scan;Positron Emission Tomography Scan;Positron emission tomography (procedure);Positron-Emission Tomography;positron emission tomography scan;proton magnetic resonance spectroscopic imaging,Nominal,"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.",,,,C25692,C25692,Subcategory,string,
2025-09-23,Positron Emission Tomography,C17007,C17007,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures,Medical Imaging;PET;PET SCAN;PET Scan;PET scan;PT;Pet Scan;Positron Emission Tomography Scan;Positron emission tomography (procedure);Positron-Emission Tomography;positron emission tomography scan;proton magnetic resonance spectroscopic imaging,Nominal,"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.",,,,C117512,C117512,Standardized Name of Procedure,string,
2025-09-23,Positron Emission Tomography,C17007,C17007,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures,Medical Imaging;PET;PET SCAN;PET Scan;PET scan;PT;Pet Scan;Positron Emission Tomography Scan;Positron emission tomography (procedure);Positron-Emission Tomography;positron emission tomography scan;proton magnetic resonance spectroscopic imaging,Nominal,"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.",,,,C127786,C127786,Occurrence Indicator,boolean,Y;N
2025-09-23,Progesterone Receptor Measurement,C117846,C117846,C64430,Laboratory Tests;Chemistry Tests;Endocrine Tests;Hormone Measurements;Protein or Enzyme Type Measurement,PROGESTR;NR3C3;PGR;PR;Progesterone Receptor,Nominal;Quantitative,The determination of the amount of progesterone receptor present in a sample.,,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Allred Proportion Positive Score;Allred  Staining Intensity Score;Allred Total Score
2025-09-23,Progesterone Receptor Measurement,C117846,C117846,C64430,Laboratory Tests;Chemistry Tests;Endocrine Tests;Hormone Measurements;Protein or Enzyme Type Measurement,PROGESTR;NR3C3;PGR;PR;Progesterone Receptor,Nominal;Quantitative,The determination of the amount of progesterone receptor present in a sample.,,,,C82535,C82535,Test Method,string,Immunohistochemistry
2025-09-23,Progesterone Receptor Measurement,C117846,C117846,C64430,Laboratory Tests;Chemistry Tests;Endocrine Tests;Hormone Measurements;Protein or Enzyme Type Measurement,PROGESTR;NR3C3;PGR;PR;Progesterone Receptor,Nominal;Quantitative,The determination of the amount of progesterone receptor present in a sample.,,,,C170500,C170500,Result Anatomical Location,string,Breast
2025-09-23,Progesterone Receptor Measurement,C117846,C117846,C64430,Laboratory Tests;Chemistry Tests;Endocrine Tests;Hormone Measurements;Protein or Enzyme Type Measurement,PROGESTR;NR3C3;PGR;PR;Progesterone Receptor,Nominal;Quantitative,The determination of the amount of progesterone receptor present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Tissue
2025-09-23,Progesterone Receptor Measurement,C117846,C117846,C64430,Laboratory Tests;Chemistry Tests;Endocrine Tests;Hormone Measurements;Protein or Enzyme Type Measurement,PROGESTR;NR3C3;PGR;PR;Progesterone Receptor,Nominal;Quantitative,The determination of the amount of progesterone receptor present in a sample.,,,,C70856,C70856,Observation Result,string,
2025-09-23,Progesterone Receptor Measurement,C117846,C117846,C64430,Laboratory Tests;Chemistry Tests;Endocrine Tests;Hormone Measurements;Protein or Enzyme Type Measurement,PROGESTR;NR3C3;PGR;PR;Progesterone Receptor,Nominal;Quantitative,The determination of the amount of progesterone receptor present in a sample.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Progesterone Receptor Positive,C15496,C15496,C16149,Laboratory Tests;Chemistry Tests;Endocrine Tests;Hormone Measurements;Protein or Enzyme Type Measurement,PGR Positive;PR Positive,Ordinal,An indication that progesterone receptor (PRG; PR) expression has been detected in a sample.,,,,C25372,C25372,Category,string,Hormone Receptor
2025-09-23,Progesterone Receptor Positive,C15496,C15496,C16149,Laboratory Tests;Chemistry Tests;Endocrine Tests;Hormone Measurements;Protein or Enzyme Type Measurement,PGR Positive;PR Positive,Ordinal,An indication that progesterone receptor (PRG; PR) expression has been detected in a sample.,,,,C70713,C70713,Biospecimen Type,string,
2025-09-23,Progesterone Receptor Positive,C15496,C15496,C16149,Laboratory Tests;Chemistry Tests;Endocrine Tests;Hormone Measurements;Protein or Enzyme Type Measurement,PGR Positive;PR Positive,Ordinal,An indication that progesterone receptor (PRG; PR) expression has been detected in a sample.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Progesterone Receptor Positive,C15496,C15496,C16149,Laboratory Tests;Chemistry Tests;Endocrine Tests;Hormone Measurements;Protein or Enzyme Type Measurement,PGR Positive;PR Positive,Ordinal,An indication that progesterone receptor (PRG; PR) expression has been detected in a sample.,,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Overall Status
2025-09-23,Progesterone Receptor Positive,C15496,C15496,C16149,Laboratory Tests;Chemistry Tests;Endocrine Tests;Hormone Measurements;Protein or Enzyme Type Measurement,PGR Positive;PR Positive,Ordinal,An indication that progesterone receptor (PRG; PR) expression has been detected in a sample.,,,,C171435,C171435,Specimen Anatomic Site,string,
2025-09-23,Progesterone Receptor Positive,C15496,C15496,C16149,Laboratory Tests;Chemistry Tests;Endocrine Tests;Hormone Measurements;Protein or Enzyme Type Measurement,PGR Positive;PR Positive,Ordinal,An indication that progesterone receptor (PRG; PR) expression has been detected in a sample.,,,,C70856,C70856,Observation Result,boolean,Y;N
2025-09-23,Progesterone Receptor Positive,C15496,C15496,C16149,Laboratory Tests;Chemistry Tests;Endocrine Tests;Hormone Measurements;Protein or Enzyme Type Measurement,PGR Positive;PR Positive,Ordinal,An indication that progesterone receptor (PRG; PR) expression has been detected in a sample.,,,,C25692,C25692,Subcategory,string,Nuclear Receptor
2025-09-23,Progesterone Receptor Status,C16149,C16149,C188928,Laboratory Tests;Chemistry Tests;Endocrine Tests;Hormone Measurements;Protein or Enzyme Type Measurement,PgR Status;Progesterone Receptor,Ordinal,Indicates the progesterone receptor level measured in a primary tumor or in metastases. (>=10 is positive if measured in fmols/mg cytosol protein; Otherwise use institutional standards),,,,C25372,C25372,Category,string,
2025-09-23,Progesterone Receptor Status,C16149,C16149,C188928,Laboratory Tests;Chemistry Tests;Endocrine Tests;Hormone Measurements;Protein or Enzyme Type Measurement,PgR Status;Progesterone Receptor,Ordinal,Indicates the progesterone receptor level measured in a primary tumor or in metastases. (>=10 is positive if measured in fmols/mg cytosol protein; Otherwise use institutional standards),,,,C70856,C70856,Observation Result,string,Positive;Negative
2025-09-23,Progesterone Receptor Status,C16149,C16149,C188928,Laboratory Tests;Chemistry Tests;Endocrine Tests;Hormone Measurements;Protein or Enzyme Type Measurement,PgR Status;Progesterone Receptor,Ordinal,Indicates the progesterone receptor level measured in a primary tumor or in metastases. (>=10 is positive if measured in fmols/mg cytosol protein; Otherwise use institutional standards),,,,C70713,C70713,Biospecimen Type,string,
2025-09-23,Progesterone Receptor Status,C16149,C16149,C188928,Laboratory Tests;Chemistry Tests;Endocrine Tests;Hormone Measurements;Protein or Enzyme Type Measurement,PgR Status;Progesterone Receptor,Ordinal,Indicates the progesterone receptor level measured in a primary tumor or in metastases. (>=10 is positive if measured in fmols/mg cytosol protein; Otherwise use institutional standards),,,,C25692,C25692,Subcategory,string,
2025-09-23,Progesterone Receptor Status,C16149,C16149,C188928,Laboratory Tests;Chemistry Tests;Endocrine Tests;Hormone Measurements;Protein or Enzyme Type Measurement,PgR Status;Progesterone Receptor,Ordinal,Indicates the progesterone receptor level measured in a primary tumor or in metastases. (>=10 is positive if measured in fmols/mg cytosol protein; Otherwise use institutional standards),,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Overall Status
2025-09-23,Progesterone Receptor Status,C16149,C16149,C188928,Laboratory Tests;Chemistry Tests;Endocrine Tests;Hormone Measurements;Protein or Enzyme Type Measurement,PgR Status;Progesterone Receptor,Ordinal,Indicates the progesterone receptor level measured in a primary tumor or in metastases. (>=10 is positive if measured in fmols/mg cytosol protein; Otherwise use institutional standards),,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Progesterone Receptor Status,C16149,C16149,C188928,Laboratory Tests;Chemistry Tests;Endocrine Tests;Hormone Measurements;Protein or Enzyme Type Measurement,PgR Status;Progesterone Receptor,Ordinal,Indicates the progesterone receptor level measured in a primary tumor or in metastases. (>=10 is positive if measured in fmols/mg cytosol protein; Otherwise use institutional standards),,,,C171435,C171435,Specimen Anatomic Site,string,
2025-09-23,Progression-free Survival,C28234,C28234,,Disease Response;Disease Response Criteria;Survival,PFS,Temporal,The length of time during and after treatment in which a patient is living with a disease that does not get worse. Progression-free survival may be used in a clinical study or trial to help find out how well a new treatment works.,,,,C42574,C42574,Unit of Time,string,Days;Weeks;Months;Years
2025-09-23,Progression-free Survival,C28234,C28234,,Disease Response;Disease Response Criteria;Survival,PFS,Temporal,The length of time during and after treatment in which a patient is living with a disease that does not get worse. Progression-free survival may be used in a clinical study or trial to help find out how well a new treatment works.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Progression-free Survival,C28234,C28234,,Disease Response;Disease Response Criteria;Survival,PFS,Temporal,The length of time during and after treatment in which a patient is living with a disease that does not get worse. Progression-free survival may be used in a clinical study or trial to help find out how well a new treatment works.,,,,C25372,C25372,Category,string,
2025-09-23,Progression-free Survival,C28234,C28234,,Disease Response;Disease Response Criteria;Survival,PFS,Temporal,The length of time during and after treatment in which a patient is living with a disease that does not get worse. Progression-free survival may be used in a clinical study or trial to help find out how well a new treatment works.,,,,C25692,C25692,Subcategory,string,
2025-09-23,Progression-free Survival,C28234,C28234,,Disease Response;Disease Response Criteria;Survival,PFS,Temporal,The length of time during and after treatment in which a patient is living with a disease that does not get worse. Progression-free survival may be used in a clinical study or trial to help find out how well a new treatment works.,,,,C70856,C70856,Observation Result,decimal,
2025-09-23,Recurrence Indicator,C93645,C93645,C25180,Disease Response;Recurrence;Indicators,Recurrence,Ordinal,"Specifies whether this is a reappearance of an entity, event or activity.",,,,C25692,C25692,Subcategory,string,
2025-09-23,Recurrence Indicator,C93645,C93645,C25180,Disease Response;Recurrence;Indicators,Recurrence,Ordinal,"Specifies whether this is a reappearance of an entity, event or activity.",,,,C25372,C25372,Category,string,
2025-09-23,Recurrence Indicator,C93645,C93645,C25180,Disease Response;Recurrence;Indicators,Recurrence,Ordinal,"Specifies whether this is a reappearance of an entity, event or activity.",,,,C70856,C70856,Observation Result,string,Positive;Negative
2025-09-23,Recurrence Indicator,C93645,C93645,C25180,Disease Response;Recurrence;Indicators,Recurrence,Ordinal,"Specifies whether this is a reappearance of an entity, event or activity.",,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Recurrence Risk Score,C190808,C190808,,Diagnostic Tests,,,A score that estimates the likelihood that an individual with have a recurrence of a disease.,,,,,,,,
2025-09-23,Recurrence in Distant Nodes,C192424,C192424,C55073,Disease Response;Recurrent Disease,Nodal-Distant;Recurrence in Distant Nodes,Ordinal,A recurrence of disease in distant lymph nodes.,,,,C70856,C70856,Observation Result,string,Present;Absent
2025-09-23,Recurrence in Distant Nodes,C192424,C192424,C55073,Disease Response;Recurrent Disease,Nodal-Distant;Recurrence in Distant Nodes,Ordinal,A recurrence of disease in distant lymph nodes.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Recurrence in Distant Nodes,C192424,C192424,C55073,Disease Response;Recurrent Disease,Nodal-Distant;Recurrence in Distant Nodes,Ordinal,A recurrence of disease in distant lymph nodes.,,,,C25372,C25372,Category,string,
2025-09-23,Recurrence in Distant Nodes,C192424,C192424,C55073,Disease Response;Recurrent Disease,Nodal-Distant;Recurrence in Distant Nodes,Ordinal,A recurrence of disease in distant lymph nodes.,,,,C25692,C25692,Subcategory,string,
2025-09-23,Recurrent Disease,C38155,C38155,,Disease Response;Recurrent Disease,Recurrence;Disease Relapse,Ordinal,The return of a disease after a period of remission.,,,,C70856,C70856,Observation Result,string,Positive;Negative;Absent Present
2025-09-23,Recurrent Disease,C38155,C38155,,Disease Response;Recurrent Disease,Recurrence;Disease Relapse,Ordinal,The return of a disease after a period of remission.,,,,C25372,C25372,Category,string,
2025-09-23,Recurrent Disease,C38155,C38155,,Disease Response;Recurrent Disease,Recurrence;Disease Relapse,Ordinal,The return of a disease after a period of remission.,,,,C25692,C25692,Subcategory,string,
2025-09-23,Recurrent Disease,C38155,C38155,,Disease Response;Recurrent Disease,Recurrence;Disease Relapse,Ordinal,The return of a disease after a period of remission.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Residual Cancer Burden,C160722,C160722,,Tumor Results;Disease Response,RCB Class,Ordinal,An indication of the amount of invasive cancer in breast or lymph node tissue after completion of neoadjuvant chemotherapy.,,,,C70713,C70713,Biospecimen Type,string,Tissue
2025-09-23,Residual Cancer Burden,C160722,C160722,,Tumor Results;Disease Response,RCB Class,Ordinal,An indication of the amount of invasive cancer in breast or lymph node tissue after completion of neoadjuvant chemotherapy.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Residual Cancer Burden,C160722,C160722,,Tumor Results;Disease Response,RCB Class,Ordinal,An indication of the amount of invasive cancer in breast or lymph node tissue after completion of neoadjuvant chemotherapy.,,,,C25692,C25692,Subcategory,string,
2025-09-23,Residual Cancer Burden,C160722,C160722,,Tumor Results;Disease Response,RCB Class,Ordinal,An indication of the amount of invasive cancer in breast or lymph node tissue after completion of neoadjuvant chemotherapy.,,,,C171435,C171435,Specimen Anatomic Site,string,Breast;Lymph Node
2025-09-23,Residual Cancer Burden,C160722,C160722,,Tumor Results;Disease Response,RCB Class,Ordinal,An indication of the amount of invasive cancer in breast or lymph node tissue after completion of neoadjuvant chemotherapy.,,,,C25372,C25372,Category,string,
2025-09-23,Residual Cancer Burden,C160722,C160722,,Tumor Results;Disease Response,RCB Class,Ordinal,An indication of the amount of invasive cancer in breast or lymph node tissue after completion of neoadjuvant chemotherapy.,,,,C70856,C70856,Observation Result,string,0;I;II;III
2025-09-23,Residual Cancer Burden Class,C160724,C160724,C160723,Tumor Results;Disease Response,RCB Class,Ordinal,Residual cancer burden classes that use pre-defined cut-points representing progressively greater extents of residual cancer and indicating a greater risk of recurrence.,,,,C70856,C70856,Observation Result,string,0;I;II;III
2025-09-23,Residual Cancer Burden Class,C160724,C160724,C160723,Tumor Results;Disease Response,RCB Class,Ordinal,Residual cancer burden classes that use pre-defined cut-points representing progressively greater extents of residual cancer and indicating a greater risk of recurrence.,,,,C25372,C25372,Category,string,
2025-09-23,Residual Cancer Burden Class,C160724,C160724,C160723,Tumor Results;Disease Response,RCB Class,Ordinal,Residual cancer burden classes that use pre-defined cut-points representing progressively greater extents of residual cancer and indicating a greater risk of recurrence.,,,,C25692,C25692,Subcategory,string,
2025-09-23,Residual Cancer Burden Class,C160724,C160724,C160723,Tumor Results;Disease Response,RCB Class,Ordinal,Residual cancer burden classes that use pre-defined cut-points representing progressively greater extents of residual cancer and indicating a greater risk of recurrence.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Residual Cancer Burden Class,C160724,C160724,C160723,Tumor Results;Disease Response,RCB Class,Ordinal,Residual cancer burden classes that use pre-defined cut-points representing progressively greater extents of residual cancer and indicating a greater risk of recurrence.,,,,C70713,C70713,Biospecimen Type,string,Tissue
2025-09-23,Residual Cancer Burden Class,C160724,C160724,C160723,Tumor Results;Disease Response,RCB Class,Ordinal,Residual cancer burden classes that use pre-defined cut-points representing progressively greater extents of residual cancer and indicating a greater risk of recurrence.,,,,C171435,C171435,Specimen Anatomic Site,string,Breast;Lymph Node
2025-09-23,Residual Cancer Burden Index,C160723,C160723,,Tumor Results;Disease Response,RCB Index,Ordinal,"A score estimated from routine pathologic sections of the primary breast tumor site and the regional lymph nodes after the completion of neoadjuvant therapy. Variables used in the calculation include: primary tumor bed area, overall cancer cellularity, percentage of cancer that is in situ disease, number of positive lymph nodes, and diameter of largest metastasis. These scores are divided into 4 classes that stratify patients based on their chance of disease recurrence.",,,,C171435,C171435,Specimen Anatomic Site,string,Breast;Lymph Node
2025-09-23,Residual Cancer Burden Index,C160723,C160723,,Tumor Results;Disease Response,RCB Index,Ordinal,"A score estimated from routine pathologic sections of the primary breast tumor site and the regional lymph nodes after the completion of neoadjuvant therapy. Variables used in the calculation include: primary tumor bed area, overall cancer cellularity, percentage of cancer that is in situ disease, number of positive lymph nodes, and diameter of largest metastasis. These scores are divided into 4 classes that stratify patients based on their chance of disease recurrence.",,,,C25692,C25692,Subcategory,string,
2025-09-23,Residual Cancer Burden Index,C160723,C160723,,Tumor Results;Disease Response,RCB Index,Ordinal,"A score estimated from routine pathologic sections of the primary breast tumor site and the regional lymph nodes after the completion of neoadjuvant therapy. Variables used in the calculation include: primary tumor bed area, overall cancer cellularity, percentage of cancer that is in situ disease, number of positive lymph nodes, and diameter of largest metastasis. These scores are divided into 4 classes that stratify patients based on their chance of disease recurrence.",,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Residual Cancer Burden Index,C160723,C160723,,Tumor Results;Disease Response,RCB Index,Ordinal,"A score estimated from routine pathologic sections of the primary breast tumor site and the regional lymph nodes after the completion of neoadjuvant therapy. Variables used in the calculation include: primary tumor bed area, overall cancer cellularity, percentage of cancer that is in situ disease, number of positive lymph nodes, and diameter of largest metastasis. These scores are divided into 4 classes that stratify patients based on their chance of disease recurrence.",,,,C70856,C70856,Observation Result,string,RCB-0;RCB-I;RCB-II;RCB-III
2025-09-23,Residual Cancer Burden Index,C160723,C160723,,Tumor Results;Disease Response,RCB Index,Ordinal,"A score estimated from routine pathologic sections of the primary breast tumor site and the regional lymph nodes after the completion of neoadjuvant therapy. Variables used in the calculation include: primary tumor bed area, overall cancer cellularity, percentage of cancer that is in situ disease, number of positive lymph nodes, and diameter of largest metastasis. These scores are divided into 4 classes that stratify patients based on their chance of disease recurrence.",,,,C25372,C25372,Category,string,
2025-09-23,Residual Cancer Burden Index,C160723,C160723,,Tumor Results;Disease Response,RCB Index,Ordinal,"A score estimated from routine pathologic sections of the primary breast tumor site and the regional lymph nodes after the completion of neoadjuvant therapy. Variables used in the calculation include: primary tumor bed area, overall cancer cellularity, percentage of cancer that is in situ disease, number of positive lymph nodes, and diameter of largest metastasis. These scores are divided into 4 classes that stratify patients based on their chance of disease recurrence.",,,,C70713,C70713,Biospecimen Type,string,Tissue
2025-09-23,Rutgeerts Score - Rutgeerts Score,C191153,C191153,C190946,QRS;Clinical or Research Assessment Classification;Rutgeerts Score Clinical Classification;RUTGEERTS SCORE;RUTG01;Rutgeerts Score Clinical Classification Question,RUTG01-Rutgeerts Score;RUTG0101;Rutgeerts Score - Rutgeerts Score,Ordinal,Rutgeerts Score (Rutgeerts Score) Rutgeerts score.,,,,C46126,C46126,Ordinal Position,integer,i0;i1;i2;i3;i4
2025-09-23,Rutgeerts Score - Rutgeerts Score,C191153,C191153,C190946,QRS;Clinical or Research Assessment Classification;Rutgeerts Score Clinical Classification;RUTGEERTS SCORE;RUTG01;Rutgeerts Score Clinical Classification Question,RUTG01-Rutgeerts Score;RUTG0101;Rutgeerts Score - Rutgeerts Score,Ordinal,Rutgeerts Score (Rutgeerts Score) Rutgeerts score.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Rutgeerts Score - Rutgeerts Score,C191153,C191153,C190946,QRS;Clinical or Research Assessment Classification;Rutgeerts Score Clinical Classification;RUTGEERTS SCORE;RUTG01;Rutgeerts Score Clinical Classification Question,RUTG01-Rutgeerts Score;RUTG0101;Rutgeerts Score - Rutgeerts Score,Ordinal,Rutgeerts Score (Rutgeerts Score) Rutgeerts score.,,,,C25372,C25372,Category,string,RUTGEERTS SCORE
2025-09-23,Rutgeerts Score - Rutgeerts Score,C191153,C191153,C190946,QRS;Clinical or Research Assessment Classification;Rutgeerts Score Clinical Classification;RUTGEERTS SCORE;RUTG01;Rutgeerts Score Clinical Classification Question,RUTG01-Rutgeerts Score;RUTG0101;Rutgeerts Score - Rutgeerts Score,Ordinal,Rutgeerts Score (Rutgeerts Score) Rutgeerts score.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,"no lesions;<5 aphthous lesions;>5 aphthous lesions with normal mucosa between the lesions, or skip areas of larger lesions or lesions confined to the ileocolonic anastomosis (i.e., <1 cm in length);diffuse aphthous ileitis with diffusely inflamed mucosa;diffuse inflammation with already larger ulcers, nodules, and/or narrowing"
2025-09-23,Rutgeerts Score Clinical Classification,C191039,C191039,C118969,QRS;Clinical or Research Assessment Classification;Rutgeerts Score Clinical Classification;RUTGEERTS SCORE;RUTG01,,,A standardized scoring system developed by Rutgeerts et al. in 1990 that is used to assess postoperative disease recurrence in patients that have undergone ileocecal resection as treatment for Crohn disease.,,,,,,,,
2025-09-23,Rutgeerts Score Clinical Classification Question,C190946,C190946,C211913,QRS Instrument Questions,Rutgeerts Score Clinical Classification;RUTGEERTS SCORE;RUTG01,,A question associated with the Rutgeerts Score clinical classification.,,,,,,,,
2025-09-23,Sentinel Lymph Node Biopsy,C15667,C15667,C51900,Diagnostic Procedures;Biopsies;Breast Cancer Diagnostic Procedures,SLNB;SNB;Sentinel Node Biopsy;Sentinel node biopsy alone,Nominal,"Surgical removal and examination of the sentinel node, the lymph node which is first in receiving the lymphatic drainage of a specified anatomic location and is most likely to be affected by the lymphatic spread of cancer.",,,,C117530,C117530,End Date and Time of Procedure,datetime,
2025-09-23,Sentinel Lymph Node Biopsy,C15667,C15667,C51900,Diagnostic Procedures;Biopsies;Breast Cancer Diagnostic Procedures,SLNB;SNB;Sentinel Node Biopsy;Sentinel node biopsy alone,Nominal,"Surgical removal and examination of the sentinel node, the lymph node which is first in receiving the lymphatic drainage of a specified anatomic location and is most likely to be affected by the lymphatic spread of cancer.",,,,C117529,C117529,Start Date and Time of Procedure,datetime,
2025-09-23,Sentinel Lymph Node Biopsy,C15667,C15667,C51900,Diagnostic Procedures;Biopsies;Breast Cancer Diagnostic Procedures,SLNB;SNB;Sentinel Node Biopsy;Sentinel node biopsy alone,Nominal,"Surgical removal and examination of the sentinel node, the lymph node which is first in receiving the lymphatic drainage of a specified anatomic location and is most likely to be affected by the lymphatic spread of cancer.",,,,C117511,C117511,Reported Name of Procedure,string,Sentinel Lymph Node Biopsy
2025-09-23,Sentinel Lymph Node Biopsy,C15667,C15667,C51900,Diagnostic Procedures;Biopsies;Breast Cancer Diagnostic Procedures,SLNB;SNB;Sentinel Node Biopsy;Sentinel node biopsy alone,Nominal,"Surgical removal and examination of the sentinel node, the lymph node which is first in receiving the lymphatic drainage of a specified anatomic location and is most likely to be affected by the lymphatic spread of cancer.",,,,C171000,C171000,Prespecified Event or Intervention Indicator,boolean,Y;N
2025-09-23,Sentinel Lymph Node Biopsy,C15667,C15667,C51900,Diagnostic Procedures;Biopsies;Breast Cancer Diagnostic Procedures,SLNB;SNB;Sentinel Node Biopsy;Sentinel node biopsy alone,Nominal,"Surgical removal and examination of the sentinel node, the lymph node which is first in receiving the lymphatic drainage of a specified anatomic location and is most likely to be affected by the lymphatic spread of cancer.",,,,C127786,C127786,Occurrence Indicator,boolean,Y;N
2025-09-23,Sentinel Lymph Node Biopsy,C15667,C15667,C51900,Diagnostic Procedures;Biopsies;Breast Cancer Diagnostic Procedures,SLNB;SNB;Sentinel Node Biopsy;Sentinel node biopsy alone,Nominal,"Surgical removal and examination of the sentinel node, the lymph node which is first in receiving the lymphatic drainage of a specified anatomic location and is most likely to be affected by the lymphatic spread of cancer.",,,,C54215,C54215,Directionality,string,
2025-09-23,Sentinel Lymph Node Biopsy,C15667,C15667,C51900,Diagnostic Procedures;Biopsies;Breast Cancer Diagnostic Procedures,SLNB;SNB;Sentinel Node Biopsy;Sentinel node biopsy alone,Nominal,"Surgical removal and examination of the sentinel node, the lymph node which is first in receiving the lymphatic drainage of a specified anatomic location and is most likely to be affected by the lymphatic spread of cancer.",,,,C171435,C171435,Specimen Anatomic Site,string,
2025-09-23,Sentinel Lymph Node Biopsy,C15667,C15667,C51900,Diagnostic Procedures;Biopsies;Breast Cancer Diagnostic Procedures,SLNB;SNB;Sentinel Node Biopsy;Sentinel node biopsy alone,Nominal,"Surgical removal and examination of the sentinel node, the lymph node which is first in receiving the lymphatic drainage of a specified anatomic location and is most likely to be affected by the lymphatic spread of cancer.",,,,C117512,C117512,Standardized Name of Procedure,string,
2025-09-23,Sentinel Lymph Node Biopsy,C15667,C15667,C51900,Diagnostic Procedures;Biopsies;Breast Cancer Diagnostic Procedures,SLNB;SNB;Sentinel Node Biopsy;Sentinel node biopsy alone,Nominal,"Surgical removal and examination of the sentinel node, the lymph node which is first in receiving the lymphatic drainage of a specified anatomic location and is most likely to be affected by the lymphatic spread of cancer.",,,,C25185,C25185,Laterality,string,Left;Right;Bilateral
2025-09-23,Sentinel Lymph Node Biopsy,C15667,C15667,C51900,Diagnostic Procedures;Biopsies;Breast Cancer Diagnostic Procedures,SLNB;SNB;Sentinel Node Biopsy;Sentinel node biopsy alone,Nominal,"Surgical removal and examination of the sentinel node, the lymph node which is first in receiving the lymphatic drainage of a specified anatomic location and is most likely to be affected by the lymphatic spread of cancer.",,,,C25692,C25692,Subcategory,string,
2025-09-23,Sentinel Lymph Node Biopsy,C15667,C15667,C51900,Diagnostic Procedures;Biopsies;Breast Cancer Diagnostic Procedures,SLNB;SNB;Sentinel Node Biopsy;Sentinel node biopsy alone,Nominal,"Surgical removal and examination of the sentinel node, the lymph node which is first in receiving the lymphatic drainage of a specified anatomic location and is most likely to be affected by the lymphatic spread of cancer.",,,,C25372,C25372,Category,string,
2025-09-23,Substance Use Yes No Indicator,C219639,C219639,C82438,Event Occurrence Indicators;Substance Use,SUYN,Nominal,An indication of whether substance use has taken place.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Substance Use Yes No Indicator,C219639,C219639,C82438,Event Occurrence Indicators;Substance Use,SUYN,Nominal,An indication of whether substance use has taken place.,,,,C219639,C219639,Substance Use Yes No Indicator,string,N;Y
2025-09-23,Surgical Margins Status,C123560,C123560,C125581,Tumor Results;Pathology Results,Margin Status;SGMGSTAT,Ordinal,The determination of the presence of actual or potential neoplastic tissue which has been left outside the boundary of a resected specimen within the patient.,,,,C171435,C171435,Specimen Anatomic Site,string,
2025-09-23,Surgical Margins Status,C123560,C123560,C125581,Tumor Results;Pathology Results,Margin Status;SGMGSTAT,Ordinal,The determination of the presence of actual or potential neoplastic tissue which has been left outside the boundary of a resected specimen within the patient.,,,,C70713,C70713,Biospecimen Type,string,Tissue
2025-09-23,Surgical Margins Status,C123560,C123560,C125581,Tumor Results;Pathology Results,Margin Status;SGMGSTAT,Ordinal,The determination of the presence of actual or potential neoplastic tissue which has been left outside the boundary of a resected specimen within the patient.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Surgical Margins Status,C123560,C123560,C125581,Tumor Results;Pathology Results,Margin Status;SGMGSTAT,Ordinal,The determination of the presence of actual or potential neoplastic tissue which has been left outside the boundary of a resected specimen within the patient.,,,,C70856,C70856,Observation Result,string,Absent;Present
2025-09-23,Surgical Margins Status,C123560,C123560,C125581,Tumor Results;Pathology Results,Margin Status;SGMGSTAT,Ordinal,The determination of the presence of actual or potential neoplastic tissue which has been left outside the boundary of a resected specimen within the patient.,,,,C25692,C25692,Subcategory,string,
2025-09-23,Surgical Margins Status,C123560,C123560,C125581,Tumor Results;Pathology Results,Margin Status;SGMGSTAT,Ordinal,The determination of the presence of actual or potential neoplastic tissue which has been left outside the boundary of a resected specimen within the patient.,,,,C25372,C25372,Category,string,
2025-09-23,Tanner Scale,C82394,C82394,,QRS;Clinical or Research Assessment Classification;Tanner Scale-Boy Clinical Classification Question;Tanner Scale Boy Version;TANN02;TANNER SCALE BOY;Tanner Scale-Boy;Tanner Scale-Girl Clinical Classification Question;Tanner Scale Girl Version;TANN01;TANNER SCALE GIRL;Tanner Scale Girl Version;Tanner Scale-Girl,,,"A scale of physical development in children, adolescents and adults based on external primary and secondary sex characteristics, such as the size of the breasts, genitalia, and development of pubic hair.",,,,,,,,
2025-09-23,Tanner Scale Boy Version,C124703,C124703,C82394,QRS;Clinical or Research Assessment Classification;Tanner Scale-Boy Clinical Classification Question;Tanner Scale Boy Version;TANN02;TANNER SCALE BOY;Tanner Scale-Boy,TANN02;TANNER SCALE BOY;Tanner Scale Boy Version;Tanner Scale-Boy,,"A standardized rating scale developed by Marshal and Tanner in 1970, which is a classification system used to measure physical development in children, adolescents and adults. The boy version of the tanner scale assesses the different stages of physical maturity based on testicular volume, genitalia growth and the development of pubic hair. This instrument has 5 stages.",,,,,,,,
2025-09-23,Tanner Scale Girl Version,C124704,C124704,C82394,QRS;Clinical or Research Assessment Classification;Tanner Scale-Girl Clinical Classification Question;Tanner Scale Girl Version;TANN01;TANNER SCALE GIRL;Tanner Scale Girl Version;Tanner Scale-Girl,TANN01;TANNER SCALE GIRL;Tanner Scale-Girl,,"A standardized rating scale developed by Marshal and Tanner in 1969, which is a classification system used to measure physical development in children, adolescents and adults. The girl version of the tanner scale assesses the different stages of physical maturity based on breast development and the growth of pubic hair. This instrument has 5 stages.",,,,,,,,
2025-09-23,Tanner Scale-Boy - Genitalia Stages,C124716,C124716,C124689,QRS;Clinical or Research Assessment Classification;Tanner Scale-Boy Clinical Classification Question;Tanner Scale Boy Version;TANN02;TANNER SCALE BOY;Tanner Scale-Boy,TANN02-Genitalia Stages;TANN0201;Tanner Scale-Boy - Genitalia Stages,Ordinal,Tanner Scale Boy Version (Tanner Scale-Boy) Genitalia stages.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,Stage 1;Stage 2;Stage 3;Stage 4;Stage 5
2025-09-23,Tanner Scale-Boy - Genitalia Stages,C124716,C124716,C124689,QRS;Clinical or Research Assessment Classification;Tanner Scale-Boy Clinical Classification Question;Tanner Scale Boy Version;TANN02;TANNER SCALE BOY;Tanner Scale-Boy,TANN02-Genitalia Stages;TANN0201;Tanner Scale-Boy - Genitalia Stages,Ordinal,Tanner Scale Boy Version (Tanner Scale-Boy) Genitalia stages.,,,,C25372,C25372,Category,string,TANNER SCALE BOY
2025-09-23,Tanner Scale-Boy - Genitalia Stages,C124716,C124716,C124689,QRS;Clinical or Research Assessment Classification;Tanner Scale-Boy Clinical Classification Question;Tanner Scale Boy Version;TANN02;TANNER SCALE BOY;Tanner Scale-Boy,TANN02-Genitalia Stages;TANN0201;Tanner Scale-Boy - Genitalia Stages,Ordinal,Tanner Scale Boy Version (Tanner Scale-Boy) Genitalia stages.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Tanner Scale-Boy - Pubic Hair Stages,C124717,C124717,C124689,QRS;Clinical or Research Assessment Classification;Tanner Scale-Boy Clinical Classification Question;Tanner Scale Boy Version;TANN02;TANNER SCALE BOY;Tanner Scale-Boy,TANN02-Pubic Hair Stages;TANN0202;Tanner Scale-Boy - Pubic Hair Stages,Ordinal,Tanner Scale Boy Version (Tanner Scale-Boy) Pubic hair stages.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,Stage 1;Stage 2;Stage 3;Stage 4;Stage 5
2025-09-23,Tanner Scale-Boy - Pubic Hair Stages,C124717,C124717,C124689,QRS;Clinical or Research Assessment Classification;Tanner Scale-Boy Clinical Classification Question;Tanner Scale Boy Version;TANN02;TANNER SCALE BOY;Tanner Scale-Boy,TANN02-Pubic Hair Stages;TANN0202;Tanner Scale-Boy - Pubic Hair Stages,Ordinal,Tanner Scale Boy Version (Tanner Scale-Boy) Pubic hair stages.,,,,C25372,C25372,Category,string,TANNER SCALE BOY
2025-09-23,Tanner Scale-Boy - Pubic Hair Stages,C124717,C124717,C124689,QRS;Clinical or Research Assessment Classification;Tanner Scale-Boy Clinical Classification Question;Tanner Scale Boy Version;TANN02;TANNER SCALE BOY;Tanner Scale-Boy,TANN02-Pubic Hair Stages;TANN0202;Tanner Scale-Boy - Pubic Hair Stages,Ordinal,Tanner Scale Boy Version (Tanner Scale-Boy) Pubic hair stages.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Tanner Scale-Boy Clinical Classification Question,C124689,C124689,C211913,QRS Instrument Questions,,,A question associated with the Tanner Scale-Boy clinical classification.,,,,,,,,
2025-09-23,Tanner Scale-Girl - Breast Stages,C124718,C124718,C124690,QRS;Clinical or Research Assessment Classification;Tanner Scale-Girl Clinical Classification Question;Tanner Scale Girl Version;TANN01;TANNER SCALE GIRL;Tanner Scale Girl Version;Tanner Scale-Girl,TANN01-Breast Stages;TANN0101;Tanner Scale-Girl - Breast Stages,Ordinal,Tanner Scale Girl Version (Tanner Scale-Girl) Breast stages.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,Stage 1;Stage 2;Stage 3;Stage 4;Stage 5
2025-09-23,Tanner Scale-Girl - Breast Stages,C124718,C124718,C124690,QRS;Clinical or Research Assessment Classification;Tanner Scale-Girl Clinical Classification Question;Tanner Scale Girl Version;TANN01;TANNER SCALE GIRL;Tanner Scale Girl Version;Tanner Scale-Girl,TANN01-Breast Stages;TANN0101;Tanner Scale-Girl - Breast Stages,Ordinal,Tanner Scale Girl Version (Tanner Scale-Girl) Breast stages.,,,,C25372,C25372,Category,string,TANNER SCALE GIRL
2025-09-23,Tanner Scale-Girl - Breast Stages,C124718,C124718,C124690,QRS;Clinical or Research Assessment Classification;Tanner Scale-Girl Clinical Classification Question;Tanner Scale Girl Version;TANN01;TANNER SCALE GIRL;Tanner Scale Girl Version;Tanner Scale-Girl,TANN01-Breast Stages;TANN0101;Tanner Scale-Girl - Breast Stages,Ordinal,Tanner Scale Girl Version (Tanner Scale-Girl) Breast stages.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Tanner Scale-Girl - Pubic Hair Stages,C124719,C124719,C124690,QRS;Clinical or Research Assessment Classification;Tanner Scale-Girl Clinical Classification Question;Tanner Scale Girl Version;TANN01;TANNER SCALE GIRL;Tanner Scale Girl Version;Tanner Scale-Girl,TANN01-Pubic Hair Stages;TANN0102;Tanner Scale-Girl - Pubic Hair Stages,Ordinal,Tanner Scale Girl Version (Tanner Scale-Girl) Pubic hair stages.,,,,C91106,C91106,Clinical or Research Assessment Answer,string,Stage 1;Stage 2;Stage 3;Stage 4;Stage 5
2025-09-23,Tanner Scale-Girl - Pubic Hair Stages,C124719,C124719,C124690,QRS;Clinical or Research Assessment Classification;Tanner Scale-Girl Clinical Classification Question;Tanner Scale Girl Version;TANN01;TANNER SCALE GIRL;Tanner Scale Girl Version;Tanner Scale-Girl,TANN01-Pubic Hair Stages;TANN0102;Tanner Scale-Girl - Pubic Hair Stages,Ordinal,Tanner Scale Girl Version (Tanner Scale-Girl) Pubic hair stages.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Tanner Scale-Girl - Pubic Hair Stages,C124719,C124719,C124690,QRS;Clinical or Research Assessment Classification;Tanner Scale-Girl Clinical Classification Question;Tanner Scale Girl Version;TANN01;TANNER SCALE GIRL;Tanner Scale Girl Version;Tanner Scale-Girl,TANN01-Pubic Hair Stages;TANN0102;Tanner Scale-Girl - Pubic Hair Stages,Ordinal,Tanner Scale Girl Version (Tanner Scale-Girl) Pubic hair stages.,,,,C25372,C25372,Category,string,TANNER SCALE GIRL
2025-09-23,Tanner Scale-Girl Clinical Classification Question,C124690,C124690,C211913,QRS Instrument Questions,,,A question associated with the Tanner Scale-Girl clinical classification.,,,,,,,,
2025-09-23,Triple-Negative Breast Cancer Finding,C71428,C71428,C94299,Receptor Status,ER-Negative PR-Negative ERBB2-Negative;ER-negative PR-negative HER2/neu-negative;ER/PR/HER2 Negative;ESR1/PGR/ERBB2 Negative Finding;TNBC;Triple Negative Breast Cancer Result,Ordinal,Triple-negative breast cancer finding is a negative test result that occurs when the cells in the tumor of a breast cancer patient lack the receptors for both estrogen and progesterone and the human epidermal growth factor receptor 2.,,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Overall Status
2025-09-23,Triple-Negative Breast Cancer Finding,C71428,C71428,C94299,Receptor Status,ER-Negative PR-Negative ERBB2-Negative;ER-negative PR-negative HER2/neu-negative;ER/PR/HER2 Negative;ESR1/PGR/ERBB2 Negative Finding;TNBC;Triple Negative Breast Cancer Result,Ordinal,Triple-negative breast cancer finding is a negative test result that occurs when the cells in the tumor of a breast cancer patient lack the receptors for both estrogen and progesterone and the human epidermal growth factor receptor 2.,,,,C70713,C70713,Biospecimen Type,string,Tissue;Tumor tissue
2025-09-23,Triple-Negative Breast Cancer Finding,C71428,C71428,C94299,Receptor Status,ER-Negative PR-Negative ERBB2-Negative;ER-negative PR-negative HER2/neu-negative;ER/PR/HER2 Negative;ESR1/PGR/ERBB2 Negative Finding;TNBC;Triple Negative Breast Cancer Result,Ordinal,Triple-negative breast cancer finding is a negative test result that occurs when the cells in the tumor of a breast cancer patient lack the receptors for both estrogen and progesterone and the human epidermal growth factor receptor 2.,,,,C171435,C171435,Specimen Anatomic Site,string,Breast
2025-09-23,Triple-Negative Breast Cancer Finding,C71428,C71428,C94299,Receptor Status,ER-Negative PR-Negative ERBB2-Negative;ER-negative PR-negative HER2/neu-negative;ER/PR/HER2 Negative;ESR1/PGR/ERBB2 Negative Finding;TNBC;Triple Negative Breast Cancer Result,Ordinal,Triple-negative breast cancer finding is a negative test result that occurs when the cells in the tumor of a breast cancer patient lack the receptors for both estrogen and progesterone and the human epidermal growth factor receptor 2.,,,,C25372,C25372,Category,string,
2025-09-23,Triple-Negative Breast Cancer Finding,C71428,C71428,C94299,Receptor Status,ER-Negative PR-Negative ERBB2-Negative;ER-negative PR-negative HER2/neu-negative;ER/PR/HER2 Negative;ESR1/PGR/ERBB2 Negative Finding;TNBC;Triple Negative Breast Cancer Result,Ordinal,Triple-negative breast cancer finding is a negative test result that occurs when the cells in the tumor of a breast cancer patient lack the receptors for both estrogen and progesterone and the human epidermal growth factor receptor 2.,,,,C25692,C25692,Subcategory,string,
2025-09-23,Triple-Negative Breast Cancer Finding,C71428,C71428,C94299,Receptor Status,ER-Negative PR-Negative ERBB2-Negative;ER-negative PR-negative HER2/neu-negative;ER/PR/HER2 Negative;ESR1/PGR/ERBB2 Negative Finding;TNBC;Triple Negative Breast Cancer Result,Ordinal,Triple-negative breast cancer finding is a negative test result that occurs when the cells in the tumor of a breast cancer patient lack the receptors for both estrogen and progesterone and the human epidermal growth factor receptor 2.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Triple-Negative Breast Cancer Finding,C71428,C71428,C94299,Receptor Status,ER-Negative PR-Negative ERBB2-Negative;ER-negative PR-negative HER2/neu-negative;ER/PR/HER2 Negative;ESR1/PGR/ERBB2 Negative Finding;TNBC;Triple Negative Breast Cancer Result,Ordinal,Triple-negative breast cancer finding is a negative test result that occurs when the cells in the tumor of a breast cancer patient lack the receptors for both estrogen and progesterone and the human epidermal growth factor receptor 2.,,,,C70856,C70856,Observation Result,string,Positive;Negative
2025-09-23,Tumor Size Measurement,C106303,C106303,,Tumor Results;Tumor Measurements,,Quantitative,The measurement of the size of a tumor mass either clinically or in a surgically resected specimen.,,,,C42578,C42578,Unit of Length,string,Millimeters;Centimeters;Inches
2025-09-23,Tumor Size Measurement,C106303,C106303,,Tumor Results;Tumor Measurements,,Quantitative,The measurement of the size of a tumor mass either clinically or in a surgically resected specimen.,,,,C70713,C70713,Biospecimen Type,string,Tumor Tissue
2025-09-23,Tumor Size Measurement,C106303,C106303,,Tumor Results;Tumor Measurements,,Quantitative,The measurement of the size of a tumor mass either clinically or in a surgically resected specimen.,,,,C171435,C171435,Specimen Anatomic Site,string,
2025-09-23,Tumor Size Measurement,C106303,C106303,,Tumor Results;Tumor Measurements,,Quantitative,The measurement of the size of a tumor mass either clinically or in a surgically resected specimen.,,,,C70856,C70856,Observation Result,decimal,
2025-09-23,Tumor Size Measurement,C106303,C106303,,Tumor Results;Tumor Measurements,,Quantitative,The measurement of the size of a tumor mass either clinically or in a surgically resected specimen.,,,,C82515,C82515,Collection Date Time,datetime,
2025-09-23,Tumor Size Measurement,C106303,C106303,,Tumor Results;Tumor Measurements,,Quantitative,The measurement of the size of a tumor mass either clinically or in a surgically resected specimen.,,,,C25692,C25692,Subcategory,string,
2025-09-23,Tumor Size Measurement,C106303,C106303,,Tumor Results;Tumor Measurements,,Quantitative,The measurement of the size of a tumor mass either clinically or in a surgically resected specimen.,,,,C25372,C25372,Category,string,
2025-09-23,Tumor Size Measurement,C106303,C106303,,Tumor Results;Tumor Measurements,,Quantitative,The measurement of the size of a tumor mass either clinically or in a surgically resected specimen.,,,,C13717,C13717,Anatomic Site,string,
2025-09-23,Ultrasound Imaging,C17230,C17230,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures,Ultrasonography;2-Dimensional Ultrasound Imaging;Ultrasound;Ultrasound Test;US,Nominal,The use of high-frequency sound waves to generate images of the body.,,,,C25692,C25692,Subcategory,string,
2025-09-23,Ultrasound Imaging,C17230,C17230,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures,Ultrasonography;2-Dimensional Ultrasound Imaging;Ultrasound;Ultrasound Test;US,Nominal,The use of high-frequency sound waves to generate images of the body.,,,,C117512,C117512,Standardized Name of Procedure,string,
2025-09-23,Ultrasound Imaging,C17230,C17230,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures,Ultrasonography;2-Dimensional Ultrasound Imaging;Ultrasound;Ultrasound Test;US,Nominal,The use of high-frequency sound waves to generate images of the body.,,,,C13717,C13717,Anatomic Site,string,Abdomen;Pelvis;Heart;Breast
2025-09-23,Ultrasound Imaging,C17230,C17230,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures,Ultrasonography;2-Dimensional Ultrasound Imaging;Ultrasound;Ultrasound Test;US,Nominal,The use of high-frequency sound waves to generate images of the body.,,,,C117530,C117530,End Date and Time of Procedure,datetime,
2025-09-23,Ultrasound Imaging,C17230,C17230,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures,Ultrasonography;2-Dimensional Ultrasound Imaging;Ultrasound;Ultrasound Test;US,Nominal,The use of high-frequency sound waves to generate images of the body.,,,,C117511,C117511,Reported Name of Procedure,string,Ultrasound
2025-09-23,Ultrasound Imaging,C17230,C17230,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures,Ultrasonography;2-Dimensional Ultrasound Imaging;Ultrasound;Ultrasound Test;US,Nominal,The use of high-frequency sound waves to generate images of the body.,,,,C54215,C54215,Directionality,string,
2025-09-23,Ultrasound Imaging,C17230,C17230,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures,Ultrasonography;2-Dimensional Ultrasound Imaging;Ultrasound;Ultrasound Test;US,Nominal,The use of high-frequency sound waves to generate images of the body.,,,,C25185,C25185,Laterality,string,Left;Right;Bilateral
2025-09-23,Ultrasound Imaging,C17230,C17230,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures,Ultrasonography;2-Dimensional Ultrasound Imaging;Ultrasound;Ultrasound Test;US,Nominal,The use of high-frequency sound waves to generate images of the body.,,,,C127786,C127786,Occurrence Indicator,boolean,Y;N
2025-09-23,Ultrasound Imaging,C17230,C17230,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures,Ultrasonography;2-Dimensional Ultrasound Imaging;Ultrasound;Ultrasound Test;US,Nominal,The use of high-frequency sound waves to generate images of the body.,,,,C171000,C171000,Prespecified Event or Intervention Indicator,boolean,Y;N
2025-09-23,Ultrasound Imaging,C17230,C17230,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures,Ultrasonography;2-Dimensional Ultrasound Imaging;Ultrasound;Ultrasound Test;US,Nominal,The use of high-frequency sound waves to generate images of the body.,,,,C117529,C117529,Start Date and Time of Procedure,datetime,
2025-09-23,Ultrasound Imaging,C17230,C17230,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures,Ultrasonography;2-Dimensional Ultrasound Imaging;Ultrasound;Ultrasound Test;US,Nominal,The use of high-frequency sound waves to generate images of the body.,,,,C25372,C25372,Category,string,
